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Abstract 
 
The function of bicarbonate transporters has been extensively studied in epithelial tissues, 
but their function in heart is not well understood. Cardiac tissue expresses an abundance of 
bicarbonate transporters (Cl-/HCO3- exchangers and Na+/ HCO3- cotransporters) that are typically 
viewed as being involved in the regulation of intracellular pH (pHi). However, the high 
expression of bicarbonate transporters in heart and results of the current thesis research suggests 
that pHi regulation may not be their major function. 
  Anion exchanger isoform 3 (AE3) is the most abundant Cl-/HCO3- exchanger in heart. 
Mice lacking AE3 have normal cardiac function, but loss of AE3 in a hypertrophic 
cardiomyopathy (HCM) model leads to heart failure and reduces survival. Moreover, AE3 KO 
mice have an impaired force-frequency response (FFR) when paced at higher heart rates in vivo. 
AE3 has been proposed to work in a coupled system with the Na+/H+ exchanger, with the 
resulting increase in Na+-loading leading to Ca2+-loading, which in turn contributes to cardiac 
hypertrophy. Studies have shown that AE3-null mice have reduced heart weight to body weight 
ratio, suggesting that AE3 may play such a role in hypertrophy. However, loss of AE3 does not 
reduce hypertrophy or impair cardiac function in response to pressure overload.     
 To further understand the molecular mechanism of why loss of AE3 impaired cardiac 
function in the HCM model and impaired FFR during atrial pacing, RNA seq analysis of WT and 
AE3 KO hearts was performed to analyze differential gene expression patterns in great detail. 
Detailed analysis of RNA seq data suggested the occurrence of impaired O2/CO2 balance in AE3 
KO cardiomyocytes. Genes encoding proteins involved in hypoxia responses, angiogenesis, 
vasodilation, glucose and fatty acid metabolism, cardiac conduction and electrical activity, and 
myofibrillar organization were differentially expressed in AE3 KO hearts. The pattern of 
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changes support a model in which AE3-mediated Cl-/HCO3- exchange, in a coupled system likely 
involving parallel H+ and Cl- extrusion mechanisms, is responsible for efficient disposal of CO2.   
Most of the differential expression changes in AE3 KO hearts could be interpreted as 
adaptive changes that provide compensation for the loss of AE3-mediated HCO3- extrusion in 
heart. Other Cl-/HCO3- exchangers, AE2 and PAT1, were slightly upregulated and may provide 
partial compensation for the loss of AE3 in heart. Mice with cardiac specific knockdown of AE2, 
which is expressed at much lower levels than AE3, have normal cardiovascular performance and 
expression of major calcium handling proteins in heart, consistent with a supplementary role. 
 The sodium dependent bicarbonate cotransporters (NBC) are HCO3- uptake mechanisms 
in heart. Of the two NBCs in heart, the electrogenic NBC (NBCe1) is expressed at higher levels 
than the electroneutral NBC (NBCn1). Previous studies have reported that inhibition of NBCe1 
protects against ischemia reperfusion (I/R) injury. In order to understand the role of NBCe1 in 
heart, we generated a conditional cardiac-specific NBCe1 KO mouse. Though loss of NBCe1 did 
not affect cardiovascular function, NBCe1 KO mice had less apoptotic cell death in response to 
in vivo I/R suggesting that loss of NBCe1 may protect against I/R injury. 
The studies presented here suggest that bicarbonate transporters have important functions 
in heart. Though loss of AE3 did not reduce hypertrophy in response to pressure-overload, RNA 
seq analysis indicates that AE3 may be involved in efficient disposal of CO2 from the 
cardiomyocytes. These observations along with the previous studies from our lab, indicate that 
AE3 has an important function in heart and that inhibition of AE3 for the treatment of heart 
disease, as proposed by others, would not be an appropriate therapeutic strategy.   
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Chapter 1: Introduction 
 
Regulation of intracellular pH (pHi) is critical for various physiological functions in 
heart, including excitation-contraction coupling, calcium signaling, and cellular metabolism. 
Cardiomyocytes express (Figure 1.1A) Na+-independent Cl-/HCO3- exchangers (AE1, AE2, 
AE3, and PAT1), a Na+/H+ exchanger (NHE1), and two Na+-dependent HCO3- cotransporters 
(NBCe1, NBCn1) [1] that are involved in the regulation of pHi. RNA seq analysis also indicates 
the presence of an additional H+ extruding mechanism, the voltage gated proton channel 
(HVCN1) in heart. NHE1, HVCN1, NBCe1 and NBCn1 extrude a proton or bring in bicarbonate 
to alkalinize the cell. The expression levels (RPKM values) of the major bicarbonate transporters 
and acid extruders in FVBN mice hearts are shown below (Figure 1.1B). 
 
  
 
Figure 1.1. Major acid-base transporters in heart. (A) Schematic representation of major acid 
loaders (AE1, AE2, AE3, and PAT1) and acid extruders (NHE1, NBCn1, NBC1, and Hvcn1) 
expressed in cardiomyocytes and (B) RPKM values of the transporters shown in panel A in WT 
FVBN mice hearts obtained from RNA seq data. The acid loaders and acid extruders together 
regulate pHi and volume. Combined Cl-/HCO3- exchanger with the acid extruders (NHE1 or 
NBCs) can result in pH neutral Na+ loading, and eventually Ca2+ loading via Na+ / Ca2+ NCX 
activity.   
 
A B 
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The high expression levels of HCO3- transporters in heart suggest that pHi regulation may 
not be their major function. In fact, studies in isolated rat cardiomyocytes have shown that 
HCO3- affects myocyte contractility independent of calcium [2]. Moreover, RNA seq analysis of 
AE3 knockout mice hearts indicates that AE3 may be involved in CO2 disposal from 
cardiomyocytes (Chapter 5). The combined activities of acid loaders and acid extruders in the 
myocardium regulate not only pHi, but also [Na+]i, and cell volume. 
The role of NHE1 in ischemia-reperfusion injury and hypertrophy has been demonstrated 
in various studies and inhibition of NHE1 has been shown to reduce hypertrophy and progression 
to heart failure [3]. Sustained NHE1 activity is possible only when coupled with a HCO3- 
extrusion mechanism like Cl-/HCO3- exchange. In fact, studies in both spontaneously 
hypertensive rats and a transgenic model carrying an activated NHE1 have shown that increased 
NHE1 activity did not result in an increase in pHi in isolated myocytes maintained in bicarbonate 
buffer, but did increase pHi when switched to HEPES buffer lacking bicarbonate [4, 5]. These 
results suggest that activation of H+ extrusion via NHE1 is accompanied by simultaneous 
activation of Cl-/HCO3- exchange [4, 5], which could allow a substantial increase in intracellular 
Na+ concentrations under pathological conditions. These observations support the hypothesis that 
one function of Cl-/HCO3- exchange is to facilitate Na+ loading. 
 
SLC4a family of sodium independent chloride/bicarbonate exchangers 
The main members of the SLC4a family involved in Cl-/HCO3- exchange include the 
AE1, AE2, and AE3 anion exchangers. Cl-/HCO3- exchangers are involved in the exchange of 
intracellular bicarbonate for extracellular chloride with the exception of AE1 as erythrocytes pass 
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through the lungs. The low CO2 in lungs drives the exchanger in reverse where bicarbonate enters 
the erythrocyte in exchange for chloride. The bicarbonate is then converted to CO2 and exhaled. 
Members of the SLC4a family share a common domain structure, which includes an N-
terminal cytoplasmic domain of 400-700 amino acids, a transmembrane domain of ~ 500 amino 
acids and a C-terminal cytoplasmic domain of 30–100 amino acids. Most Slc4a members use 
alternate promoters to generate multiple polypeptide isoforms. Although the exact number of 
transmembrane domains in the anion exchangers is not known, hydropathy analysis of the human 
AE1 amino acid sequence suggests 12-14 transmembrane regions with 2 re-entrant loops in the 
lipid bilayer (Figure 1.2).  The anion exchange activity of the transporter resides within the 
transmembrane regions. AE1 is glycosylated on the 4th extracellular loop, whereas AE2 and AE3 
are glycosylated on the 3rd extracellular loop [6].  Information about specific isoforms is 
discussed below.  
 
 
 
Figure 1.2. Proposed topology model for the membrane domain of human AE1 [7]. The 
branched structure at Asn642represents N-linked glycosylation and numbers indicate residue 
number. The numbers in boxes represent transmembrane domains. The position of the Wright 
blood group antigen is labelled, Wra.    
 
!
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SLC4A1  
 Anion exchanger 1 (AE1, also known as band 3) was the first anion exchanger cloned. 
Erythrocytes have the highest expression of AE1 followed by the intercalated cells of the renal 
collecting duct. Alternative promoter usage generates two isoforms of AE1, the erythroid 
isoform (eAE1) containing 911 amino acids and the kidney isoform (kAE1) containing 846 
amino acids [8, 9]. PCR identified both eAE1 and truncated AE1 (nAE1) mRNA in isolated rat 
cardiomyocytes [10]. RNA seq analysis of mouse heart mRNA indicates very low expression of 
AE1 (RPKM = 0.20 ± 0.05) relative to the AE2, AE3 and PAT1 Cl-/HCO3- exchangers (Figure 
1.1B). AE1 is expressed in sarcolemma and intercalated discs of rat cardiac myocytes and has 
been shown to be associated with focal adhesion kinase (FAK) in heart and with integrin-linked 
kinase (ILK) in kidney [11, 12]. 
The N-terminal cytoplasmic domain of eAE1 binds multiple glycolytic enzymes, 
hemoglobin, ankyrin-1, protein 4.1, and protein 4.2 [13, 14]. The C-terminus has been shown to 
bind to cytoplasmic carbonic anhydrase II and form a transport metabolon, which enhances 
activity [15]. In erythrocytes, the eAE1 isoform constitutes about 50% of integral membrane 
proteins and performs dual functions. It mediates Cl-/HCO3- exchange, thus playing a critical role 
in gas exchange, and also provides mechanical stability to the erythrocyte membrane [16].  
 
Disease phenotype and animal models for AE1 
  Several mutations in AE1 cause autosomal dominant hereditary spherocytosis [17], 
which is characterized by hemolytic anemia and fragile red blood cells. Southeast Asian 
ovalocytosis is also caused by heterozygous deletion of amino acids 400-408 of AE1. The red 
blood cell membranes of patients carrying this mutation exhibit increased rigidity and 
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permeability to cations like Na+ and K+ [18]. Most of the HS mutations however do not cause 
renal defects. Mutations in AE1 can also cause autosomal dominant distal renal tubular acidosis 
(dRTA) without any erythrocyte phenotype. Mice lacking erythroid AE1 suffer from severe 
hemolytic anemia and spherocytosis [16, 19]. In another study, AE1-null mice displayed cardiac 
hypertrophy and impaired cardiac function. However, the authors speculated that hypertrophy 
and impaired cardiac function in these mice were due to anemia and not because of loss of AE1 
in the heart [20].    
 
Regulation of AE1 
eAE1 is unaffected by pH, ammonium and hypertonicity because AE1 must mediate anion 
transport in both the acidic environments of peripheral tissues and also at the neutral pH of 
blood. 
 
SLC4A2   
Anion exchanger 2 (AE2), first cloned from a mouse kidney library [21], is the 
housekeeping Cl-/HCO3- exchanger and is expressed basolaterally in various tissues. SLC4A2 
generates three different N-terminal variants (AE2a, AE2b, and AE2c) by alternative promoter 
usage. The AE2a isoform is expressed in all tissues whereas AE2b is expressed in epithelial 
tissues, with high levels in the stomach, and AE2c is expressed exclusively in the stomach [22]. 
AE2 mRNA is expressed in the heart (RPKM = 12.6 ± 0.28) [23] and protein has been shown to 
be expressed in rat neonatal cardiomyocytes [24]. AE2 plays a major role in gastric HCl 
secretion [25]. The apical H+/K+-ATPase pumps H+ into the lumen of the stomach. AE2, present 
on the basolateral surface, prevents intracellular alkalinization of gastric parietal cells by 
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exporting HCO3- into the blood, and also mediate Cl- uptake for HCl secretion. AE2 performs 
similar function in osteoclasts where it removes the bicarbonate and prevents alkalinization of 
the osteoclast [17].  AE2 works in concert with NHE1 in various tissues to facilitate NaCl uptake 
and volume regulation [26].    
 
Disease phenotype and animal knockout models for AE2  
No human diseases have been identified with mutations in AE2, probably because of its 
widespread expression in most tissues and the likelihood that mutations in AE2 could be lethal. 
AE2-/- mice die at or before weaning, exhibit severe growth retardation, failure of tooth eruption, 
osteopetrosis, and major defects in gastric HCl secretion and parietal cell development [25].  
Osteopetrosis in AE2-/- mice suggests that AE2 plays a role in the bone resorption mechanism in 
osteoclasts [17].   
 
Regulation of AE2 
  AE2 activity is regulated by NH4+ [27] and pHi. At constant pH(o), AE2 is inhibited by 
intracellular acidification and activated by intracellular alkalinization [28]. AE2 is also activated 
by hypertonicity, along with NHE1, resulting in volume increase [27]. Conserved amino acid 
residues in the N-terminus of the cytoplasmic domain are required for the regulation of AE2 by 
intracellular and extracellular pH [29]. Recently, re-entrant loop 1 (RL-1) of AE2 was shown to 
act as a pH sensor and to be involved in acute regulation of the exchanger by pHi [30]. 
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SLC4A3 (Anion exchanger 3)  
 Anion exchanger 3 (AE3) was first cloned in 1989 [31] and is predominantly expressed 
in excitable tissues like brain, retina, and heart. AE3 is also expressed in the gut and kidney. The 
SLC4A3 gene encodes 2 isoforms, which are derived by alternative promoter usage, a full-length 
isoform (flAE3) expressed in brain and retina and a cardiac isoform (cAE3), which is expressed 
in the retina and heart [32]. AE3 is the most abundant Cl-/HCO3- exchanger in heart  (RPKM = 
85.7 ± 0.64) (Table 1.1B) and is expressed in the sarcolemma and T-tubules of cardiomyocytes. 
AE3 colocalized with vinculin, a focal adhesion protein present at the level of costamers in 
myocytes [20]. Though both isoforms are expressed in cardiac tissue, cAE3 is the major isoform 
in the mouse ventricle. In fact, ventricles of mice have very little expression of the flAE3 [16, 
32]. The flAE3 variant consists of 1227 amino acids. The N-terminal 270 amino acid residues of 
flAE3 are replaced by 73 amino acids in cAE3 [33]. 
 
Disease phenotype and animal knockout models for AE3 
  There are no human null mutations identified in SLC4A3 so far. However, a polymorphic 
variant is found at high frequency in patients with idiopathic generalized epilepsy [34].  Mice 
with a gene targeted deletion of AE3 exhibit reduced seizure threshold and increased seizure-
induced mortality [35]. Another group showed that AE3-null mice have defects in the inner 
retina and degeneration of photoreceptors [36]. Cardiac performance of AE3-null mice was 
normal under basal conditions and in response to beta-adrenergic stimulation. The AE3-null 
mice, however, have slightly reduced heart weight to body weight ratio suggesting that AE3 may 
have a role in hypertrophy [1]. Though loss of AE3 alone had no major impact on cardiac 
function, the combined loss of AE3 and the Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) 
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results in impaired cardiac contractility and calcium handling [1]. Moreover, the loss of AE3 in a 
Gly180Glu α-tropomyosin hypertrophic cardiomyopathy model had no effect on hypertrophy but 
reduced survival and led to rapid decompensation of cardiac function [37], suggesting a 
protective role for AE3-mediated Cl-/HCO3- exchange in the heart. 
    In more recent studies, the loss of AE3 has been shown to cause a reduction in the force-
frequency response when mice were subjected to a pacing-induced increase in heart rate [38]. 
When biochemical analyses were performed on hearts from mice subjected to atrial pacing, 
activation of AKT, as measured by phosphorylation of Ser473, was sharply increased in AE3-
null mice in which the heart rate was increased to 550 beats per minute, but was not changed 
under baseline conditions. These data suggest that an impaired force-frequency response 
contributes to the increased susceptibility to heart failure of AE3-null mice [37]. 
 
Regulation of AE3 
AE3 activity is stimulated by an increase in pHi.  Angiotensin II has been reported to 
activate flAE3 and increase Cl-/HCO3- exchange in the myocardium of hypertensive rats through 
a PKC dependent phosphorylation of serine 67 [39]. The role of the NHE1 Na+/H+ exchanger in 
the slow force response to stretch is well established. Stretch activates NHE1 through an 
autocrine/paracrine mechanism, which leads to pH neutral sodium uptake, reversal of the sodium 
calcium exchanger-1 (NCX1) and an increase in intracellular calcium [40, 41]. Increase in pHi in 
response to stretch was observed only in the absence of bicarbonate suggesting that NHE1 
activity is balanced by anion exchange activity. Studies using AE3 antibodies to inhibit anion 
exchange activity suggested that AE3 is the anion exchanger that couples with NHE1 during the 
stretch-induced slow force response in the myocardium [42]. An increase in carbonic anhydrase 
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XIV expression has been shown in the myocardium of hypertensive rats. Carbonic anhydrase 
generates both H+ and HCO3-, which are proposed to stimulate both NHE1 and AE3 activity [43].  
  
SLC26A family of anion exchangers 
The SLC26A family was initially identified as a family of sulfate transporters and later 
shown to include Cl-/HCO3- exchangers. Based on hydropathy plots, the SLC26A transporters 
are predicted to have 10-14 transmembrane segments with cytoplasmic N and C-termini. All of 
the SLC26A members except for SLC26A4 contain a PDZ motif at the extreme C-terminus that 
may be involved in protein-protein interactions. The C-terminus also contains a STAS domain 
that has been shown to interact with the regulatory domain of CFTR and also form a binding site 
for carbonic anhydrase II [44]. Information about specific Slc26a isoforms is discussed below. 
 
SLC26A6 
The SLC26A6 gene was cloned from humans [45] and mice [46]. Alternative splicing 
generates 2 major transcripts, a full-length form and a truncated form lacking the first 23 N-
terminal amino acids. Human and mouse Slc26a6 share about 78% amino acid identity. There is 
still controversy as to whether SLC26A6-mediated Cl-/HCO3- exchange is electrogenic or 
electroneutral. Recent studies however suggest that the exchanger is electroneutral. Protein 
encoded by both SLC26A6 (human) and Slc26a6 (mouse) can also transport formate, Cl-, SO4-, 
HCO3-, OH-, and oxalate with different specificities [47]. Microarray data of RNA from WT and 
Slc26a6 knockout hearts suggests formate as the primary ion transported by Pat1 in heart 
(unpublished results). Slc26a6 is expressed in the brush border membranes of proximal tubule 
cells in kidney and duodenal villus cells, pancreatic duct cells, and stomach parietal cells. 
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Slc26a6 was suggested as the major anion exchanger in the mouse heart and is expressed mainly 
in the ventricles [48]. However, studies using RNA seq analysis indicates that PAT1 (RPKM = 
4.56 ± 0.26) is expressed at lower levels than AE2 and AE3 and hence does not support the 
finding that PAT1 is the major anion exchanger in heart. In myocytes, Slc26a6 is expressed in T-
tubules and possibly in the SR [20].  
 
Disease phenotype and animal knockout models for Slc26a6 
 No human mutations in SLC26A6 have been identified so far. Slc26a6 knockout mice 
exhibit enhanced oxalate absorption in the small intestine resulting in increased oxalate excretion 
in urine [49]. This suggests that the exchanger is involved in oxalate transport. SLC26A6 has also 
been implicated in ion transport processes affecting cystic fibrosis since the STAS domain is 
found to interact with CFTR in the pancreatic duct [44, 50].  
 
Regulation of SLC26A6 
  PKC decreases transport activity of Slc26a6 by disrupting the Slc26a6-carbonic 
anhydrase II metabolon [51], a complex that facilitates sustained transport activity. SLC26A6 
may also be regulated by CFTR since the exchanger is physically and functionally associated 
with CFTR. The STAS domain of SLC26A6 mediates interaction with CFTR [44, 50].  
 
SLC4A family of sodium bicarbonate cotransporters  
The sodium bicarbonate (Na+/HCO3-) cotransporters include electrogenic (SLC4A4 and 
SLC4A5) and electroneutral (SLC4A7) transporters. SLC4A4 and SLC4A5 encode NBCe1 
(SLC4A4) and NBCe2 (SLC4A5), which mediate the movement of one Na+ and two or three 
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HCO3- in the same direction resulting in one or two net negative charges across the membrane 
with each Na+ transported. The direction of transport depends on the stoichiometry; when 2 
HCO3- are transported, the direction is inward [2]. When 3 HCO3- are transported, as in the 
proximal tubule, the direction is outward. SLC4A7 encodes NBCn1, which is involved in the 
electroneutral transport of Na+ and HCO3-, which mediated inward transport of Na+ and HCO3-.  
Slc4a4: The renal electrogenic Na+/HCO3- cotransporter was first cloned from salamander [52]. 
Subsequently, the renal human [53] and rat [54] NBCe1-A (renal splice variants) were cloned. 
Two other splice variants have been identified since then (Figure 1.3). NBCe1-B, cloned from 
pancreas [55] and heart [56], is the most widespread variant. The N-terminal 41 amino acids of 
NBCe1-A are replaced by 85 amino acids in NBCe1-B. In the NBCe1-C isoform, found 
exclusively in the brain, 46 C-terminal amino acids of NBCe1-B are replaced by a unique 61 
amino acid sequence.  
 
 
Figure 1.3. Alternate splicing of NBCe1 and direction (efflux/influx) of Na+ and HCO3- 
transport 
 
All three splice variants of NBCe1 have motifs similar to those of AE1 that bind carbonic 
anhydrase II (CAII), and in vitro studies suggest that the C-terminus of NBCe1-A and NBCe1-B 
can bind CAII [57]. NBCe1 is expressed in the basolateral membranes of epithelial cells of the 
renal proximal tubule, pancreatic ducts, and epididymis. It is also expressed in several tissues of 
the eye, blood vessels and T-tubules within the heart [58]. In proximal tubule of kidney, NBCe1 
is involved in the reabsorption of HCO3- from the lumen to blood where it transports 3 HCO3- 
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and 1 Na+ from the cell to the blood. In tissues like pancreas and heart, NBCe1 transports HCO3- 
and Na+ in a 2:1 stoichiometry. In the pancreas NBCe1 is involved in the accumulation of 
cytoplasmic HCO3-, which is then secreted into the lumen of exocrine ducts. In non-epithelial 
tissues such as the myocardium, NBCe1 has been proposed to regulate pHi by moving HCO3- 
into cells, but it might also be involved in regulating intracellular HCO3- levels in response to an 
acid load [2]. The expression of NBCe1 is elevated in hearts from patients with heart failure but 
the levels of NBCn1, an electroneutral sodium bicarbonate cotransporter are unaltered. 
Moreover, inhibition of NBCe1 in rat hearts with an anti-NBCe1 antibody reduced ischemic 
injury [59]. In a rat model of pressure overload hypertrophy induced by aortic constriction, 
mRNA levels of both NBCe1 and NBCn1 were elevated [60]. This study also reported increased 
acid extrusion by Na+/HCO3- cotransport activity (NBC) compared to NHE1 and attenuation of 
NBC activity by Angiotensin II Type I receptor antagonist [60]. Another study demonstrated that 
AngII inhibits NBCe1 activity through a p38-mediated mechanism and activates NBCn1 activity 
through an Erk1/2 mediated mechanism [61]. 
 
Disease phenotype and animal knockout models for NBCe1  
  Four naturally occurring mutations in NBCe1 have been reported so far in humans. All of 
these mutations cause severe and persistent recessive proximal tubular acidosis and ocular 
abnormalities such as bilateral glaucoma, bilateral cataracts, band keratopathy, and blindness 
[62] [53]. Mice with targeted disruption of Slc4a4 exhibit severe metabolic acidosis, growth 
retardation, hyperaldosteronism, splenomegaly, abnormal dentition and die before weaning [63].    
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Regulation of NBCe1 
 Hormones and other stimuli regulate NBCe1 activity. Acidosis [64] and angiotensin II 
[65] have been shown to activate NBCe1 activity in rabbit kidney. Recent studies in cat 
cardiomyocytes suggest inhibition of NBCe1 activity by angiotensin II [61]. Metabolic alkalosis 
[64], parathyroid hormone [66], and cAMP through PKA have been shown to inhibit NBCe1 
activity [67]. 
 
SLC4A7 
 Several groups identified electroneutral Na+/HCO3- cotransport in vascular smooth 
muscle [68], cardiac Purkinje fibers [69] and cardiac myocytes [70]. The electroneutral NBCn1 
was first cloned from human skeletal muscle in 1999 [71]. Later, 3 additional NBCn1 cDNAs 
(variants B, C, and D) were cloned from rat aorta [72]. The rat NBCn1 variants are 89 -92% 
identical to the human skeletal muscle isoform, which is called the NBCn1-A. When expressed 
in Xenopus oocytes, NBCn1-B mediates electroneutral Na+/HCO3- cotransport activity [72]. 
NBCn1 colocalizes with the H+-ATPase in rabbit collecting duct [73]. Human northern blots 
probed with a 95-bp oligonucleotide directed against exon 7 identified NBCn1 expression in 
heart and skeletal muscle. Northern blot analysis of various tissues identified high expression of 
NBCn1 mRNA in spleen and testes, and lower levels in heart, brain, lung, liver and kidney but 
not in skeletal muscle [72]. NBCn1 (slc4a7) was shown to mediate Na+-dependent bicarbonate 
transport in vascular smooth muscle cells of mouse mesenteric, coronary, and cerebral small 
arteries. Bicarbonate transport by NBCn1 was important for pHi recovery after an acid load as 
well as for regulation of steady-state pHi in these arteries [74]. The C-terminus of NBCn1 
interacts with the 56 kDa subunit of the H+-ATPase through Na+/H+ exchanger regulatory     
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factor 1 (NHERF-1) [75].   
 
Disease phenotype and animal knockout models oforNBCn1 
  No mutations in SLC4A7 have been identified so far in humans. NBCn1 knockout mice 
develop blindness and auditory impairment as a result of degeneration of sensory receptors in the 
eye and ear [76]. Possible cardiac functions have not been examined using the knockout. 
 
Regulation of NBCn1 
NBCn1 has been shown to interact with carbonic anhydrase II, thereby increasing the 
HCO3- transport rate. Though NBCn1 activity is reduced by PKA, NBCn1 is not phosphorylated 
by PKA [77].  
 
Transporters and channels involved in acid extrusion 
SLC9A1   
Human SLC9A1, encoding the NHE1 Na+/H+ exchanger, was first cloned in 1989 by 
Sardet et al [78]. A total of nine isoforms of the SLC9A family (NHE1-NHE9) have been 
identified since then. Isoforms 1-5 are localized on the plasma membrane whereas isoforms 6-9 
are expressed in intracellular membranes. NHE1 is the housekeeping isoform expressed in all 
tissues and is also considered the primary isoform in heart.  Recently NHE2 and NHE8 mRNA 
were shown to be expressed in mouse hearts [79]. However the role of these isoforms in heart is 
not known. NHE1 catalyzes the electroneutral exchange of extracellular sodium for intracellular 
protons in a 1:1 stoichiometry. NHE1 is activated by intracellular acidity and is involved in the 
regulation of [pH]i, [Na+]i, and cell volume. Human NHE1 contains 815 amino acids and has a 
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molecular mass of ~91 kDa. The 500 amino acid N-terminus comprising the membrane domain 
is involved in ion transport and pH sensing whereas the 315 aa C-terminal cytoplasmic region 
contains the regulatory domains. Based on topology analysis, Wakabayashi et al proposed a 12 
transmembrane model with cytoplasmic N- and C-terminus and a glycosylation residue (N75) 
located between TM I and II [80]. The C-terminal cytoplasmic region also has putative 
phosphorylation residues and binding sites for cytoplasmic interacting proteins. The structure of 
NHE1 is currently not known because of the difficulty in overexpressing and crystallizing 
membrane proteins.  
 
Disease phenotype and animal knockout models of NHE1 
 Since NHE1 is considered the housekeeping isoform expressed in all tissues, it was 
thought that loss of NHE1 in mice would be lethal. NHE1 KO mice survive through 
embryogenesis but exhibit reduced postnatal growth and also exhibit ataxia and epileptic seizures 
[81]. Various studies using inhibitors of NHE1 have demonstrated cardioprotective effects 
during ischemia-reperfusion (I/R) [82-89]. Studies performed with the isolated Langendorff heart 
from WT and NHE1 KO mice showed that genetic loss of NHE1 also protected against I/R 
injury [90].  
 Recently, a homozygous missense (Gly305Arg) mutation was identified in a large 
consanguineous family as the cause for Lichtenstein-Knorr syndrome [91]. This mutation 
(Gly305Arg) resulted in deglycosylation, mistargeting and loss of proton transport activity of 
NHE1. The patients with this mutation had cerebral ataxia and hearing loss [91]. However, no 
cardiac phenotype has been reported in patients with this syndrome.  
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Regulation of NHE1 
NHE1 is allosterically regulated by low intracellular pH. Hormones like endothelin-1 
[92], angiotensin II [93], α1-adrenergic agonists [94, 95] and growth factors have been shown to 
stimulate NHE1 mainly through a PKC mediated phosphorylation event [93]. MAPK-dependent 
phosphorylation and regulation of NHE1 has been demonstrated in rat myocardium [96]. 
Myocardial stretch, which is a stimulus for hypertrophy has been shown to activate NHE1 in 
feline papillary muscle through a mechanism that involves endothelin, angiotensin II and PKC 
[97]. Angiotensin II has also been shown to activate the full-length isoform of AE3 through a 
PKC dependent mechanism [39, 98] and combined activities of NHE1 and AE3 results in pH 
neutral sodium uptake, increase in intracellular calcium, and cardiac hypertrophy [5]. 
 
HVCN1  
Proton currents were identified in different species before the actual gene encoding the 
mammalian hydrogen voltage gated proton channel (HVCN1) was cloned. The human and 
murine gene that encodes the proton channel was cloned in 2006 [99, 100]. Proton channels have 
been identified in different cell types of various species and are perfectly selective for protons 
and mediate outward transport only [101]. The channel is activated by intracellular acidity, 
extracellular alkalinity and a positive membrane potential. RNA seq data revealed expression of 
HVCN1 mRNA in mouse heart (RPKM = 2.11 ± 0.13) (Table 1.1B). It is also expressed in other 
mammalian species and interestingly, in humans its expression was higher than that of NHE1. 
RNA seq data from the EBI expression atlas show that HVCN1 is ubiquitously expressed in all 
tissues and ENCODE cell lines.  
In phagocytes, proton channels regulate the activity of NAPDH oxidase by providing 
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charge compensation during the respiratory burst [102]. In neutrophils, which lack NADPH 
oxidase, HVCN1 is involved in histamine release [103, 104]. HVCN1 has also been shown to be 
involved in pH regulation in various other tissues including airway epithelial cells [105]. The 
expression of HVCN1 in hearts of all mammalian species suggest that it could have a potential 
role in cellular pH homeostasis in heart. The expression of HVCN1 protein was confirmed in 
ventricular tissue and activity in isolated myocytes (Dr. Hong Sheng Wang, unpublished results). 
HVCN1 has been proposed to be involved in CO2  elimination in alveolar epithelial cells [106] 
and as a potential mechanism along with AE3 for disposal of CO2 from cardiac myocytes 
(Vairamani K, manuscript under review).   
HVCN1 has homology to the voltage gated domain of Na+, Ca2+ and K+ channels but 
conducts only ~104 ions/s, unlike Na+ and K+ channels that conduct ~107 ions/s [107]. Moreover 
the proton channel does not have an aqueous pore for ions to conduct through like most ion 
channels [99, 100]. The protons  pass through the channel by a hydrogen bonded chain 
mechanism [108]. There is evidence that the proton channel exists as a dimer with a conduction 
pathway in each monomer [109, 110]. The two monomers interact during gating but do not 
conduct independently [111-114] 
 
Regulation of HVCN1 
 Phosphorylation of HVCN1 at a threonine residue (Thr29) by PKC has been shown to 
activate the channel in human leucocytes [115]. The divalent cation Zinc (Zn2+) is a potent 
inhibitor of HVCN1. Zn2+ binds to external surface of the channel and slows channel opening 
and shifts the voltage dependence positively. This indicates that in the presence of Zn2+ a much 
more positive membrane potential is required to activate the channel [116].  
 
18	  	  
Disease phenotype and animal knockout models for HVCN1 
 A naturally occurring missense mutation in HVCN1 was identified in the human 
population. This mutation resulted in the substitution of methionine at position 91 to threonine 
(M91T). The mutant protein required more alkaline extracellular pH than the wild-type protein in 
order for the channel to open [105]. Hvcn1-null mice have an enlarged spleen, autoantibodies 
and nephritis. The null mice also have a large number of T-cells, which is further enhanced upon 
viral infection, suggesting a role for Hvcn1 in T-cell homeostasis [117]. In a different study, the 
authors demonstrated that HVCN1-deficient mouse eosinophils failed to maintain membrane 
polarization and intracellular pH [118]. 
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Research plan 
 The function of bicarbonate transporters is well established in epithelial tissues, but little 
is known about their role in heart. AE3 is the most abundant Cl-/HCO3- exchanger in heart, but its 
physiological function is not clear. Three different functions have been proposed for AE3:1) 
Recovery from an alkaline load, 2) Facilitation of Na+ loading and Ca2+ loading, and 3) CO2 
disposal, also referred to as CO2 siphoning. The first two functions have been proposed for 
cardiac muscle, whereas CO2 disposal has been proposed for retina and neurons. 
 Regarding the hypothesis that AE3 mediates recovery from an alkaline load, studies in 
cardiac myocytes isolated from WT and AE3-null hearts, showed that AE3 mediates 60-70% of 
the HCO3- extrusion from cardiac myocytes [119]. Thus, it clearly has the potential to mediate 
recovery from an alkaline load. However, since the heart is a highly metabolic tissue generating 
huge amounts of metabolic acid, it is difficult to visualize a physiological or pathological 
condition, which would require recovery from an alkaline load. For example, pacing to higher 
heart rates revealed that AE3 mice have an impaired force-frequency response [38], but it is 
unlikely that the increase in heart rate, which should lead to increased generation of metabolic 
acid, would also lead to an increased alkaline load.   
 AE3 has been proposed to work in a coupled system with NHE1 to mediate pH neutral 
Na+ uptake and Ca2+ loading. The increase in intracellular calcium can enhance contractility and 
also activate hypertrophic signaling in heart [5]. The role of NHE1 in cardiac hypertrophy is well 
established. Sustained NHE1 activity is possible only when coupled with a HCO3- extrusion 
mechanism like Cl-/HCO3- exchange. In fact, studies in both spontaneously hypertensive rats and 
a transgenic model carrying an activated NHE1 have shown that increased NHE1 activity did not 
result in an increase in pHi in isolated myocytes maintained in bicarbonate buffer, but did 
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increase pHi when switched to HEPES buffer lacking bicarbonate [4, 5]. These results show that 
activation of NHE1 is accompanied by simultaneous activation of Cl-/HCO3- exchange [4, 5], 
which could allow a substantial increase in intracellular Na+ concentrations under pathological 
conditions. However, loss of AE3 had no effect on hypertrophy in the HCM model [37]. 
Moreover, no difference in Ca2+ transients was observed in AE3-null cardiac myocytes [38], 
suggesting that Na+ loading is not the major function of AE3 in heart.  
 In excitable tissues like retina and neuronal tissues, HCO3- extrusion by AE3 has been 
suggested to aid in CO2 disposal or siphoning [36, 120, 121]. However, the overall mechanism 
by which AE3 could mediate CO2 disposal, which would also require a parallel H+ extrusion 
mechanism, has not been identified.   
 The main goal of this dissertation research was to understand the functions of AE3 in 
heart. This was accomplished in part by inducing pressure overload hypertrophy in WT and 
AE3-null hearts (Chapter 4) to determine whether AE3 is required for cardiac hypertrophy. 
These experiments have a strong relevance to the Na+ loading hypothesis, as Na+ loading has 
been proposed to be strongly stimulated by AE3/NHE1-mediated Na+ loading and subsequent 
Ca2+ loading [119]. RNA seq Analysis of AE3-null and wild-type hearts was performed to 
analyze differential gene expression in great detail, in order to correlate the observed changes to 
the proposed functions of AE3 in heart (Chapter 5). Characterization of mice with a cardiac 
specific deletion of AE2 (Chapter 3), which has the potential to provide compensation for loss of 
AE3, and determining the role of NBCe1 in ischemia-reperfusion injury were also initiated as 
part of this dissertation research (Chapter 6). 
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Chapter 2: Materials and methods 
RNA Seq Analysis of Heart RNA  
Total RNA was isolated from hearts of 4-month-old FVB/N WT and AE3-null male mice 
(n = 4 of each genotype). Samples were subjected to RNA Seq analysis in the University of 
Cincinnati Genomics and Sequencing Core using the Illumina HiSeq 1000 platform. Sequence 
reads were aligned to the reference mouse genome using TopHat aligner [122]. Statistical 
analysis to identify differentially expressed genes was performed using the negative-binomial 
model of read counts as implemented in DESeq Biocondoctor package [123]. Most of the genes 
(80%) included in the figures had an FDR (False Discovery Rate) < 0.05, which is a measure of 
the probability of a false positive given the inclusion of over 22,000 genes in the analysis. Some 
genes with P < 0.01 and FDR > 0.05 were also included because they were in significantly 
enriched GO categories that were a major part of the phenotype (see Table 1 and legends for 
Online Files). Inclusion of significant genes that were also present in significant GO categories, 
which were derived from a small subset of genes, protected against exclusion of false negatives 
(discussed below). mRNA expression is presented as Reads Per Kilobase per Million mapped 
reads (RPKM), which normalizes for the size of the mRNA and provides a measure of relative 
transcript abundance.  Approximately 20 million reads were achieved per sample. 
Cardiac RNA Seq expression data for mammalian hearts and data for other tissues was obtained 
from the European Bioinformatics Institute (EBI) Expression Atlas 
(http://www.ebi.ac.uk/gxa/home). Heart data was for mRNA expression in hearts from both male 
and female Fisher 344 rats at 4 developmental stages [124] and from hearts of C57Bl6 mice, 
opossum, rhesus monkey, and human [125]. The latter study used a normalization procedure that 
allowed cross-species comparisons of genes.  
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Gene Ontology Analysis of mRNA Differential Expression data  
The online GOrilla program [126] (Gene Ontology enRIchment anaLysis and 
visuaLizAtion tool) was used for Gene Ontology analyses (http://cbl-gorilla.cs.technion.ac.il/). It 
can be accessed and used without registering and is self-explanatory and easy to use. Two 
analysis options were used: 1) Single Rank List in which the entire gene set was ranked 
according to P values and 2) Two Unranked Lists, in which a target list of genes with an FDR 
value or P value within a specified range was compared against the background list of all genes 
(over 22,000 total) to which reads were mapped in the experiment. 
Enrichment analysis for both options uses the hypergeometric distribution to calculate 
statistical probabilities [126]. The Single Rank option avoids setting an arbitrary cutoff of P 
values to be considered and was particularly useful for identifying GO categories that were 
highly enriched at the top end of the significance range for individual genes. When using the 
Single Rank analysis, all genes were ranked by P values and the distribution of genes in each GO 
category was used to calculate significance scores and enrichment of specific GO categories. 
When using the Two List analysis, significance and enrichment in each GO category is 
calculated based on the number of genes for specific GO categories appearing in the target list 
and background list. Enrichment (N, B, n, b) is defined as follows: N is the total number of 
genes, B is the total number of genes associated with a specific GO term, n is the number of 
genes in the top of the user′s input list or in the target set when appropriate, b is the number of 
genes in the intersection, Enrichment = (b/n)/(B/N). As shown in Figure 2.1, the program 
provides a visual display of hierarchically arranged GO categories, with large broad categories 
displayed at the top and smaller, more specific categories nested within one or more of the broad 
categories. In addition, the program provides a list of GO categories ranked by significance and a 
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list of the genes in each GO category, which can be shown or hidden. When performing GOrilla 
analysis, the genes were not separated into upregulated or downregulated genes since a given 
process might be affected positively (or negatively) by upregulation of some genes and 
downregulation of others. Significant GO categories were inspected, grouped by related 
functions, and a list of non-redundant genes for each broad category was prepared as described in 
the legends for Appendix 1-5. In some cases, particularly 1) Hypoxia, Vasodilation,  
 
Figure 2.1. Representative output from the Gorilla Gene Ontology (GO) program (Gene 
Ontology enrichment analysis and visualization tool; http://cbl-gorilla.cs.technion.ac.il). The 
program illustrates some of the nested GO Molecular Function categories obtained during 
analysis of genes that were significantly changed in AE3-null hearts.  
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Angiogenesis (Online Table 2) and 2) Energy Metabolism (Online Table 3), additional 
genes were included based on PubMed literature searches of genes with FDR < 0.05, which 
relied heavily on PubMatrix. Those searches can be publicly accessed as described below. 
 
PubMatrix Analysis  
Pubmatrix, an online literature search tool [127], was used to search PubMed to identify 
relevant publications describing the functions of specific genes in various biological processes 
(see Figure 2.2) such as hypoxia and metabolism (http://pubmatrix.grc.nia.nih.gov/). In each run, 
PubMatrix performs pairwise literature searches of up to 100 search terms and up to 10 modifier 
terms. The search terms corresponded to the 535 genes with an FDR < 0.05; for each gene, the 
gene symbol was grouped with common names for the gene. For example, search terms for the 
angiotensin II receptor, type 1 was: (Agtr1a or AT1a or Agtr1). The 535 genes with FDR < 0.05 
were grouped into 4 sets of upregulated genes (Sets 1-4) and 4 sets of downregulated genes (Sets 
5-8) and each set was searched against modifier terms for 1) Hypoxia and related processes 
[Modifier terms: (hypoxia or hypoxic), (HIF1 or Hif1alpha or Hif1a or Hif), (Egln3 or PHD3), 
(Epas or Hif2a), (Vegf or Vegfa), angiogenesis, vasodilation, vasoconstriction, (ischemia or 
ischemic), (heart or cardiac)] and 2) Energy Metabolism [Modifier terms: “energy metabolism”, 
“lipid metabolism”, “beta oxidation”, (mitochondria or mitochondrial), “glucose metabolism”, 
“glucose oxidation”, Glucose, Glycolysis, Ampk, AKT]. As illustrated in Figure 2.2, each set of 
searches is displayed on a grid that allows any pairwise search to be opened; the searches are 
stored and can be reopened at any time. The reader can access the searches performed here for 
Hypoxia and Metabolism genes (under Public Results, username Vair&Shull) by registering on 
PubMatrix. 
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Figure 2.2. Representative output from PubMatrix literature searches. Significantly 
changed genes (535 genes, FDR<0.05) were run against modifier terms for various aspects of 
energy metabolism as shown in the top panel. Each set of searches is displayed on a grid that 
allows any pairwise search to be opened. When a given search is opened, a listing of papers is 
provided by PubMed (bottom panel).   
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RNA isolation from whole heart, ventricles and cardiomyocytes 
Total RNA was isolated from RNA from whole heart, ventricles or isolated 
cardiomyocytes using Tri-reagent (Molecular Research Center, Cincinnati, OH). cDNA was 
prepared by random priming using Superscript III First-strand synthesis kit from Life 
Technologies.  
 
Quantitative real time PCR (qRT-PCR) 
qRT-PCR analysis to determine relative mRNA levels of differentially expressed was 
performed on an ABI 7300 Real Time PCR system according to the manufacturer recommended 
protocol using both SYBR green and TaqMan assays. TaqMan assays were purchased from Life 
Technologies. Assay IDs for the TaqMan assays and primer sequences for the SYBR green are 
shown in tables 2.2, 2.3, and 2.4. The ΔΔCt method was used to calculate relative expression of 
analyzed transcripts after normalization with Gapdh. Values are means ± SE and significance 
was determined by Student′s t-test. 
 
 
Table 2.1. TaqMan assays used for RTPCR 
Gene symbol Assay ID 
Chapter 5 
Gapdh Mm99999915_g1 
Adra1b  Mm00431685_m1 
Kcnj5 Mm01175829_m1 
Gja5  Mm00433619_s1 
Myl7 Mm01183005_g1 
Myl1 Mm00659043_m1 
Myot  Mm00498877_m1 
Agtr1a Mm01957722_s1 
Carns1 Mm01236521_m1 
Chapter 6 
Slc4a4 Mm01347935_m1 
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Table 2.2. 	  SYBR	  green	  primers	  used	  for	  RTPCR 
Primer Name        Primer Sequence 
Chapter 3 
GAPDH Forward  5'- AGGTCGGTGTGAACGGATTTG -3' 
GAPDH Reverse  5'- TGTAGACCATGTAGTTGAGGTCA -3' 
Hif1a Reverse  5'-CTGTTAGGCTGGGAAAAGTTAGG-3' 
Cirbp Forward  5'-GGACTCAGCTTCGACACCAAC-3'   
Cirbp Reverse   5'-ATGGCGTCCTTAGCGTCATC-3' 
Rbm3 Forward    5'-CTTCGTAGGAGGGCTCAACTT-3' 
Rbm3 Reverse 5'-CTCCCGGTCCTTGACAACAAC-3'  
Egln3 Forward 5' GGCTGGGCAAATACTATGTCAA 3'    
Egln3 Reverse 5'-GGTTGTCCACATGGCGAACA-3' 
Tbx5 Forward    5'-TTGGATGAGGTGGAGAGAGC-3' 
Tbx reverse 5'-ACACAGGATGTCTCGGATGC-3 
Adm Forward  5'-AACCAGCTTCATTCTGTGGC-3'  
Adm Reverse 5'-TGGACTTTGGGGTTTTGCTA-3'  
Slc26a6 Forward 5'-GTGGCGAACTTGGTTCCGAT-3'  
Slc26a6 Reverse 5'-AGCCATTCACGCACAGGATAC-3' 
Chapter 4 
GAPDH Forward  5'- AGGTCGGTGTGAACGGATTTG -3' 
GAPDH Reverse  5'- TGTAGACCATGTAGTTGAGGTCA -3' 
ANP Forward  5'-GCTTCCAGGCCATATTGGAG-3' 
ANP Reverse  5'-GGGGGCATGACCTCATCTT-3' 
Acta1 Forward  5'- CCCAAAGCTAACCGGGAGAAG-3' 
Acta1 Reverse  5'- CCAGAATCCAACACGATGCC-3' 
Myh7 (βMHC) Forward  5'-ACAACCCCTACGATTATGCGT-3' 
Myh7 (βMHC) Reverse  5'- ACGTCAAAGGGACTATCCGTG-3' 
Chapter 6 
Slc4a4 Forward 5'-TTCAGGCTCTCTCTGCGATT-3' 
Slc4a4 Reverse 5'- CTCAAGATGGTAAGCGGTTGA -3' 
Chapter 7 
GAPDH Forward  5'- AGGTCGGTGTGAACGGATTTG -3' 
GAPDH Reverse  5'- TGTAGACCATGTAGTTGAGGTCA -3' 
L-Type Ca2+ channel Forward  5'-ATGAAAACACGAGGATGTACGTT-3' 
L-Type Ca2+ channel Reverse 5'-ACTGACGGTAGAGATGGTTGC-3' 
PLN Forward  5'-AAGTGCAATAACTCACTCG-3' 
PLN Reverse  5'-GATCAGCAGCAGACATATC-3' 
PP1C Forward  5'-ATGTCCGACAGCGAGAAGC-3' 
PP1C Reverse  5'-ACAGCCGTAGAAGGTCATAGT-3' 
Camk2d Forward  5'-GATGGGGTAAAGGAGTCAACTG-3' 
Camk2d Reverse  5'-GCCCAATGCTTCAGGTTCAAAG-3' 
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Transverse aortic constriction (TAC) 
  Pressure overload hypertrophy was induced in 3-4 month old WT and AE3 KO male 
mice by transverse aortic constriction [128]. These studies were performed in the laboratory of 
Dr. John Lorenz [128]. Mice were anesthetized with isoflorane and intubated. The chest cavity 
opened and the aortic arch was located. A blunt 27-gauge needle was then placed beside to the 
aorta, and a 7-0 silk suture was tied around the aorta and needle between the brachiocephalic and 
left common carotid artery. The needle was then removed to generate the appropriate 
constriction. WT and KO sham operated mice underwent a similar surgery except that the aorta 
was not constricted. None of the TAC operated or sham mice dies during or post surgery.  
 
Echocardiography 
Transthoracic echocardiography for AE3-TAC studies (Chapter 4) was done using the 
iE33 Ultrasound System (Phillips, Andover, MA) equipped with a 15-MHz probe [129]. For 
NBCe1 I/R studies (Chapter 6). the Visual Sonics 2100 system with a 22-55MHz (MS-550D) 
microscan transducer was used. Mice were anesthetized with isofluorane and hearts were imaged 
in 2-D long-axis view. The systolic and diastolic dimensions and thickness of the anterior wall of 
the left ventricle (LV) were obtained from M-mode recordings. LV ejection fraction index (EF) 
was calculated using the formula: EF (%) = [left ventricular end-diastolic dimension (LVDd)3  
minus left ventricular end systolic dimension (LVDs)3/(LVDd)3×100. % fractional shortening 
(%FS) was calculated using the formula %FS= [(LVDd–LVDs)/LVDd]×100. All measurements 
were averaged over three consecutive cardiac cycles. 
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Measuring pressure gradients after TAC surgery 
At the end of 9 weeks and 17 weeks, the mice were anesthetized with a mixture of 
Ketamine and Inactin and their body temperatures were monitored with a rectal probe and 
maintained constantly at 37 ºC by using a thermally controlled surgical stage. The pressure in the 
right carotid and right femoral artery was measured using pressure transducers [128]. A high-
fidelity pressure transducer (Millar Instruments, Houston, TX) was used to measure pressure in 
the right carotid. This transducer was then advanced into the left ventricle to measure cardiac 
performance. 
 
Analysis of cardiovascular performance 
Cardiovascular performance was obtained from IVP measurements as described 
previously [130]. These studies were conducted in the laboratory of Dr John Lorenz of the 
Department of Cellular and Molecular Physiology for the AE2 conditional KO study (Chapter 5), 
AE3-TAC study (Chapter 4) and in the NBCe1 conditional KO study (Chapter 6) and FVB/N-
C57Bl/6 strain differences study (Chapter 7). The mice were anesthetized with a mixture of 
Ketamine and Inactin and their body temperatures were monitored with a rectal probe and 
maintained constantly at 37 ºC using a thermally controlled surgical stage. A high fidelity 
pressure transducer (Millar Instruments, Houston, TX) is then introduced into the left ventricle 
through the right carotid artery to measure left ventricular pressure. Another transducer in the 
femoral artery was used to measure mean arterial pressure. The IVP measurements is used to 
determine the heart rate (HR), contractility (+dP/dt), relaxation (-dP/dt), and left ventricular end 
diastolic pressure (LVEDP) under both basal conditions and in response to infusion of various 
doses of dobutamine (β-adrenergic receptor agonist) through the femoral vein. 
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Measurement of Heart Weight (HW) and Tibia Length (TL) to Body Weight (BW) Ratios 
Hearts were dissected immediately after IVP measurements. Heart to body weight ratios 
(HW/BW) were obtained by measuring the whole heart weight (in mg) after brief rinsing in PBS 
and trimming of extra tissues and dividing it by the body weight (in g).  Similarly, The left tibia 
was dissected and placed in 1M KOH solution for 48 hours to digest extraneous tissues. After 48 
hours the tibiae were rinsed with water and the length was measured (in mm). 
 
Genotyping of AE2 and NBCe1 mice 
Tails biopsies collected on day 15 were digested in 1X tail lysis buffer (10X tail lysis 
buffer-0.5M Tris pH8.5, 1M KCl, 2ml HCl in 100ml), 0.45% tween 20, 0.45% NP-40 and 
0.5µg/µl proteinase K overnight at 55°C. The digest was boiled for 10 min to inactivate 
proteinase K and used for PCR analysis using specific primers (Table 2.1). The PCR products 
are then run on an agarose gel  to determine the genotype of mice. 
Table 2.3. Genotyping primers 
Primer name  Primer sequence 
Slc4a2 Forward 5'-CAGTCCAAGGTCATGTTGTACC-3' 
Slc4a2 Reverse 5'-CCTCCCTCCTTGAAAAACTGC-3' 
Slc4a4 Forward  5'-TGGTGGCTTAAATTGCAAATGGC-3' 
Slc4a4 Reverse 5'-CATAACCCACTAAGTCCAGTACG-3' 
Cre Forward 5'-GGCGTTTTCTGAGCATACCT-3' 
Cre Reverse 5'-CTACACCAGAGACGGAAATCC-3' 
 
 
Cardiomyocyte isolation and RNA preparation 
Ventricular cardiomyocytes were isolated from 3-month-old adult mice hearts as 
described (reference Afcs protocol). Mice were anesthetized with isofluorane, hearts isolated and 
cannulated and mounted in a Langendorff apparatus. The hearts were then perfused with a 
31	  	  
modified Krebs-Henseleit Buffer (perfusion buffer) containing 113 mM NaCl, 4.7 mM KCl, 0.6 
mM KH2PO4, 1.2 mM MgSO4.7H2O, 10 mM NaHCO3, 10 mM HEPES, 30 mM taurine, 2,3 –
butanedione monoxime (BDM) and 5.5 mM glucose (pH 7.46) for 5 min at 37°C. The hearts 
were then perfused with digestion buffer (perfusion buffer with 0.25 mg/ml Liberase Blendzyme 
IV (Liberase DL, Roche, 0.14 mg/ml trypsin and 12.5 µM CaCl2 final concentration) for ~10-15 
minutes. When the hearts appeared flaccid and swollen, the ventricles were dissected and gently 
dispersed in 2.5 ml of digestion buffer using a plastic pipette. The isolated myocytes were then 
passed through a sieve to remove cell debris. The volume of the suspension was brought up to 5 
ml with perfusion buffer containing 10% bovine calf serum and 12.5 µM CaCl2 and the 
myocytes were allowed to settle by gravity for 15 minutes. The supernatant was gently removed 
and 1 ml of Tri Reagent was added to the pellet. The suspension was then homogenized using a 
Dounce glass homogenizer for 15-20 strokes. The suspension was rapidly frozen in liquid 
nitrogen and stored at -80°C for RNA isolation. 
 
Immunoblot analysis  
Mice were anesthetized with 2.5% Avertin (15 µl/g bodyweight) and allowed to stabilize 
on a heating pad. Hearts were dissected and placed in ice cold PBS, cleared of extraneous tissue 
and snap frozen in liquid nitrogen and stored at -80°C. Ventricular homogenates were prepared 
in 10 mM Tris-HCl (pH 7.4) buffer containing 1 mM EDTA, 2 mM DTT, 0.25% Nonidet P-40, 
0.5% Triton X-100, and inhibitors (Catalog numbers P8340 and P5726, Sigma, USA). The tissue 
was then homogenized on ice using a Brinkmann Polytron mechanical homogenizer (30sec at 
6500 rpm and 60 sec at 13000 rpm). Protein was estimated by Bradford assay (Thermo 
Scientific). The proteins were then separated by SDS-PAGE, transferred onto nirocellulose or 
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PVDF membranes and incubated with primary and secondary antibodies. Protein signals were 
detected using the KPL Lumi-Glochemiluminescent substrate system (KPL, Gaithersburg MD, 
USA). The primary antibodies used for different studies are: SERCA2a (catalog number ab2861, 
abcam, USA), PLN (catalog number MA3-922. ABR. USA), phospho-Ser16 and phospho-Thr17 
of PLN (catalog numbers A010-12 and A010-13, Badrilla, UK), NCX1 (catalog number R3F1, 
Swant, Switzerland), protein phosphatase 1 catalytic subunit (PP1) (catalog number MAB3000, 
R&D, USA), and the non-methylated form of protein phosphatase 2A catalytic subunit (PP2A) 
(catalog number 4957, Cell signalling, USA) were used as before [1] (Jbc 2008, Prasad). Total 
PP2A was analyzed after membranes were treated with ice-cold 0.2 N NaOH with gentle shaking 
for 5 minutes, followed by rinsing with cold Tris buffered saline containing Tween-20. The 
catalog number for NHE1 (MAB3140, Chemicon International, USA), L-type Ca2+ channel 
alpha2 subunit (catalog number MA3-921, ABR, USA), calmodulin-dependent kinase II 
(CamKII) (a pan-CamKII antibody that recognizes delta and other isoforms; Catalog number 
611292; BD Transduction Laboratories, USA), TnI and pTnI (Ser 23/24) (catalog numbers 4002 
and 4004, Cell signalling, USA), myosin binding protein-C (MyBP-C) (sc-67353, Santa Cruz 
Biotechnology); phosphor-ser282 MyBP-C (ALX-215, Alexis Biochemicals) and RyR2 (Catalog 
number MA3-916, Thermo Scientific, USA). For all blots, s-actin was used as loading controls 
(catalog number A2172, Sigma, USA) [1, 37].   
      
Ischemia-reperfusion surgery 
Ischemia –reperfusion (I/R) surgery was performed on 4-5 month old male mice. Mice 
were anesthetized with ketamine-inactin and were mechanically ventilated using a rodent 
ventilator (Model 845, Harvard Apparatus, South Natick, MA) connected to an endotracheal 
tube. The heart was then exposed by a left side limited thoracotomy and pass a 6-0 silk suture 
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underneath the left anterior descending artery (LAD) with a tapered needle [131]. A loose double 
knot was made with the suture and a 5 mm long piece of PE-10 tubing that is placed through the 
loop. The loop is tightened around the artery and the tubing (Ischemia). After 30 minutes, the 
knot was untied and the PE-10 tubing was removed. The chest cavity was closed with continuous 
sutures using 4-0 silk and the heart was reperfused for 3 hours before the heart was collected.    
 
Perfusion and fixation of heart tissue 
The mouse was euthanized by cervical dislocation and the chest cavity was opened to 
isolate the heart. The aorta was cannulated and perfused initially with PBS buffer containing 
Heparin (10 units Heparin per ml) followed by a modified Krebs-Henseleit buffer (pH 7.4) 
consisaining 110 mM NaCl, 16 mM KCl, 16 mM MgCl2, 1.2 mM CaCl2, and 10 mM NaHCO3. 
Finally, the isolated heart was perfused with 10% buffered formalin and left in 10% buffered 
formalin for 48 hours. The LV was sectioned into 3 parts (apical, mid and basal regions) and was 
taken to the pathology core at Cincinnati Children’s for embedding in paraffin blocks and 
sectioning. The sections were stained with Masson’s trichrome to determine fibrosis. Images 
were taken on a Olympus BX40 microscope mounted with a Nikon DS-Ri1 12 megapixel 
camera.   
 
TUNEL assay 
To observe cardiomyocyte death by apopotosis, In Situ Cell Death Detection Kit, TMR red from 
Roche was used. Sections were deparaffinized, hydrated and pretreated with proteinase K (20 
µg/ml in 10 mM tris/HCl, pH-7.4) for 30 minutes at 37°C. The sections were then incubated with 
the TUNEL mixture for 60 minutes at 37°C. The sections were rinsed with PBS and 
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counterstained with 1:200 dilution of α-Sarcomeric actin antibody  (Sigma, A2172) for 60 
minutes at 37°C. The section was then rinsed and stained with 1:200 dilution of Fluorescein 
(FITC) anti-mouse secondary antibody (Jackson immunoresearch, 115-095-146) for 60 minutes 
at 37°C.  The sections were then mounted with ProLong gold antifade moutant with DAPI from 
Life technologies. Images were taken under 40x objective on a Olympus BX41 microscope 
equipped with a digital camera and MagnaFireTM software.      
 
Statistics 
Values are presented as means ± standard error of the mean. Individual comparisons were made 
using two-tailed Student’s t-test, and a P-value < 0.05 was considered significant.  
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Chapter 3: RNA SEQ Analysis Indicates that the AE3 Cl-/HCO3- Exchanger is 
Involved in Active Transport-Mediated CO2 Disposal in Cardiac Myocytes  
Summary 
Mice lacking the AE3 (Slc4a3) Cl-/HCO3- exchanger appear normal and healthy but 
undergo rapid decompensation and heart failure when crossed with a hypertrophic 
cardiomyopathy model and have both an impaired force-frequency response and enhanced 
activation of Akt when subjected to atrial pacing. To understand the mechanisms by which loss 
of AE3 exacerbates heart disease and impairs contractility during pacing we performed RNA Seq 
analysis of mRNA from wild-type and AE3-null hearts. Gene Ontology and PubMatrix analyses 
revealed patterns of differentially expressed genes that were consistent with impaired O2/CO2 
balance in AE3-null myocytes. These included genes for proteins that directly regulate hypoxia 
responses and for proteins that enhance O2 delivery via vasodilation. However, angiogenesis 
genes were down-regulated, consistent with well-oxygenated non-myocyte tissue in heart. 
Differential expression of genes involved in energy metabolism, which indicated increased 
glucose utilization and decreased fatty acid utilization, and genes for ion transporter/channel 
activities and other functions were consistent with adaptive responses to perturbations of O2/CO2 
balance in AE3-null myocytes. Given that the myocardium is an obligate aerobic tissue and 
consumes large amounts of O2, the data suggest that loss of AE3, which has the potential to 
extrude CO2 in the form of HCO3-, impairs O2/CO2 balance in cardiac myocytes. These results 
challenge the notion that extrusion of CO2 from cardiac myocytes occurs by diffusion alone and 
support a model in which the AE3 Cl-/HCO3- exchanger, coupled with parallel Cl- and H+ 
extrusion mechanisms and extracellular carbonic anhydrase, is responsible for active transport-
mediated disposal of CO2. 
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Introduction 
Anion exchanger isoform 3 (AE3, gene symbol Slc4a3) is the most abundant Cl-/HCO3- 
exchanger in heart [2], but its physiological function is unclear. Mice lacking AE3 appear 
healthy and exhibit normal contractility under basal conditions [1]; however, when the AE3 
mutation was combined with a null mutation in the NKCC1 Na+-K+-2Cl- cotransporter, double 
mutants exhibited reduced contractility [1], and when combined with a Glu180Gly α-
tropomyosin mutation that causes hypertrophic cardiomyopathy, the double mutants exhibited 
rapid decompensation and heart failure[37]. Also, the loss of AE3 alone caused both a mild 
impairment of the force-frequency response and activation of Akt when hearts were paced to 
higher rates in vivo [38].  
Some of the above observations and other data [39, 98, 119, 132] are consistent with the 
hypothesis that AE3 coupled with a Na+/H+ exchanger contributes to Na+-loading, which in turn 
causes Ca2+-loading and affects both contractility and hypertrophy. However, the lack of an 
effect of AE3 ablation on Ca2+-transients in isolated myocytes [38] or on the degree of 
hypertrophy in a hypertrophic cardiomyopathy model [37] suggests that this is not its major 
function. A second hypothesis is that Cl-/HCO3- exchange facilitates recovery of cardiac 
myocytes from an alkaline load [133, 134]. AE3 mediates 60-70% of the maximum HCO3- 
extrusion activity in isolated myocytes [119], so it is clear that it could, in principle, perform this 
function. However, given the high rate of metabolism in the intact heart, with the accompanying 
generation of acid, it is difficult to envision physiological	  conditions in vivo that would require a 
major capacity for recovery from an alkaline load. For example, it would be difficult to propose 
that the heart failure phenotype [37], and particularly the impaired force-frequency response of 
AE3-null mice during pacing [38], might be due to an enhanced alkaline load. 
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In the current study we performed RNA Seq analysis of mRNA from wild-type and AE3-
null hearts. Our objective was to identify differential expression patterns that might provide 
insights about why the loss of AE3 causes an increased susceptibility to heart failure and an 
impaired force-frequency response. Among the more interesting patterns were changes in 
hypoxia, angiogenesis, and energy metabolism genes that seemed consistent with the possibility 
that AE3 plays a role in maintenance of O2/CO2 balance in cardiac myocytes. This is consistent 
with a third hypothesis, suggested for retinal and neuronal cells, that HCO3--extrusion via AE3 
could contribute to CO2 “siphoning” [121] or disposal [7, 36, 120]. Transport-mediated CO2 
disposal has strong precedents in secretory and absorptive epithelial tissues, which extrude 
massive quantities of CO2 in the form of HCO3- and H+ to facilitate transepithelial acid-base and 
electrolyte transport (discussed later). In addition, almost all of the CO2 expelled from the body 
goes through a phase in which it exits red blood cells in the form of HCO3- via the AE1 Cl-
/HCO3- exchanger. In the latter example, the accompanying protons are bound to hemoglobin 
until CO2 is reformed in the lung, whereas in the other tissues H+ is expelled by an appropriate 
H+ extrusion mechanism.  
Transport-mediated CO2 disposal in heart is an intriguing possibility as a recent study using 
cardiac myocytes showed that intracellular carbonic anhydrase facilitates CO2 venting from 
mitochondria by generating HCO3- and H+, with the latter buffered by high concentrations of 
histidyl dipeptides [135]. Furthermore, oxidative phosphorylation was reduced when CO2 
venting from mitochondria was impaired by carbonic anhydrase inhibition [135], indicating that 
the intracellular conversion of waste CO2 to HCO3- and H+ is critical for robust energy 
metabolism in cardiac myocytes. Finally, extracellular carbonic anhydrase is associated with 
AE3 [43], suggesting that HCO3- extruded by AE3 is combined with H+ extruded via some other 
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mechanism to form CO2 on the extracellular surface. These previous observations and the 
differential mRNA expression patterns in AE3-null hearts support the hypothesis that the major 
function of AE3 is CO2 disposal. Such a function would require an efficient H+ extrusion 
mechanism to accompany the extrusion of HCO3-. We propose a model in which this activity is 
provided by the HVCN1 voltage-gated H+ channel. 
 
Results and discussion  
RNA Seq analysis of WT and AE3-null hearts - RNA Seq analysis was used to determine 
differential mRNA expression patterns in hearts of WT and AE3-null mice. The expression 
changes were modest, but variability between samples of each genotype was remarkably low. 
The RNA Seq data were validated by quantitative PCR (Figure 3.1) of fifteen genes that were 
selected from the various categories discussed below. The PCR data exhibited greater variability, 
as expected, but provided strong validation of the RNA Seq data. 
Genes exhibiting expression changes were subjected to Gene Ontology (GO) analyses using 
the GOrilla program and clear patterns were identified. The GO categories included genes 
involved in hypoxia, angiogenesis, energy metabolism, ion/solute transport, and various cardiac 
functions and components (Table 3.1).  	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Figure 3.1. Validation of RNA Seq Data by Real-time PCR Analysis. Expression of selected 
genes that exhibited significant changes by RNA-Seq Analysis were analyzed by Quantitative 
RT-PCR and normalized to Gapdh expression. Among the 15 genes analyzed (n = 4 hearts of 
each genotype), all exhibited changes in the same direction as observed in RNA Seq analysis, 
and 12/15 genes were statistically significant at P < 0.05. P values for remaining 3 genes were: 
Kcnj5, 0.122; Myl1, 0.135; and Carns1, 0.116).  Black bars represent WT and white bars 
represent AE3-null. 	   	  
Egln3 Cirbp Tbx5 Rbm3 Hif1a 
Gja5 Adra1b Myl7 Kcnj5 Adm 
Slc26a6 Myot Carns1 Agtr1a Myl1 
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GO Category P-value Enrichment (N,B,n,b) 
Hypoxia/Angiogenesis/Vasodilation 
GO:0001525   Angiogenesis 8.08E-12 3.57 (21238,231,979,38) 
GO:0001666   Response to hypoxia 7.5E-05 2.71 (21238,152,979,19) 
GO:0019229   Regulation of vasoconstriction 6.51E-04 3.39 (21238,64,979,10) 
GO:0042312   Regulation of vasodilation 7.86E-04 3.96 (21238,44,979,8) 
Lipid/Carbohydrate metabolism 
GO:0006109   Regulation of carbohydrate metabolic  
                        process  2.74E-07 8.79 (21239,151,176,11) 
GO:0010906   Regulation of glucose metabolic    
                        process  6.16E-05 4.6 (21257,99,607,13) 
GO:0008286   Insulin receptor signaling pathway  8.09E-05 6.52 (21257,49,599,9) 
GO:0019216   Regulation of lipid metabolic process  1.11E-04 2.57 (21257,230,863,24) 
GO:0032868   Response to Insulin  4.36E-04 3.84 (21257,120,599,13) 
GO:0006110   Regulation of Glycolytic Process  3.48E-04 19.35 (21257,26,169,4) 
Cardiac conduction/Transporters/Channels 
GO:0008016   Regulation of heart contraction 3.76E-10 4.22 (21228,132,990,26) 
GO:0061337   Cardiac conduction 2.22E-08 8.42 (21228,28,990,11) 
GO:0002027   Regulation of heart rate 1.55E-08 5.21 (21228,70,990,17) 
GO:0006811   Ion transport 3.56E-06 1.67 (21239,1054,990,82) 
GO:0006813   Potassium ion transport 2.72E-05 2.82 (21239,152,990,20) 
GO:0086001   Cardiac muscle cell action   
                        potential 1.89E-07 7.95 (21239,27,990,10) 
GO:0051899   Membrane depolarization 1.59E-04 3.09 (21228,97,990,14) 
GO:0086015   SA node cell action potential 3.9E-04 16.09 (21239,4,990,3) 
GO:0086069   Bundle of His cell to Purkinje    
                        myocyte communication       4.9E-04 9.53 (21239,9,990,4) 
GO:0086067   AV node cell to bundle of His cell   
                         communication 9.41E-04 12.87 (21239,5,990,3) 
GO:0006816   Calcium ion transport 9.84E-04 2.17 (21239,198,990,20) 
Sarcomere/Z-disc/Cytoskeleton 
GO:0044449   Contractile fiber part 2.93E-14 4.57 (21238,166,979,35) 
GO:0032432   Actin filament bundle 3.06E-11 6.54 (21238,63,979,19) 
GO:0042641   Actomyosin 4.97E-09 5.59 (21238,66,979,17) 
GO:0030018   Z disc 8.18E-09 4.62 (21238,94,979,20) 
GO:0030315   T-tubule 2.19E-07 5.76 (21238,49,979,13) 
GO:0014704   Intercalated disc 3.71E-05 4.72 (21238,46,979,10) 
Table 3.1. Significantly enriched Gene Ontology (GO) categories. GO categories were 
identified using the GOrilla program [126]. (N, B, n, b) is defined as follows: N is the total 
number of genes, B is the total number of genes associated with a specific GO term, n is the 
number of genes in the target set, b is the number of genes in the intersection. Enrichment = 
(b/n)/(B/N). 
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Genes exhibiting highly significant changes (535 genes with FDR < 0.05; were subjected to 
PubMatrix analysis to identify additional genes associated with hypoxia responses, angiogenesis, 
energy metabolism, and other functions as indicated by GO analysis. These genes are included in 
Appendix 1-5, which list differentially expressed genes related to specific groups of GO 
categories discussed below. 
Expression changes indicate increased hypoxia response, vasodilation, and reduced 
angiogenesis - Some mRNA expression changes were consistent with mild hypoxia, while others 
were consistent with vasodilation and reduced angiogenesis (Figure 3.2; see Appendix 1 for full 
gene set). The changes indicating increased hypoxia but reduced angiogenesis initially seemed 
contradictory. As discussed below, however, these results are consistent with mild O2 deficiency 
in myocytes caused by impaired CO2 disposal. The apparent hypoxia response is not due to 
whole body hypoxia, as a recent study [136] using a global AE3-null mouse model showed that 
loss of AE3 caused no differences in respiratory function, systemic acid-base homeostasis, or 
blood gasses (O2, CO2) under either basal conditions or when subjected to alterations in O2 or 
CO2 levels.  
When considering the RNA Seq data, it should be noted that cardiac muscle is highly 
aerobic [137]. Thus, any hypoxia or O2/CO2 imbalance in myocytes of an otherwise non-
diseased heart is necessarily mild, unlike that occurring during ischemia or in tumors, and would 
be expected to elicit adaptive changes that should provide clues about the nature of the deficit. 	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Figure 3.2. Differential expression of genes involved in hypoxia responses, vasodilation, or 
angiogenesis. Genes relevant to hypoxia (A), vasodilation (B), or angiogenesis (C) were 
identified by Gene Ontology analyses and/or by PubMatrix analyses of genes with an FDR < 
0.05 as described in Supplemental Methods. RPKM (Reads Per Kilobase of Mapped Reads) 
values for WT (black bars) and AE3-null (white bars) hearts are shown. The genes shown here 
are a subset of 137 genes presented in Appendix 1; values are means ± SE; n = 4 for each 
genotype; *p < 0.01 vs WT.  
Genes involved in hypoxia responses A 
Hif1a! Epas1! Cirbp! Egln3!Rbm3! Sqstm1!
Usp20! Ncor2! Rcor2! Tbx5! Mitf! Thra!
Map2k6! Map3k7! Camk2g! Camk2d! Igfbp3! Ppp1r1b!
Adm! Ramp1 Mvri1! Rxfp1! Asb5!Nppa!
Genes involved in Vasodilation B 
Genes involved in Angiogenesis C 
Nrp2 VegfA Acvrl1 Kdr Eng Flt1 
Tfpi Pvr Notch1 Lrp5 Bmpr2 Eltd1 
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Expression changes indicating a hypoxia response (Figure 3.2A) included small increases in 
mRNAs for the transcription factors Hif1a and Epas1 (Hif2a), which play a central role in 
hypoxia responses [137-139], and larger changes for the RNA binding proteins Cirbp and 
Rbm3, which mediate Hif1a-independent hypoxia responses [140]. Also included were genes 
involved in direct regulation of hypoxia responses by a variety of mechanisms. Egln3 (prolyl 
hydroxylase 3), one of the most significantly down-regulated genes, contributes to O2-mediated 
degradation of Hif1a and other substrates [141]. Egln3 is normally upregulated in hypoxia, an 
apparent discrepancy; however, it is down-regulated in high altitude hypoxia [142]. This led to 
the suggestion that under mild hypoxia, in which O2 is available at sufficient levels to stimulate 
enzyme activity, reduced Egln3 expression would limit prolyl hydroxylase activity [142]. 
Sqstm1 (Sequestosome 1) is down-regulated by hypoxia and regulates metabolism and 
degradation of proteins, including Egln3 [143]. Upregulation of Usp20, a deubiquitinase that acts 
on Hif1a and other proteins [144], should reduce degradation of Hif1a. 
Downregulation of Ncor2, a transcriptional corepressor that inhibits Hif1a-mediated 
transcription [145], should enhance Hif1a activity. Additional hypoxia-related transcription 
factors were affected. These are Rcor2, a transcriptional corepressor that is a Hif1a target and 
upregulated by hypoxia [146]; Tbx5, a major cardiac transcription factor that is a Hif1a target 
[147], is upregulated by hypoxia [147], and works synergistically with Gata6 (a member of the 
response to hypoxia GO category, 1.15-fold increase, Online Table 2) to induce atrial natriuretic 
factor [148]. Mitf (microphthalmia associated transcription factor) and Thra (thyroid hormone 
receptor a) were increased and are known to upregulate Hif1a mRNA [149-151]. The effects of 
hypoxia on Mitf are complex as it appears to be down-regulated by Hif1a, a possible negative 
feedback mechanism in severe hypoxia [151].  
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Among major signaling proteins, Map2k6, which is involved in activation of Hif1a during 
hypoxia [152], and Map3k7, which is required for hypoxia-induced NF-kB activity [153], were 
both upregulated. Camk2g and Camk2d were upregulated; both genes are in the response to 
hypoxia GO category and it is known that Ca2+/calmodulin-dependent protein kinase II 
contributes to cardioprotection after intermittent hypoxia [154]. Igfbp3 (insulin-like growth 
factor-binding protein-3), a Hif1a target involved in many signaling pathways [155], was 
increased. Ppp1r1b, an inhibitory subunit of protein phosphatase 1 that is induced by hypoxia 
[156], was also upregulated. 
Changes indicating vasodilation (Figure 3.2B) included upregulation of Nppa (ANF, atrial 
natriuretic factor) and Adm (adrenomedullin), which are induced by hypoxia [157, 158]. Both 
proteins are secreted from myocytes and mediate vasodilation [159]. As noted above, both Tbx5 
and Gata6 are involved in ANF induction. Also included were upregulation of Ramp1, which 
can form part of an adrenomedulin receptor [160], and Mrvi1 (IRAG) and Rxfp1, which mediate 
smooth muscle relaxation in response to ANF [161] and relaxin [162], respectively. A change 
that could be a consequence of vasodilation is upregulation of Asb5; it is associated with 
arteriogenesis, which may be stimulated by shear stress resulting from increased blood flow 
[163]. The resulting growth of collateral arteries could further enhance blood flow. These 
expression changes, if they led to increased blood flow and O2 delivery, would provide some 
compensation for a mild hypoxia occurring in myocytes as a result of impaired CO2 disposal. 
Changes in angiogenesis genes (Figure 3.2C) included down-regulation of VegfA, its 
receptors Kdr and Flt1, and its coreceptor Nrp2 [164]. Eng (endoglin), Acvrl1 (ALK1), and 
Bmpr2, which interact and serve as receptors for bone morphogenetic proteins (BMPs) during 
angiogenesis [165] were also downregulated, along with other proteins (Notch1, Eltd1, Pvr 
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(Necl-5), Lrp5) with major roles in angiogenesis [166-169]. Tfpi, which was upregulated, serves 
as an inhibitor of angiogenesis [170]. These changes, which tended to be small, are consistent 
with reduced angiogenesis in AE3-null hearts. 
Reduced angiogenesis would likely be non-adaptive in a heart in which myocytes have 
impaired O2/CO2 balance. However, the overall pattern of changes is consistent with restriction 
of a primary deficit in O2/CO2 balance to AE3-null myocytes, which in turn secrete vasodilators 
such as ANP and adrenomedullin to increase blood flow. The increased oxygenation of the 
surrounding stromal tissue would be expected to lessen the degree of hypoxia in myocytes but 
would also reduce the stimulus for angiogenesis. There may, of course, be other explanations for 
the differential expression patterns shown in Figures 3.2A-C. Nevertheless, the observed patterns 
are consistent with impaired O2/CO2 balance. Among the functions proposed for AE3, these 
results appear to be consistent only with the CO2 disposal hypothesis. Other changes, discussed 
below, support this hypothesis.  
Expression changes indicate greater reliance on glucose for energy metabolism – If AE3-null 
myocytes do exhibit mild cellular hypoxia due to impaired CO2 disposal, one would predict 
changes in energy metabolism and substrate utilization to make the heart more efficient with 
respect to O2 utilization. 
Glycolysis and glucose oxidation are more efficient for ATP generation than fatty acid 
oxidation, and a reduction in the use of ATP and substrates for biosynthesis would allow	  greater 
utilization of ATP for contractile function. Changes in GO categories involving energy 
metabolism were highly significant (Table 3.1), with expression changes indicating increased 
glucose metabolism, reduced fatty acid metabolism, and reduced biosynthesis (Figure 3.3; see 
Appendix 2 for full gene set). 
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Among major regulators of energy metabolism (Figure 3.3A), Ppard (a member of the response 
to hypoxia GO category) and Pparg, transcription factors involved in fatty acid metabolism, 
were down- regulated. The expression of both Ppard and Pparg are reduced by hypoxia [171, 
172], consistent with a role for AE3 in maintenance of O2/CO2 balance. Prkag2 and Prkab1, 
regulatory subunits of AMPK, which plays a major role in energy sensing and energy 
metabolism [173], were up-regulated. In a previous study we showed that phosphorylation of 
Thr172 of the AMPK catalytic subunit was reduced in hearts of AE3-null mice subjected to atrial 
pacing [38]. This indicated a perturbation of AMPK activity that might have been due to chronic 
stimulation of Akt [174], which was more highly phosphorylated in paced AE3-null hearts [38]. 
Thus, alterations in AMPK regulatory subunits might serve a compensatory function. Ppip5k2 
(diphosphoinositol pentakisphosphate kinase 2, increased 1.38-fold) regulates inositol 
pyrophosphate metabolism and is an AMPK-independent energy sensor and regulator [175]. The 
hypoxia-responsive ATP-sensitive K+ channels, Abcc8 (Sur1, see Online Table 3) and Abcc9 
(Sur2), were upregulated. Both channels interact with Kcnj11 (Kir6.2, not changed), with Abcc8 
the predominant form in atria and Abcc9 the predominant form in ventricles [176]. Abcc9 
protects the heart against ischemia and both channels serve as metabolic sensors, couple energy 
metabolism and membrane excitability, play major roles in carbohydrate metabolism, and are 
induced by hypoxia [177, 178]. 	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Figure 3.3. Differential expression of genes involved in energy, glucose, and fatty acid 
metabolism. Genes relevant to regulation of energy metabolism (A), glucose metabolism (B), 
fatty acid metabolism (C), and regulation of ATP and substrate utilization (D) were identified by 
Gene Ontology analyses and/or by PubMatrix analyses of genes with an FDR < 0.05 as 
described in Experimental Procedures. In panel B, genes for glucose metabolism proteins that are 
regulated by Akt are indicated. RPKM values for WT (black bars) and AE3-null (white bars) 
hearts are shown. The genes shown here are a subset of 138 genes presented in Appendix 2; 
values are means ± SE; n = 4 for each genotype; *p < 0.01 vs WT.  
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Expression of genes for many proteins that stimulate glycolysis, glucose uptake, and 
glucose oxidation were increased. These include Hif1a and Thra (Figure 3.2), which play major 
roles in glucose metabolism [179, 180]. Changes in additional genes involved in glucose 
metabolism are shown in Fig. 3B. The α1-adrenergic receptor (Adra1b, 1.39-fold increase) is 
cardioprotective during myocardial infarction and ischemia in part because of enhanced glucose 
metabolism [181]. Many of the encoded proteins are affected by activation of Akt via 
phosphorylation of Ser473, which was significantly increased in AE3-null hearts subjected to 
atrial pacing [38]. For example, after myocardial infarction, signaling through the leptin receptor 
(Lepr) mediates cardioprotection and a shift from fatty acid to glucose metabolism in a process 
involving phosphatidylinositol 3-kinase/Akt signaling [182]. C2cd5 contributes to insertion of 
GLUT4 into the plasma membrane [183], Cd28 stimulates glucose uptake and glycolysis [184], 
and Ehbp1 is involved in insulin-regulated GLUT4 recycling and glucose transport [185], all in 
response to Akt activation. Smarcd3 is a transcriptional cofactor that drives glycolytic 
metabolism through a mechanism involving Akt [186].  Entpd5, a UDPase, is involved in Akt 
responses and has been shown to increase the catabolic efficiency of aerobic glycolysis in tumor 
cells [187]. Ptk2b (Pyk2 tyrosine kinase, focal adhesion kinase 2) mediates insulin-independent 
insertion of GLUT4 into the plasma membrane [188] and contributes to a1-adrenergic receptor-
mediated activation of Akt [189]. Tpk1 (thiamine pyrophosphokinase, 1.63-fold increase), 
generates thiamine pyrophosphate, a cofactor needed for oxidative decarboxylation of pyruvate 
and other substrates in mitochondria [190]. Upregulation of Pdp1 (pyruvate dehydrogenase 
phosphatase 1) would favor dephosphorylation and activation of pyruvate dehydrogenase, which 
would enhance pyruvate (glucose) oxidation	   [191]. Activation of Crhr2, the urocortin 2 
receptor, causes increased AMPK activation, glucose uptake, and phosphorylation of acetyl-CoA 
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carboxylase (which inhibits fatty acid biosynthesis) in cardiomyocytes [192]; cardioprotective 
effects of Crhr2 activation during ischemic injury include activation of phosphatidylinositol 3-
kinase/Akt signaling [193].  Gene knockout studies showed that loss of Tbc1d1 impairs insulin-
stimulated glucose uptake and increases fatty acid oxidation [194], so upregulation of Tbc1d1 
should favor a switch to glucose metabolism. All of these changes would likely increase 
utilization of glucose for energy metabolism. 
The ~60% increase in Akt phosphorylation observed in AE3-null hearts during pacing [38] 
and the upregulation of glucose metabolism genes that are known to respond to Akt signaling 
(indicated in Figure 3.3B), suggests that glucose metabolism is strongly stimulated in AE3-null 
hearts during acute biomechanical stress, when increased O2 utilization for energy metabolism 
would normally occur. If glucose metabolism is increased to improve the ATP/O2 ratio, a 
reduction in fatty acid metabolism would also be expected. 
Expression changes indicate a reduction in fatty acid metabolism - Reduced utilization of 
fatty acids for energy metabolism is suggested by reduced expression of the following genes 
(Figure 3.3C) Cd36, which mediates fatty acid uptake across the plasma membrane [195]; Tlr4, 
which interacts with Cd36 and stimulates fatty acid uptake [196]; Iqgap2, which also interacts 
with Cd36 and serves a signaling pathway that stimulates fatty acid uptake and processing [197]; 
Mgll, which hydrolyzes monoglycerides to produce fatty acids and glycerol for energy 
metabolism and biosynthetic processes [198]; and Acadl (long-chain acyl-CoA dehydrogenase), 
which is expressed at high levels and catalyzes the initial step of fatty acid b-oxidation. Acadl 
expression has been shown to be down-regulated by Hif1a in tumor cells [199]. Mid1ip1 
(Mig12, 1.22-fold) by itself or in a complex with Thrsp (Spot14, 0.77-fold) interacts with acetyl-
CoA carboxylase [200]; increased Mid1ip1 and decreased Thrsp expression leads to higher 
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acetyl-CoA carboxylase activity, which reduces β-oxidation of fatty acids [200]. Scd1 and Scd2 
(stearoyl-CoA desaturase 1 and 2) were both upregulated (1.74- and 1.36-fold), which would be 
expected to reduce fatty acid b-oxidation and improve glucose oxidation [201, 202]. Although an 
increase in stearoyl-CoA desaturase activity might be expected to increase lipid accumulation 
[202], reduced expression of Plin4 (perilipin 4) and Plin3 (in Online Table 3), which coat 
cytosolic lipid droplets [203], may reflect a reduction in storage of cytosolic lipids in 
cardiomyocytes due to reduced fatty acid uptake. Abcd2 (1.61-fold) transports very long chain 
acyl-CoA into peroxisomes and contributes to fatty acid degradation and to synthesis of 
docosahexaenoic acid (DHA) [204]. Hypoxia has been shown to increase the DHA content of 
lipid membranes in heart [205] and, along with eicosapentaenoic acid (EPA), DHA is protective 
in hypoxia-reoxygenation injury in cardiomyocytes [206]. Acsl1, the most abundant Acyl-CoA 
synthetase in heart, was slightly up-regulated (1.12-fold). This is one of the few examples of 
genes that changed in a direction opposite to what might have been expected. However, Acyl-
CoA synthetases activate fatty acids for both catabolic and anabolic processes, and the functions 
of individual isoforms (26 total, most of which were not changed) are not well understood [207]. 
Expression changes indicate reduced use of ATP and substrates for biosynthesis - The 
differential expression patterns involving energy metabolism indicated an increase in glucose 
metabolism and a decrease in fatty acid metabolism. These changes would be expected to 
improve the ATP/O2 ratio, thereby providing partial compensation for an O2/CO2 imbalance. 
Additional changes in metabolic genes would be expected to reduce the use of ATP and 
substrates for biosynthesis (Figure 3.3D). Reduced expression of Pcx (pyruvate carboxylase) 
would reduce the conversion of pyruvate to oxaloacetate [208] and the reduction in Ucp2 
(uncoupling protein 2, a member of the response to hypoxia GO category) would reduce the 
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transport of oxaloacetate and other 4-carbon intermediates out of the mitochondria [209]. Both 
changes would increase the use of pyruvate and other intermediates for oxidative 
phosphorylation and reduce their use in ATP-utilizing biosynthetic processes. Reduced 
expression of Mlxipl (ChREBP), which regulates glycolysis and fatty acid synthesis, would also 
be expected to reduce the use of glucose metabolites for biosynthesis [210]. Two genes involved 
in glycolysis, Pgam1 (phosphoglycerate mutase 1) and Pfkfb2 (6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 2), were down-regulated. The substrates and products (2-
phosphoglycerate, 3-phosphoglycerate, and fructose 2,6-bisphosphate) of the enzymes encoded 
by these genes serve regulatory functions in glycolysis [211, 212]. Pgam1 is upregulated in 
cancer cells and stimulates the use of glycolytic intermediates for biosynthesis [212]. Increased 
expression of Eef2k (eukaryotic elongation factor-2 kinase, 1.31-fold), which reduces 
consumption of energy by inhibiting protein synthesis during O2 deficiency [213], would also 
conserve ATP for contractile function. A reduction in use of ATP and substrates for biosynthesis 
is consistent with the observation that AE3-null mice have smaller hearts than WT mice [1, 119]. 
Expression changes in genes involved in membrane excitability and cardiac conduction – 
One of the most striking differences between WT and AE3-null hearts was altered expression of 
genes encoding Na+, Ca+, and K+ channels and other proteins in GO categories dealing with heart 
rate, membrane excitability, and cardiac conduction (Table 3.1). These changes suggest that loss 
of AE3 leads to remodeling of cardiac electrical systems. 
Relevant genes discussed in this section are shown in Figure 3.4 (see Appendix 3 for the 
full gene set). In addition, appendix 4 includes all transporters, pumps, and channels that were 
significantly changed. Although many of these will not be discussed in detail here, some have 
the potential to affect conduction and electrical properties, as well as Na+-loading and Ca2+-
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loading discussed later. For example, Na/Ca/K exchangers of the Slc24a family are expressed at 
relatively low levels but their combined expression is ~20% of the levels of the NCX1 Na/Ca 
exchanger (Slc8a1) and both Slc24a2 and Slc24a4 were upregulated (1.51- and 2.0-fold). 
 
 
Figure 3.4. Differential expression of genes involved in membrane excitability and cardiac 
conduction. Genes relevant to these categories were identified by Gene Ontology analyses. 
RPKM values for WT (black bars) and AE3-null (white bars) hearts are shown. The genes shown 
here are a subset of 104 genes presented in Appendix 3; values are means ± SE; n = 4 for each 
genotype; *p < 0.01 vs WT controls. 
 
The Na+/K+-ATPase a4 subunit (Atp1a4), expressed at ~5% of the levels of the α2 subunit 
(Atp1a2), was downregulated (0.83-fold, similar to Atp1a2 at 0.91-fold). Although they are 
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expressed at low levels and cardiac expression has not been shown previously, if these genes 
were expressed in conductive tissue, they could play important roles.      
Among the voltage-sensitive sodium channels, Scn5a (Nav1.5) and Scn10a (Nav1.8) were 
upregulated and Scn1b and Scn4b regulatory beta subunits were downregulated (Figure 3.4). 
Scn5a is the primary Na+ channel responsible for depolarization in atria, ventricles, and the 
conduction system [214]. Scn10a, expressed at much lower levels, has been reported in the 
conduction system [214]. Among voltage-sensitive Ca2+ channels, there was no change in 
expression of Cacna1c (Cav1.2; L-type a1C), the major Ca2+ channel in heart (RPKM = 45 in 
both genotypes). Cacna2d2 (L-type a2/d2 auxiliary subunit), Cacna1d (Cav1.3; L-type a1d), and 
Cacna1g (Cav3.1; T-type a1G) were upregulated. Cacna2d2 is expressed in atria [215], and 
Cacna1d and Cacna1g are expressed in pacemaking cells [216, 217]. Cacna1s (Cav1.1; L-type 
a1S), the major skeletal muscle Ca2+ channel, was present at relatively low levels and was 
downregulated. 
Most of the affected K+ channel genes were upregulated. In addition to the KATP channels 
(Abcc8 and Abcc9) discussed above, these included Hcn4, a hyperpolarization-activated cyclic 
nucleotide-gated K+ channel expressed in the sinoatrial node [218]; Kcnd2 (Kv4.2; a member of 
the response to hypoxia GO category) and Kcna4 (Kv1.4), which mediate transient outward 
currents during the initial phase of depolarization [214]; Kcnh2 (Kv11.1, ERG1), which is a 
major long QT syndrome gene; Kcnj3 and Kcnj5, which are activated by acetylcholine and 
affect the atrial action potential and pacing [214, 219]; and Kcnn2, a Ca2+-activated K+ channel 
that functions in the atrioventricular node [220]. The modulatory subunit Kcne4 can associate 
with Kcnq1 (Kv7.1, 1.13-fold, p = 0.023) and inhibit its activity [221], suggesting that reduced 
expression could increase Kcnq1 activity in the later phase of repolarization. Kcne1 (minK), a 
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modulatory subunit that associates with Kcnq1 and is a member of the cardiac conduction GO 
category, was upregulated; loss or mutations in Kcne1 leads to pacing-induced ventricular 
arrhythmias or long QT syndrome [222]. Kcnj4 (Kir2.3), an inwardly rectifying channel that 
operates in the final phases of repolarization and helps set the resting membrane potential [214], 
was the only major K+ channel that was downregulated. 
Additional upregulated genes with prominent functions in electrical excitability and 
conduction were Gja1, Gja5, Dsc2, Dsg2, Hopx, and Popdc2. All were members of one or 
more GO categories involved in cardiac conduction (Table 3.1). Gja1 and Gja5 (connexins 43 
and 40) are gap junction proteins that function in electrical coupling for propagation of the 
depolarizing current [223]. Dsc2 (desmocollin 2) and Dsg2 (desmoglein 2) are components of 
the cell junction; they are required for mechanical coupling of cardiac myocytes, and particularly 
those of the conduction system, where mutations in desmosomal proteins are known to cause 
arrhythmias [224]. Hopx is a transcription factor that is essential for the development and 
maintenance of the conduction system [225]. Popdc2 is a popeye domain-containing protein that 
plays a critical role in the pacemaking and conduction system, possibly by increasing expression 
of certain K+ channels at the sarcolemma [226]. 
The above results suggest that AE3-null myocytes have altered electrical properties and that 
conductive tissue is particularly affected. It is known that many ion channels are affected by 
hypoxia [227, 228]. Furthermore, hypoxia has a strong effect on the action potential and is 
known to cause atrial fibrillation [229]. Thus, the expression changes likely represent an adaptive 
response to impaired O2/CO2 balance rather than a pathological response to the loss of AE3.  
Expression changes in genes encoding sarcomere and sarcomeric cytoskeletal proteins – 
Differentially expressed genes encoding myofibrillar proteins localized to the sarcomere,	   M-
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band, Z-discs, t-tubules, and intercalated discs are shown in Figure 3.5; see Appendix 5 for full 
gene set. These changes suggest that the loss of AE3 leads to remodeling of the myofibrillar 
apparatus. 
 
 
Figure 3.5. Differential expression of genes encoding sarcomere and sarcomeric 
cytoskeletal proteins. Genes relevant to these categories were identified by Gene Ontology 
analyses. RPKM values for WT (black bars) and AE3-null (white bars) hearts are shown. The 
genes shown are a subset of 116 genes presented in Appendix 5. Values are means ± SE; n = 4 
for each genotype; *p < 0.01 vs WT,   
 
Among the myosin chains [230], the atrial myosin essential and regulatory light chains 
(Myl4 and Myl7) were upregulated, but the corresponding ventricular light chains (Myl3 and 
Myl2) were not changed, suggesting that the atria were more affected than the ventricles by loss 
of AE3. Myl12a and Myl12b were both down-regulated. They are thought to serve as non-
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muscle myosin regulatory light chains [231]; however, each isoform is expressed at about half 
the levels of the atrial regulatory myosin light chain, suggesting an important function in heart. 
Mybphl (myosin binding protein H-like; 1.33-fold) has not been studied in heart, however, it is 
expressed at much higher levels than the closely related myosin binding protein H (Mybph), a 
skeletal muscle protein that has been identified in cardiac purkinje fibers [232]. The relatively 
high Mybphl levels and high similarity to the titin-binding domain of cardiac myosin binding 
protein C (data not shown) suggest that it is likely to be a titin-binding protein and play a 
significant role in heart. Myl1, the skeletal muscle myosin essential light chain, was sharply 
downregulated (0.22-fold) and Acta1, skeletal muscle actin, was also reduced (0.37-fold); 
although they are expressed at only low levels relative to the cardiac isoforms, their 
downregulation suggests significant remodeling of the myofibrils. In contrast to the myosin light 
chains, expression of cardiac myosin heavy chains was not changed. 
A number of differentially expressed mRNAs encode proteins that localize to the M-band. 
These include Myom2 (myomesin 2, 1.32-fold; Myom1 was not changed), which crosslinks 
myosin heavy chains [233], and both Obscn (obscurin) and Obsl1 (obscurin-like 1), which are 
downregulated and are targeted to the M-band by interactions with titin and myomesin [234]. 
Obscurin is necessary for localization of Ank2 (Ankyrin B, 1.10-fold) to the M-band, where 
Ank2 helps organize costameres and subsarcolemma microtubules [235]. Lrrc39 (Momasp, 
Myosin interacting, M-band-associated stress-responsive protein; 1.21-fold) interacts with 
myosin heavy chains, is localized to the M-band, and regulates gene expression in response to 
biomechanical stress [236]. These M-band proteins may function in mechanical stress sensing 
[237] and modulation of passive force by titin. 
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mRNAs for some Z-disc proteins were also differentially expressed. Myot (myotilin), a Z-
disc protein that can localize to the M-band under some conditions, was sharply downregulated. 
It has been suggested to function in myofibrillar assembly [238], although targeted deletion of 
Myot had no effect on contractility or muscle mass, possibly due to compensation by Tcap and 
other Z-disc proteins [239]. Tcap (titin-cap, 1.41-fold) is a Z-disc, titin-interacting protein that, 
among other functions, links t-tubules and myofibrils through its interaction with Kcne1 [240], a 
K+ channel β subunit discussed above. Nebl (nebulette), the smaller cardiac isoform of nebulin 
that interacts with various myofibrillar proteins, was upregulated. Interaction of Nebl with 
tropomyosin is important for thin filament stability in cardiac muscle [241]. Mypn 
(myopalladin) a multifunctional protein with many interacting partners, was downregulated. 
Interaction of Mypn with nebulette is necessary for Z-disc assembly, and its interactions with 
CARP (cardiac ankyrin repeat protein, Ankrd1) regulate muscle gene expression [242]. Palld 
(palladin), which is related to myotilin and myopalladin, was upregulated; it binds actin and a-
actinin, and is expressed in Z-discs, focal adhesions, and other structures, where it may function 
as a molecular scaffold [243]. Lims2 (Pinch2, 0.78-fold) localizes to Z-discs and focal adhesions 
[244] and appears to be important in organization of intercalated discs and costameres and in 
signaling through integrin linked kinase and Akt [245]. Xirp2, which was downregulated, 
interacts with nebulette in the mature Z-disc and in developing myofibrils, and was proposed to 
function in myofibril development and remodeling [246]. Targeted deletion of Xirp2 also leads 
to defects in the development and maturation of intercalated discs [247]. 
Jph2 (junctophilin 2, 0.87-fold) is a structural protein that connects the t-tubule to the 
sarcoplasmic reticulum by positioning the L-type calcium channel and ryanodine receptor. 
Cardiac specific knockdown of Jph2 in mice resulted in development of heart failure and	  reduced 
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Ca2+-induced Ca2+ release from the SR by regulating Ryr2 [248]. Ankyrin B, discussed above, 
also plays an important role in positioning of transporters and channels [249]. Fhl1 and Fhl2 
(four-and-a half LIM-only proteins 1 and 2; both decreased) and Ankrd23 (DARP, diabetes-
related ankyrin-repeat protein; 0.65-fold) interact with titin, have been proposed to be involved 
in stretch sensing, and all 3 proteins can relocalize to the nucleus to affect transcription [250]. 
Fhl1 localizes to both the Z-disc/I-band and M-band regions, interacts with myosin-binding 
protein C, and regulates sarcomere assembly [251]. Fhl2 also localizes to the I-band and M-band 
and is involved in the recruitment of metabolic enzymes to titin [252]. When Cryab (aB-
crystallin, 0.80-fold) binds to titin in the I-band region, it increases passive tension [253], 
suggesting that its reduced expression may reduce tension. 
Unlike some of the genes discussed earlier, it is more difficult to relate the changes in 
myofibrillar genes to deficits in CO2 disposal and O2 utilization. However, after translocation to 
the nucleus, both Fhl1 and Fhl2 inhibit Hif1a-mediated transcription [254, 255], suggesting that 
reduced expression may increase transcription of Hif1a-regulated genes. Sqstm1, mentioned 
earlier for its role in hypoxia responses (Figure 3.2A), interacts with Nbr1 at the protein kinase 
domain of titin [256]. A possible function of the changes in some of the titin-binding proteins, 
including the reduction in aB-crystallin mentioned above [253], is to reduce passive tension. 
Phosphorylation of titin by PKA following b-adrenergic stimulation was shown to reduce passive 
tension [257] and the authors speculated that this allows more rapid and complete ventricular 
filling. A reduction in passive tension/stiffness may allow maintenance of appropriate cardiac 
output, despite reduced O2 utilization. Regarding myocardial stiffness, expression of Col4a1 and 
Col4a2, the most highly expressed collagens in heart, was reduced (0.78- and 0.79-fold, 
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respectively). Reduced expression of these basement membrane collagens, produced by 
cardiomyocytes [258], may reduce myocardial stiffness. 
Expression changes in other genes with potential for adaptation in AE3-null hearts – When 
AE3-null mice were subjected to atrial pacing a contractility defect was observed and 
phosphorylation of Akt was increased [38]. Because Akt mediates biomechanical stress signaling 
at costameres and enhances contractility [174], it seemed likely that the increase in 
phosphorylation was a compensatory mechanism to increase contractility under stress conditions, 
which it does in part by stimulating the use of glucose for energy metabolism [174]. If energy 
metabolism is altered to adapt to perturbations of O2/CO2 balance, one might expect additional 
expression changes to improve contractility, the efficiency of O2 utilization, HCO3- handling, and 
pH regulation. Relevant genes discussed in this section are shown in Figure 3.6. 	  
	  
Figure 3.6. Differential expression of genes with potential for adaptation via Na+-loading, 
O2 utilization, and acid-base handling. RPKM values for WT (black bars) and AE3-null (white 
bars) hearts are shown. Agtra1, Nr3c2, and Egf contribute to increased contractility via Na+-
loading and Hspb2 and Sfrp5 affect work efficiency and O2 utilization; these genes are also 
included among metabolism genes (Appendix 2). The other genes are affected by or involved in 
acid-base metabolism. Values are means ± SE; n = 4 for each genotype; *p < 0.01 vs WT, except 
Car14 (P < 0.02). 
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Several genes for proteins that affect contractility by increasing Na+-loading and Ca2+-
loading were upregulated. These included Agtr1a (angiotensin receptor 1a, 1.76-fold), Nr3c2 
(mineralocorticoid receptor, 1.57-fold), and Egf (epidermal growth factor, 1.52-fold). Activation 
of Agtr1a [259] and treatment with Egf [260] stimulates contractility in cardiac myocytes and 
isolated hearts. Increased contractility in response to myocardial stretch (Anrep effect), which 
should be activated during pacing, requires angiotensin, mineralocorticoid, and Egf receptor 
activities [261], along with that of the downstream effector NHE1, which was upregulated at the 
protein level [38]. Because activation of this pathway increases contractility via Na+- and Ca2+-
loading [262], these expression changes support the view that one function of AE3 is to enhance 
Na+-loading by coupling Cl-/HCO3- exchange and NHE1-mediated Na+/H+ exchange. Such a 
coupled system, by extruding both HCO3- and H+, would also contribute to CO2 disposal. It 
would not, however, provide charge and ion balance and would therefore necessitate additional 
expenditure of ATP, with additional consumption of O2. 
Regarding O2 utilization, Hspb2 (1.17-fold) is a small heat shock protein that dramatically 
increases the efficiency of coupling between ATP hydrolysis and contractile work [263]. When 
challenged with b-adrenergic stimulation, mice lacking Hspb2 hydrolyzed more ATP but 
performed less work [263]. Thus, upregulation of Hspb2 should provide better protection of 
energy reserves and improved contractility in response to b-adrenergic stimulation and other 
stress conditions. By utilizing less ATP for a given amount of work, it should allow the AE3-null 
heart to more efficiently utilize available O2. Oxygen utilization may also be reduced by 
upregulation of Sfrp5 (1.85-fold), a WNT inhibitor that suppresses O2 consumption by 
mitochondria [264].  
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A change that might be related to impaired HCO3- homeostasis is upregulation of Myoc 
(myocilin). Myocilin associates with syntrophins in the dystrophin protein complex, a 
component of costameres, stimulates Akt signaling, and is a member of GO:0014066, Regulation 
of Phosphatidylinositol 3-Kinase Signaling. Processing and secretion of myocilin is affected by 
extracellular pH and HCO3- concentrations [265], which could be affected by loss of AE3.  
 
Slc4a4 (NBCe1 Na+/HCO3- cotransporter), the major mechanism of HCO3--uptake in 
cardiomyocytes [2, 266] was downregulated, and Slc26a6 (Pat1 anion exchanger), which 
mediates Cl-/HCO3- exchange, along with Cl-/OH- and Cl-/formate exchange [48], was 
upregulated. Reductions in NBCe1 protein and mRNA expression in AE3-null hearts were 
reported previously, but an increase in Slc26a6 mRNA was not observed [38]. Additional RT-
PCR analysis, however, confirmed upregulation of Slc26a6 (Figure 3.1). Expression of the AE2 
Cl-/HCO3- exchanger (Slc4a2) was not significantly changed (RPKM = 12.6 ± 0.6, WT; 13.5 ± 
0.9, KO), and AE1 (Slc4a1) was expressed at very low levels in adult mouse heart [38]. RPKM 
values for the 3 major Cl-/HCO3- exchangers indicate that the combined transcript abundance for 
AE2 and Slc26a6 is ~20% of that of AE3. These data are consistent with studies showing that 
WT cardiomyocytes have ~3 times the HCO3- extrusion capacity of AE3-null myocytes [119]. 
Thus, AE3 is the major cardiac Cl-/HCO3- exchanger in mouse, and expression data suggest that 
this is also true for other mammalian species (discussed below). Nevertheless, the other 
Cl-/HCO3- exchangers have the capacity to provide some compensation for the loss of AE3-
mediated HCO3- extrusion. Additional compensation for the proposed CO2 disposal function 
could occur via a reduction in NBCe1-mediated HCO3--uptake (but see additional discussion at 
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end of this section) and increased CO2 diffusion, particularly from subsarcolemmal 
mitochondria, which undoubtedly contributes to CO2 disposal. 
Carbonic anhydrases play critical roles in cellular acid-base homeostasis. Car14, the most 
abundant carbonic anhydrase in mouse heart, was upregulated (Figure 3.6; see Table 3.2 for 
expression levels of all CA isoforms). Car14 is associated with the sarcoplasmic reticulum and 
colocalizes with mitochondria, where it facilitates CO2 venting [135]. Car14 binds to AE3 on the 
extracellular surface of mouse cardiomyocytes, where it catalyzes the conversion of HCO3- 
extruded by AE3 and H+ extruded by some other mechanism (see model below) to CO2 [43]. 
Car14 also associates with AE3 in retina and brain [120]. Car14 mRNA was increased in neurons 
of AE3-null mice [267], consistent with a deficit in CO2 disposal in AE3-null neurons. This 
could be related to the epilepsy phenotype in AE3-null mice [35] and in humans with a 
heterozygous AE3 mutation [34], as hypoxia can contribute to epilepsy [268]. Although 
mitochondrial CA is expressed at very low levels in heart [135], Car5b, a mitochondrial CA 
isoform, was significantly increased (Table 3.2). This change is consistent with a perturbation of 
CO2 venting from mitochondria. This would be expected if disposal of HCO3- were impaired, 
since a reduction in its transport-mediated removal from the cell (as a result of AE3 ablation) 
would shift the equilibrium toward a reduction in hydration of CO2 venting from the 
mitochondria, which in turn would both increase cytosolic CO2 and impair metabolism. 
One of the most interesting changes was upregulation of Carns1 (carnosine synthase 1, 
1.38-fold), which is involved in synthesis of carnosine, homocarnosine, and anserine [269]. 
These histidyl dipeptides are present at very high levels in cardiac muscle, serve as a major 
intracellular buffer, and would be essential for efficient venting of CO2 from mitochondria [135]. 
Upregulation of Carns1 mRNA and NHE1 protein [38] suggests increased demand for both 
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buffering of intracellular H+ via histidyl dipeptides and H+ extrusion via NHE1. This indicates 
that a deficit in HCO3- disposal causes a parallel deficit in H+ disposal. These expression changes 
are not consistent with the hypothesis that the function of AE3 is to counter an alkaline load but 
are consistent with transport-mediated CO2 disposal. 	  
Gene 
Symbol Description 
WT 
(Mean ± SE) 
KO 
(Mean ± 
SE) 
Fold 
Change P-value 
Car1# Carbonic anhydrase 1 0 0 n/a n/a 
Car2 Carbonic anhydrase 2 3.47 ± 0.10 3.43 ± 0.17 0.97 0.99 
Car3 Carbonic anhydrase 3   12.89 ± 1.16 14.96 ± 3.24 1.14 0.88 
Car4 Carbonic anhydrase 4 10.59 ± 0.81 9.75 ± 0.61 0.91 0.28 
Car5a# Carbonic anhydrase 5a 0.01 ± 0.01 0.03 ± 0.02 n/a n/a 
Car5b Carbonic anhydrase 5b 0.40 ± 0.07 0.64 ± 0.02 1.60 0.01 
Car6# Carbonic anhydrase 6 0 0.01 ± 0.01 n/a n/a 
Car7 Carbonic anhydrase 7 3.54 ± 0.50 4.42 ± 0.12 1.23 0.14 
Car8 Carbonic anhydrase 8 3.16 ± 0.18 3.54 ± 0.21 1.10 0.12 
Car9 Carbonic anhydrase 9 0.48 ± 0.06 0.46 ± 0.02 0.94 0.80 
Car10# Carbonic anhydrase 10 0.01 ± 0.01 0.01 ± 0.01 n/a n/a 
Car11 Carbonic anhydrase 11 3.39 ± 0.35 3.74 ± 0.13 1.09 0.63 
Car12 Carbonic anhydrase 12 0.01 ± 0.01 0.02 ± 0.01 n/a n/a 
Car13 Carbonic anhydrase 13 0.63 ± 0.11 0.64 ± 0.08 1.02 0.95 
Car14 Carbonic anhydrase 14   75.2 ± 3.03 85.7 ± 3.67 1.13 0.02 
Car15 Carbonic anhydrase 15 1.19 ± 0.16 1.39 ± 0.13 1.15 0.59 
	  
Table 3.2. Expression Levels of Carbonic Anhydrase (CA) mRNAs in Heart. mRNA 
expression levels (RPKM values) of all CA isoforms in WT and AE3-null (KO) heart are shown, 
with fold-change and P-values. Car1, Car5a, Car6, Car10, and Car12 had no transcripts in one or 
more samples of both WT and KO samples (n = 4 of each genotype), and are therefore 
considered not expressed in FVB/N mouse heart (n/a, not applicable). 
 
If loss of AE3 does not cause an increased alkaline load, why would NBCe1 mRNA and 
protein [38] be reduced? One possibility is that cardiac myocytes require an optimum 
concentration of HCO3-, which is a major intracellular anion and buffer. If HCO3- extrusion is 
reduced by loss of AE3, maintenance of appropriate HCO3- concentrations might be facilitated 
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by a reduction in NBCe1. HCO3- has a dramatic stimulatory effect on contractility in both 
isolated myocytes [2] and in isolated hearts [2, 270]; the effect of HCO3- on contractility is 
independent of intracellular Ca2+, which is unaffected by switching between buffers containing 
HEPES and HCO3- [2, 270]. This suggests that physiological HCO3- levels,	   which could be	  
tightly regulated by both extrusion and loading mechanisms are required for normal contractility. 
Coordinated extrusion of HCO3- and H+ coupled with extracellular carbonic anhydrase 
activity and Cl- recycling as a mechanism CO2 disposal – Intracellular CA-mediated conversion 
of CO2 à HCO3- and H+, followed by extrusion of HCO3- and H+ is common in epithelial 
tissues. It is often used to drive transport of other ions, such as Na+ and Cl-, via coupled 
Cl-/HCO3- exchange and Na+/H+ exchange, but is also used for transepithelial movements of 
acid-base equivalents. For example, acid secretion in the stomach and HCO3- recovery in the 
renal proximal tubule require extrusion of prodigious quantities of H+ and HCO3- across apical 
and basolateral membranes, respectively, and in both cases, the H+ and HCO3- are generated by 
CA-catalyzed hydration of CO2. Gastric acid secretion involves H+,K+-ATPase-mediated 
extrusion of H+ and AE2 Cl-/HCO3- exchanger-mediated extrusion of HCO3- [25, 271]. HCO3- 
recovery in the proximal tubule involves NHE3 Na+/H+ exchanger-mediated extrusion of H+ and 
NBCe1 Na+-HCO3- cotransporter-mediated extrusion of HCO3- [272, 273]. Although these 
processes are not for the function of CO2 disposal per se, they do illustrate the potential for 
active HCO3- and H+ extrusion as a means of CO2 disposal. Also, on the basis of studies by 
Schroeder et al. [135], showing that CA-mediated hydration of CO2 waste is essential to maintain 
robust oxidative phosphorylation in myocytes, it is possible that the secondary function of CO2 
disposal is important in maintaining high rates of metabolism in epithelial tissues. The most 
dramatic example of transport-mediated CO2 extrusion occurs in the red blood cell, where the 
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AE1 Cl-/HCO3- exchanger extrudes, in the form of HCO3-, virtually all of the CO2 that is 
destined to be expelled from the lung. 
Transport-mediated CO2 disposal, referred to as CO2 siphoning, has been proposed to occur 
in glial cells of the salamander retina [274], which exhibit high O2 consumption. An electrogenic 
Na+-HCO3- cotransporter with a Na+: HCO3- ratio of 1:3, similar to that of NBCe1 in the renal 
proximal tubule, was identified as a possible HCO3- extrusion mechanism. The H+ extrusion 
mechanism was not identified, but the author speculated that it might be a Na+/H+ exchanger 
[274]. However, such a system would not be energetically efficient. With these specific 
transporters, if HCO3- and H+ extrusion were balanced, each cycle would result in the extrusion 
of 2 negative charges, which would require two cycles of Na+ pump activity (and expenditure of 
2 ATP) to balance effects on the membrane potential. 
While AE3-mediated HCO3- extrusion has been proposed to contribute to CO2 disposal in both 
retina [36, 121] and neuronal cells [120], Cl- recycling and parallel H+ extrusion would also be 
needed. In heart, there are many Cl- channels that could mediate Cl- recycling (Table 3.3), and 
the negative membrane potential throughout most of the excitation-relaxation cycle would allow 
maintenance of low intracellular Cl-. Thus, there may not be any one Cl- channel that functions in 
concert with AE3. The Cl- channels in heart include those of the Clcn family [275]; Ostm1, an 
accessory subunit that interacts with Clcn7 [275] ; the Anoctamin and Bestrophin families, which 
function as Ca2+-activated Cl- channels [276, 277];	  Clca Ca2+-activated Cl- channels and Cftr, 
which were expressed at only low levels; and Lrrc8 isoforms, recently identified as components 
of the ubiquitous volume-regulated anion channel (VRAC) [278, 279]. A clear pattern of 
changes indicative of Cl- channel activity that might function in Cl- recycling was not observed, 
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although reductions in the relatively abundant Ostm1 and Lrrc8c suggest that they are responsive 
to conditions resulting from the loss of AE3. 
The nature of the H+ extrusion mechanism is more problematic because NHE1 is heavily 
concentrated at intercalated discs [266, 280] and if it were involved (or any other electroneutral 
Na+/H+ exchanger), the process would not be electrically balanced unless additional transporters 
were included. The simplest and most energetically efficient mechanism would be H+ extrusion 
via a voltage-sensitive H+ channel such as HVCN1 [281, 282], which would maintain both 
charge and ionic balance. 
Gene 
Symbol Description 
WT 
(Mean ± SE) 
KO 
(Mean ± SE) 
Fold 
Change P-value 
Clcn1 Chloride channel 1   1.94 ± 0.27 2.60 ± 0.17 1.33 0.04 
Clcn2 Chloride channel 2   1.55 ± 0.07   1.69 ± 0.12 1.08 0.29 
Clcn3 Chloride channel 3 10.62 ± 0.35 11.22 ± 0.36 1.04 0.41 
   Clcn4-2 Chloride channel 4-2 22.8 ± 0.4 23.8 ± 0.4 1.03 0.39 
Clcn5 Chloride channel 5   0.60 ± 0.04 0.66 ± 0.05 1.09 0.53 
Clcn6 Chloride channel 6   4.36 ± 0.36 4.45 ± 0.14 1.01 1 
Clcn7 Chloride channel 7 11.7 ± 0.09 11.8 ± 0.30 1.00 1 
  Clcnkb Chloride channel Kb   0.40 ± 0.10   0.45 ± 0.05 1.11 0.50 
 Ostm1 Osteopetrosis associated transmembrane protein 1 13.7 ± 0.3 11.18 ± 0.15 0.8 0.000023 
   Cftr Cystic fibrosis transmembrane conductance regulator    0.07 ± 0.02 0.11 ± 0.02 1.59 0.31 
Best 1 Bestrophin 1   0.07 ± 0.02 0.09 ± 0.02 1.32 0.63 
Best 3 Bestrophin 3   5.07 ± 0.36 4.40 ± 0.06 0.86 0.04 
   Ano1 Anoctamin 1, Ca
2+ activated Cl- 
channel   4.72 ± 0.01 4.74 ± 0.11 1.00 0.96 
   Ano3 Anoctamin 3   0.11 ± 0.02 0.14 ± 0.01 1.28 0.55 
   Ano4 Anoctamin 4   2.0 ± 0.11 2.64 ± 0.14     1.30   0.001 
   Ano5 Anoctamin 5   0.93 ± 0.12 0.47 ± 0.03     0.50   0.001 
   Ano6 Anoctamin 6   8.43 ± 0.19   8.63 ± 0.2 1.01 0.95 
   Ano8 Anoctamin 8   8.51 ± 0.39   9.78 ± 0.34 1.13 0.01 
 Ano10 Anoctamin 10 25.8 ± 0.4 24.7 ± 0.97 0.94 0.25 
Clca1 Ca2+ activated Cl- channel 1   0.44 ± 0.03 0.39 ± 0.06 0.88 0.73 
   Clca2 Ca2+ activated Cl- channel 2   0.15 ± 0.01   0.16 ± 0.02 1.05      0.90 
 Lrrc8a Leucine rich repeat containing 8A 21.5 ± 1.61 20.0 ± 0.55 0.92 0.35 
 Lrrc8b Leucine rich repeat containing 8B   3.00 ± 0.08  2.96 ± 0.15 0.97 0.75 
 Lrrc8c Leucine rich repeat containing 8C   9.75 ± 0.33  8.57 ± 0.31 0.87 0.01 
 Lrrc8d Leucine rich repeat containing 8D   1.69 ± 0.01 1.59 ± 0.06 0.93 0.37 
 Lrrc8e Leucine rich repeat containing 8E   0.15 ± 0.03 0.20 ± 0.03 1.33 0.32 
Table 3.3. Expression Levels of Cl- Channel mRNAs in Heart. Expression levels (RPKM 
values) of potential sarcolemmal/t-tubule Cl- channels in WT and AE3-null (KO) heart are 
shown, with fold-changes and P-values. Genes that were not detected in one or more samples 
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were considered not expressed (all of these had mean RPKM < 0.05) and are not included. The 
Clic (Chloride Intracellular Channel) isoforms also are not shown.  	  	  	  
HVCN1 as a possible H+ extrusion mechanism in cardiac CO2 disposal – Although 
HVCN1 (also known as HVN or Hv1) has not been reported previously in heart, RNA Seq data 
revealed its mRNA expression in mouse heart (RPKM = 2.11 ± 0.13, WT; 2.28 ± 0.07, KO; 
1.07-fold; p = 0.09). As shown in Table 4, HVCN1 is also expressed in heart of other 
mammalian species. In mouse and opossum, HVCN1 expression was much less than that of 
NHE1. Expression of the two H+ extruders was more comparable in rat and rhesus monkey, and  
in human, HVCN1 was expressed at higher levels than NHE1. RNA Seq data for 33 human 
tissues and the ENCODE (Encyclopedia of DNA Elements) cell lines, available in the EBI 
Expression Atlas, indicate that both NHE1 and HVCN1 are ubiquitously expressed. This 
suggests that both mechanisms contribute to pHi homeostasis in heart and other mammalian 
tissues. In other studies we have confirmed the presence of HVCN1 protein in ventricular tissue 
and have identified HVCN1 activity in isolated myocytes (unpublished observations)3. With 
regard to additional activities that would be needed for transport-mediated CO2 disposal, AE3 
was the most highly expressed Cl-/HCO3- exchanger in all mammalian species examined, and 
was particularly prominent in humans, and AE2 levels appeared sufficient to provide some 
HCO3- extrusion activity in all species examined (Table 3.4). Among carbonic anhydrases, CA 
XIV is known to associate with AE3 in mouse heart [43] and is the predominant cardiac isoform 
in mouse and opossum; however, in rhesus monkey and human, the predominant cardiac isoform 
is CA IV (Table 4), which also associates with AE3 [267]. 
 
HVCN1 has properties that make it well suited for regulating the rate of H+ extrusion in cardiac 
myocytes. It is perfectly selective for H+, mediates outward transport only, and is strongly 
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activated by i) intracellular acidity, ii) extracellular alkalinity, and iii) a positive membrane 
potential [281]. 
 
 
Table 3.4. mRNA expression of H+ extrusion mechanisms (NHE1 and HVCN1), Cl-/HCO3- 
exchangers, and extracellular carbonic anhydrases in heart of mammalian species. RPKM 
values for mRNA expression is from: aCurrent study, Mean ± SE for WT FVB/N mouse; bEBI 
Expression Atlas, mean values for Fisher 344 Rat from [124]; cEBI Expression Atlas, mean 
values for Mouse (C57Bl6), gray short-tailed opossum, rhesus monkey, and human from [125]. 
Data were normalized in the latter study, allowing approximate cross-species comparisons of 
individual transporters; the other studies cannot be directly compared due to differences in the 
number of genes examined.  
 
 
As illustrated in Figure 3.7, if HVCN1 were co-localized with AE3 and extracellular CA, 
they would likely form an efficient mechanism for transport-mediated CO2 disposal. Because 
AE3 is electroneutral and unaffected by changes in membrane potential, its activity would be 
driven by the inwardly directed Cl- gradient and electrically balanced by outward transport of 
HCO3- derived primarily from CA-mediated conversion of CO2 being continuously vented from 
mitochondria [135]. Extrusion of HCO3- would likely lead to increased acidity in an intracellular 
microdomain in the vicinity of each AE3 molecule and increased alkalinity in the corresponding 
extracellular microdomain. However, with each action potential occurring 7-12 times/second in 
the awake mouse, the positive membrane potential would allow activation of HVCN1 and  
Gene  Protein      Mousea                    Fisher             Ratb 
C57Bl6     
Mousec Opossum
c Rhesus
c 
Monkey Human
c 
Slc9a1 NHE1 9.10 ± 0.20 2.4 8 7 17 5 
Hvcn1 HVCN1 2.11 ± 0.13 1.1 1 1 5 9 
Slc4a1 AE1 0.20 ± 0.05 3.1 0.2 2 0.5 0.3 
Slc4a2 AE2 12.6 ± 0.28 3.6 7 16 23 7 
Slc4a3 AE3 85.7 ± 0.64 25 47 45 77 178 
Slc26a6 PAT1 4.56 ± 0.26 4 4 n/a 6 3 
Car14 CA14 75.2 ± 3.0 24.9 41 101 3 1 
Car4 CA4 10.6 ± 0.8 3.9 9 n/a 9 8 
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Figure 3.7. Hypothetical role of the AE3 Cl-/HCO3- exchanger in transport-mediated CO2 
disposal. Oxygen entering the myocyte is rapidly converted to CO2 in mitochondria. CO2 
venting from mitochondria  [135] is facilitated by CA-mediated conversion of CO2 to HCO3- and 
H+, with H+ buffered by histidyl dipeptides (HDP). CO2 disposal is mediated by a combination of 
HCO3- extrusion by AE3, Cl- recycling via Cl- channel activity, H+ extrusion via HVCN1, and 
extracellular carbonic  anhydrase (CA) activity to generate CO2 
 
passage of H+ through the membrane, dissipating the transient pH microdomains that stimulate 
activity. H+ passing through HVCN1 could be catalytically combined with HCO3- via 
extracellular CA. With recycling of Cl- through one or more sarcolemmal Cl- channels (Table 
3.3), which would not have to be co-localized with AE3, efficient transport of HCO3- and H+ 
would be maintained, with rapid conversion to CO2 preventing a buildup of extracellular acid. 
Interestingly, HVCN1 has been proposed to play a role in CO2 elimination by lung epithelial 
cells [106]. 
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Utility of RNA Seq Data  
The RNA Seq expression data for most genes exhibited remarkably low variability, much better 
than typically observed in quantitative RT-PCR, thus allowing relatively small changes in large 
numbers of genes to be reliably measured.	  Because	  there is no background, quantitation is more 
reliable than in microarray experiments where variable background hybridization can introduce 
uncertainties about levels of expression. Normalization of expression by use of RPKM values 
allows a good estimate of absolute mRNA expression levels and differences in expression 
between various genes and between isoforms of a given gene. To the degree that expression 
levels may be informative about relative importance (and recognizing that changes in mRNA 
levels may not always exactly reflect changes in protein levels) RNA Seq data are particularly 
useful.  
Analysis of the data was greatly facilitated by use of the publically available GOrilla gene 
ontology program [126], which provided a ranked list of significant GO categories, with a list of 
significantly changed genes in each category. When using the GOrilla program we employed the 
single rank option and both 1) very stringent cutoffs (FDR values of 0.01 to 0.05) to identify GO 
categories that were highly enriched and highly significant using lists that would contain few if 
any false positives and 2) less stringent cutoffs to identify additional genes in GO categories 
already identified as highly significant. It was then possible to group GO categories together into 
broader categories (see Table 3.1) that allowed clear patterns of differential expression to be 
identified. These data show that loss of AE3-mediated Cl-/HCO3- exchange, which by itself 
causes no outward manifestations of disease, leads to modest changes in large networks of genes 
that are involved in many biological processes.   
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In our view, a major problem in differential expression studies is identifying and presenting 
relevant information about specific genes and the question or hypothesis being addressed. 
Various standard means of presenting bioinformatics data, including heat maps, Venn diagrams, 
and tables of GO categories and significantly expressed genes can be useful as starting points but 
cannot substitute for detailed information about the functions and interactions of genes involved 
in various biological processes. Readers who would like to consider and understand complex 
interactions of many genes and systems need to have specific information, even if in condensed 
form, about gene functions and differential expression patterns and what they might mean.    
The PubMatrix literature search program [127] was very useful as it allowed up to 1000 
PubMed literature searches (up to 100 genes x 10 modifier terms) to be performed 
simultaneously, and provided an output table that could be quickly scanned to determine which 
genes had literature hits with a given modifier term (Fig. S2). It was still necessary to peruse the 
titles, abstracts, and papers to identify studies that appeared to be highly relevant but one could 
be reasonably confident that relevant literature was not being missed. For many of the genes 
identified, the available information was quite recent, reflecting a dramatic expansion in the 
number of gene products that are being studied and the amount of information about each gene 
that is being uncovered in the international scientific enterprise. This information will continue to 
expand at a rapid rate, making studies with large RNA Seq data sets potentially more 
informative. 
An additional advantage of RNA Seq data is the potential for gene discovery. For example, 
the relatively abundant Mybphl, which was induced (1.33-fold, FDR = .00000001) in AE3-null 
hearts, has not been studied in heart. However, it was induced 4-fold in an RNA Seq data set of 
mice with heart failure [283]. It exhibits 51% identity, with no gaps, to the titin-binding domain 
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of Myosin binding protein C (Mybpc3). These data imply that it is a titin-binding protein and 
raise the possibility that it might affect interactions of Mybpc3 and titin.  
 
Concluding comments – Our objective was to identify differential expression patterns that 
would indicate a likely physiological function for AE3. Of the three functions (Na+- and Ca2+-
loading; pHi control; and CO2 disposal) discussed above, a role in CO2 disposal is most 
consistent with the data. Although it seems clear that AE3 can also affect Na+-loading and likely 
that it affects subsarcolemmal pHi, its high level of expression indicates that it is a bulk 
transporter of HCO3-, as would be necessary if it contributes to CO2 disposal. As noted above, 
transport-mediated CO2 disposal has strong precedents in other tissues and is the major means of 
handling large quantities of CO2 and acid-base equivalents derived from CO2. The high levels of 
O2 utilization in cardiomyocytes in vivo and the facilitated venting of CO2 from mitochondria by 
CA-catalyzed conversion to HCO3- and H+ [135] suggest a need for rapid removal of both ions in 
order to maintain the driving force for conversion of CO2 being continuously vented from 
mitochondria. 
In the RNA Seq data, the patterns most strongly indicating impaired CO2 disposal were the 
changes in genes mediating hypoxia responses, coupled with changes that would likely increase 
blood flow via vasodilation, and reduced expression of angiogenesis genes. These patterns 
suggest decreased oxygenation of myocytes and increased oxygenation of non-myocyte tissue. 
Given the effects of hypoxia on ion channels and membrane excitability [227-229], the changes 
in ion channel expression and genes involved in the conduction system were also consistent with 
cellular hypoxia. The changes in metabolic genes suggest an increase in glucose metabolism and 
a reduction in fatty acid metabolism, which would provide a more favorable ATP/O2 ratio during 
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mild hypoxia. Indeed, if this pattern had been reversed, indicating decreased glucose and 
increased fatty acid metabolism, it would have been inconsistent with impaired O2/CO2 balance. 
Interestingly, the proteins encoded	   by many of the glucose metabolism genes that were 
upregulated are known to serve as effector proteins in response to Akt signaling. Thus, not only 
is Akt signaling more strongly activated in AE3-null hearts during pacing [38], but genes 
encoding Akt glucose metabolism response proteins are upregulated. This suggests	   that the	  
~60% increase in Akt phosphorylation in AE3-null hearts (relative to WT) in response to a 
pacing-induced increase in heart rate [38] could be directed in large part to an enhancement of 
glucose utilization for energy metabolism under these acute stress conditions. 
Although additional physiological and biochemical studies will be needed to further test the 
hypothesis that AE3 functions in CO2 disposal in cardiac myocytes, and that HVCN1 is the 
associated H+ extrusion mechanism, the differential expression patterns described here provide 
strong circumstantial evidence that AE3 contributes to this function. If this proves to be the case 
then it would also be possible that the epilepsy [34, 35, 284] and blindness [36] phenotypes 
resulting from AE3 mutations in these other tissues with high O2 utilization is due to loss of its 
CO2 disposal function.  
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Chapter 4: Loss of AE3 does not Protect against Pressure Overload 
Hypertrophy Induced by TAC  
 
Summary 
 
It has been proposed that coupling of the AE3 Cl-/HCO3- exchanger with the NHE1 
Na+/H+ exchanger contributes to cardiac hypertrophy. We hypothesized that if coupling of AE3 
and NHE1 activities is hypertrophic, then loss of AE3 will protect against pressure overload-
induced hypertrophy. In order to determine whether loss of AE3 is protective, wild-type (WT) 
and AE3 knockout (KO) mice were subjected to transverse aortic constriction (TAC) to induce 
pressure overload hypertrophy. The development of hypertrophy and progression to failure was 
monitored by echocardiography. There were no significant differences in left ventricular 
remodeling between the WT and KO mice. The % fractional shortening (FS) and ejection 
fraction (EF), which are measures of systolic function, were also similar between the two groups. 
Nine weeks after TAC, hypertrophy measured by heart weight to body weight ratio (HW:BW) 
and heart weight to tibia length ratio (HW:TL) were the same in WT and KO mice. The 
expression of the hypertrophic markers, atrial natriuretic peptide (ANP), β-MHC and skeletal 
actin was significantly higher in WT and KO TAC ventricles compared to the respective sham 
operated controls. However, neither WT nor KO mice showed any signs of heart failure 9 weeks 
post TAC. These results suggest that AE3-mediated Cl-/HCO3- exchange does not contribute to 
the development of hypertrophy and that loss of its activity does not reduce hypertrophy or 
impair cardiac function in response to pressure overload.   
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Introduction 
Anion exchanger isoform 3 (AE3) is the most abundantly expressed Cl-/HCO3- exchanger 
in the heart [2]. Coupling of AE3 and Na+/H+ exchanger 1 (NHE1) activities would cause pH 
neutral sodium uptake, which in turn would be expected to increase in intracellular calcium, and 
lead to cardiac hypertrophy [5]. The role of NHE1 in hypertrophy is well established and 
inhibition of NHE1 is known to reduce hypertrophy and progression to failure [3]. Therefore, 
loss of AE3 would appear to have the potential to reduce cardiac hypertrophy. Our lab has 
previously shown that AE3-null mice have a slightly reduced heart weight to body weight ratio, 
consistent with the possibility that AE3 plays a role in hypertrophy [1]. 
The Slc4a3 gene encodes 2 AE3 isoforms, which are derived by alternative promoter 
usage. These are a full-length isoform (flAE3) expressed in brain and retina and a shorter 
isoform (cAE3, cardiac isoform) that is expressed in both heart and retina [32]. Though both 
isoforms of AE3 are expressed in cardiac tissue, cAE3 is the major isoform in the mouse 
ventricle. In fact, ventricles of mice have very little expression of the flAE3 [16, 32]. AE3 is 
expressed in the sarcolemma and T-tubules of cardiomyocytes, and is colocalized with vinculin, 
a focal adhesion protein present at the level of costamers in myocytes [20]. Though expressed at 
very high levels, the role of AE3 in heart is not clear. Coupling of AE3 activity with one of the 
Na+-dependent transporters (mainly NHE1) has been suggested to result in pH neutral Na+ 
uptake, resulting in increased intracellular Ca2+ and activation of hypertrophic signaling in the 
heart. The role of NHE1 in ischemia-reperfusion injury and hypertrophy has been demonstrated 
in various studies, and inhibition of NHE1 has been shown to reduce hypertrophy and 
progression to heart failure [3]. Activation of NHE1 results in an increase in intracellular Na+, 
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which reduces or reverses the activity of the NCX1 Na+/Ca2+ exchanger, resulting in an increase 
in intracellular calcium, which triggers the hypertrophic response. 
Sustained NHE1 activity is possible only when coupled with a HCO3- extrusion 
mechanism such as Cl-/HCO3- exchange. In fact, studies in both spontaneously hypertensive rats 
and a transgenic model carrying an activated NHE1 have shown that increased NHE1 activity 
did not result in an increase in pHi in isolated myocytes maintained in bicarbonate buffer, but did 
increase pHi when switched to HEPES buffer lacking bicarbonate [4, 5]. These results show that 
activation of NHE1 is accompanied by simultaneous activation of Cl-/HCO3- exchange [4, 5], 
which could allow a substantial increase in intracellular Na+ concentrations under pathological 
conditions. Moreover, the apparent increase in AE3 activity in parallel with NHE1 activity 
during hypertrophy, and the inhibition of both AE3 and NHE1 and reduced hypertrophy in 
response to carbonic anhydrase inhibitors [285], suggests that inhibition of AE3 might serve as a 
treatment for cardiac hypertrophy. The KO mice have slightly reduced heart weight to body 
weight ratio consistent with the hypothesis that AE3 may play a role in hypertrophy [1]. 
However, loss of AE3 alone results in impaired FFR and the combined loss of AE3 and the Na+-
K+-2Cl- cotransporter isoform 1 (NKCC1) results in impaired cardiac contractility and calcium 
handling [1]. Moreover, the loss of AE3 in a Gly180Glu α-tropomyosin hypertrophic 
cardiomyopathy model had no effect on hypertrophy but reduced survival and led to rapid 
decompensation of cardiac function [37], suggesting a protective role for AE3 in the heart. In 
order to determine whether AE3 plays a role in cardiac hypertrophy, pressure overload 
hypertrophy was induced by transverse aortic constriction (TAC) in WT and AE3 KO mice.  The 
development of hypertrophy was monitored by echocardiography, and cardiac function was 
assessed by intraventricular pressure (IVP) measurements. 
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Results  
Pressure overload hypertrophy was induced in WT and AE3 KO male mice by transverse 
aortic constriction. As discussed below, the duration of TAC was either 9 weeks or 17 weeks. In 
both cases, echocardiography was done before (baseline) and at various time points after surgery, 
to monitor the development of hypertrophy. At the end of the study (9 or 17 weeks), the pressure 
gradient was measured to ensure that a similar degree of aortic constriction had occurred in WT 
and KO hearts.  Additionally, the left ventricular function was assessed by IVP analysis. 
 
Echocardiographic analysis of left ventricular remodeling in TAC and sham operated mice 
(9 week study):  
Echocardiography showed a significant increase in LVIDs and LVIDd (inner dimensions 
of the left ventricle during systole and diastole respectively), IVSs, IVSd, LVPWs and LVPWd 
(thickness of the interventricular septum and posterior wall during systole and diastole) in the 
WT-TAC and KO-TAC group compared to their respective sham operated controls (Table 4.1). 
However, there was no significant difference between the WT-TAC and KO-TAC groups 
suggesting a similar level of remodeling of the left ventricle in both WT and KO mice in 
response to aortic constriction. Ejection fraction (EF) and Fractional shortening (%FS), which 
are measures of systolic function of the left ventricle were also similar between WT and KO 
mice suggesting similar left ventricular function 9 weeks after TAC.  
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Table 4.1: M-mode echocardiographic analysis of mice subjected to TAC for 9 weeks.  
Functional analysis obtained from the M-mode echocardiograms measuring LV systolic and 
diastolic dimensions, intraventricular septum, LV posterior wall thickness (LVPW) and chamber 
diameter (LVID) in WT and KO sham operated and TAC mice  
 
 
HW:BW and HW:TL ratios in TAC and sham operated mice (9 week study) 
To further assess the degree of hypertrophy, hearts and tibiae were collected from WT 
and KO sham operated and TAC cohorts 9 weeks post-surgery. The TAC study was done in 2 
cohorts. The first cohort consisted of 4 WT and 3 KO mice and the second cohort consisted of 4 
WT and 4 KO mice. In the first cohort, 3 out of the 4 WT mice had enlarged and calcified left 
atria (signs of cardiac decompensation and failure), in contrast to the 4 KO mice, which had 
normal left atria. The results from this cohort suggested that loss of AE3 is protective. However, 
since we did not observe a similar result in the WT mice in the second cohort or in the 17-week 
TAC group, variation in experimental procedures might have potentially caused enlarged atria in 
the WT mice of the first cohort. 
When the HW/BW and HW/TL ratios from both cohorts were averaged, both WT and 
KO mice from the TAC group had significantly increased HW:BW and HW:TL ratios compared 
to the sham operated controls (Figure 4.1A). The WT-TAC mice had a HW:BW (mg/g) ratio of 
Wild-type  AE3-KO  
SHAM (n=4) TAC (n=8) SHAM (n=4) TAC (n=7) 
Baseline 9 weeks Baseline 9 weeks  Baseline 9 weeks Baseline 9 weeks 
LVIDs (mm) 2.36 ± 0.05 2.11 ± 0.16 2.67 ± 0.11 2.87 ± 0.11 2.42 ± 0.04 2.07 ± 0.06 2.62 ± 0.07 2.62 ± 0.20 
LVIDd (mm) 3.89 ± 0.1 4.13 ± 0.12 4.06 ± 0.12 4.25 ± 0.14 3.85 ± 0.03 3.98 ± 0.08 4.05 ± 0.10 4.01 ± 0.17 
IVSs (mm) 1.76 ± 0.06 2.08 ± 0.08 1.59 ± 0.05 1.91 ± 0.1 1.62 ± 0.06 1.94 ± 0.04 1.59 ± 0.05 1.97 ± 0.08 
IVSd (mm) 1.12 ± 0.06 1.24 ± 0.12 1 ± 0.06 1.3 ± 0.12 0.99 ± 0.04 1.08 ± 0.07 0.96 ± 0.03 1.35 ± 0.05 
LVPWs (mm) 1.44 ± 0.14 1.5 ± 0.05 1.25 ± 0.05 1.46 ± 0.05 1.31 ± 0.12 1.50 ± 0.09 1.25 ± 0.06 1.62 ± 0.05 
LVPWd (mm) 1.12 ± 0.13 1.26 ± 0.05 0.99 ± 0.6 1.18 ± 0.07 1.06 ± 0.14 1.14 ± 0.10 1.03 ± 0.05 1.40 ± 0.04 
%FS 39.37 ± 0.24 49 ± 2.4 34.2 ± 1.05 32.3 ± 1.87 36.8 ± 1.41 48.3 ± 0.68 35.29 ± 0.53 34.93 ± 3.41 
EF 77.7 ± 1.28 71.99 ± 1.6 62.26 ± 2.54 65.19 ± 3.02 76.04  ± 2.64 72.29 ± 1.5 70 ± 2.12 61.8 ± 3.19 
Gradient 
(mmHg) -3.19 ± 0.64 58.28 ± 2.95 0.73 ± 1.9 67 ± 6.55 
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7.58 ± 0.71 and the KO-TAC mice had a ratio of 6.5 ± 0.25 (Sham operated controls: WT 4.74 ± 
0.14; KO 4.58 ± 0.18). The average HW:BW was slightly lower in the KO-TAC relative to WT-
TAC but was not significant. The HW:TL (Figure 4.1B) was 14.31 ± 0.96 for the WT-TAC 
group and 11.88  ± 0.48 for the KO-TAC group (WT Sham: 9.43 ± 0.31; KO Sham: 8.45 ± 0.36). 
The HW:TL was significantly lower in the KO-TAC relative to WT-TAC. Though these results 
suggest reduced hypertrophy in the KO-TAC relative to WT-TAC mice, it should be noted that 
the 3 WT in the first cohort had enlarged atria that skewed the results.   
 
 
            
Figure 4.1:  HW:BW ratio and HW:TL ratios in TAC and sham operated WT and KO mice 
9 weeks post surgery. (A) HW:BW ratio and (B) HW:TL ratio   WT sham n=4, WT-TAC n=8, 
KO sham n=4, and KO-TAC n=7. * WT sham vs WT TAC , ** KO sham vs KO-TAC, # WT 
sham vs KO sham, p≤0.05.   
 
 
Expression of hypertrophic markers in TAC and sham operated mouse ventricles (9 week 
study) 
Expression of hypertrophic markers, atrial natriuretic peptide (ANP), β–Myosin heavy 
chain (β-MHC), and skeletal actin was significantly increased in the WT-TAC and KO-TAC 
ventricles compared to their respective sham operated controls (Figure 4.2). The expression of 
ANP, though not significant, was trending higher in the AE3 KO sham operated and TAC groups 
A B 
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relative to the WT sham operated and WT-TAC groups respectively. Since the expression in WT 
and KO TAC is normalized to WT and KO sham respectively the increase in ANP expression in 
KO sham and KO-TAC is not seen in the figure. In our RNA seq analysis, ANP expression was 
significantly increased in AE3-KO hearts relative to WT. The expression of skeletal actin was 
significantly lower in the KO sham cohort relative to WT sham, which was also observed in our 
RNA seq analysis of AE3 KO vs AE3 WT hearts. 
 
Figure 4.2: Expression of hypertrophic markers in sham and TAC ventricles nine weeks 
post TAC by qRT-PCR. A) Expression of ANP, B) β-MHC, and C) Skeletal actin. WT sham 
n=4, WT-TAC n=8, KO sham n=4, and KO-TAC n=7. * WT sham vs WT TAC, ** KO sham 
vs KO-TAC, # WT sham vs KO sham, p≤0.05.  
 
 
Pressure gradients in WT and KO-TAC and Sham operated mice 9 weeks post surgery 
The pressure gradient was measured using pressure transducers in the right carotid and 
right femoral artery to determine if the TAC surgery was successful in creating a sufficient 
pressure gradient. WT and KO TAC mice had pressure gradients of 58.28 ± 2.95 mm/Hg and 67 
± 6.55 mm/Hg, respectively (Table 4.1). There was no significant difference in the gradients 
between the WT and KO suggesting that both cohorts had a similar degree of constriction of the 
aorta. The WT and KO sham operated controls had a gradient of -3.19 ± 0.64 and 0.73 ± 1.9 
mm/Hg respectively suggesting no pressure gradient in these mice. After measuring the gradient, 
B C A 
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the transducer in the right carotid was advanced into the left ventricle and IVP analysis of cardiac 
performance was performed. 
 
Cardiac function of WT and KO-TAC and Sham operated mice 9 weeks post-surgery 
 
Cardiac performance was assessed in anesthetized mice by IVP measurements 9 weeks 
post TAC. Measures of contractility (max dP/dT) and relaxation (min dP/dt) of the left ventricle 
were measured under basal conditions and after β-adrenergic stimulation (32ng/g/min 
dobutamine). The difference between values obtained at baseline and after β-adrenergic 
stimulation was calculated for max dP/dT (Δ +dP/dt) and min dP/dt (Δ -dP/dt). There was no 
difference in Δ +dP/dt between the WT and KO TAC cohorts (Figure 4.3A). The Δ -dP/dt 
(Figure 4.3B) was significantly lower in the KO-TAC relative to WT-TAC suggesting impaired 
relaxation in the KO. However, the relaxation defect was not significant when the left ventricular 
relaxation time constant, Tau (best index to evaluate left ventricular diastolic function) (Figure 
4.4) was calculated, suggesting no impairment in relaxation in KO-TAC relative to WT-TAC. 
 
Figure 4.3: β-adrenergic response of TAC and sham mice 9 weeks post TAC.  The difference 
between values obtained under basal conditions and in response to maximum dose of β-
adrenergic stimulation (32ng/g/min dobutamine) are shown for  (A) Δ +dP/dt and (B) Δ -dP/dt 
WT Sham n=4, WT-TAC n=8, KO Sham n=4, and KO-TAC n=7. *p < 0.05. 
 
A B 
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Figure 4.4: The LV relaxation time constant, tau to determine LV diastolic function in WT 
and KO TAC hearts. The tau values obtained at baseline and in response to β – adrenergic 
stimulation (32 ng/g/min dobutamine) are shown for WT- TAC and KO-TAC (n = 8 for WT and 
n = 7 KO) 
 
17 week TAC study 
After 9 weeks TAC to induce pressure overload hypertrophy, neither WT nor KO mice 
showed any signs of decompensation or impairment in cardiac function. In order to determine if 
a longer period would cause impairment in cardiac function, TAC surgery was done on an 
additional cohort of 4 WT and 3 KO mice. The dimensions of the left ventricle were obtained 
before TAC (baseline measurements). After TAC, the mice were monitored by echocardiography 
at the 6 and 12-week time points. Cardiac function was assessed by IVP measurements after 17 
weeks, followed by tissue collection. Sham operated controls were not included in this study. 
 
 
 
WT control 
KO control 
KO 32ng dobutamine 
WT 32ng dobutamine 
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Echocardiographic analysis of left ventricular remodeling in WT and KO TAC mice  
There was no significant difference between the WT-TAC and KO-TAC groups 
suggesting similar levels of remodeling of the left ventricle in both WT and KO mice in response 
to aortic constriction (Table 4.2). Both EF and FS% parameters calculated from the dimensions 
of the left ventricle were also similar between WT and KO mice, suggesting no impairment of 
ventricular function. 
 
                             
Table 4.2: M-mode echocardiographic analysis of mice subjected to TAC for 17 weeks.  
Functional analysis obtained from the M-mode echocardiograms measuring LV systolic and 
diastolic dimensions, intraventricular septum, LV posterior wall thickness (LVPW) and chamber 
diameter (LVID) in WT and KO-TAC mice before surgery (baseline) and 12 weeks after TAC 
 
 
HW:BW and HW:TL ratios in WT and KO-TAC (17 weeks) 	  
At 17 weeks post-TAC, the WT-TAC mice had a HW:BW (mg/g) ratio of 5.07 ± 0.29 
and the KO-TAC mice had a ratio of 4.94 ± 0.20. The HW:TL ratio was 11.84 ± 0.24 for the 
WT-TAC group and 10.97 ± 0.37 for the KO-TAC group. There were no significant differences 
in HW:BW and HW:TL (Figure 4.5) in the KO-TAC group compared to WT-TAC group.   
 
 
WT (n=4) KO (n=3) 
Baseline 12 weeks Baseline 12weeks  
LVIDs (mm) 2.24 ± 0.11 2.29 ± 0.11 2.13 ± 0.13 2.60 ± 0.13 
LVIDd (mm) 4.04 ± 0.15  4.06 ± 0.09 4.06 ± 0.12 4.19 ± 0.09 
IVSs (mm) 1.78 ± 0.02 2.09 ± 0.06 1.71 ± 0.05 1.92 ± 0.07 
IVSd (mm) 1.02 ± 0.05 1.18 ± 0.05 0.97 ± 0.05 1.17 ± 0.06 
LVPWs (mm) 1.26 ± 0.03 1.74 ± 0.01 1.64 ± 0.11 1.68 ± 0.05 
LVPWd (mm) 0.88 ± 0.05 1.47 ± 0.09 1.27 ± 0.06 1.38 ± 0.07 
%FS 44.62 ± 1.23 43.88 ± 1,52 45.5 ± 1.8 38 ± 2.29 
EF 77.3 ± 2.52 70.58 ± 2.19 75.67 ± 2.54 68.35 ± 4.74 
Gradient 
(mmHg) 65.03 ± 7.81 67.36 ± 6.17 
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Figure 4.5:  HW:BW ratio and HW:TL ratios for WT and KO TAC mice 17 weeks post 
TAC. (A) HW:BW ratio and (B) HW:TL ratio. WT-TAC: n = 4, KO-TAC: n = 3. 
 
 
Expression of Hypertrophic markers in WT and KO-TAC ventricles 17 weeks post TAC 
There were no Sham operated controls in the 17 weeks study and hence the expression of 
hypertrophic markers ANP, β-MHC and skeletal actin was compared between the WT-TAC and 
KO-TAC group. There was no significant difference in the expression of β-MHC and skeletal 
actin between the WT-TAC and AE3-KO-TAC mice (Figure 4.6B and C). However, the 
expression of ANP was significantly higher in the AE3-KO-TAC group relative to the WT-TAC 
group (Figure 4.6A). It should be noted that the KO sham operated and TAC hearts in the 9-
week study had increased, but not significant, expression of ANP relative to the respective sham 
operated and TAC WT hearts. Moreover, RNA seq data confirmed increased expression of ANP 
in AE3-KO hearts, so it is possible that the increased basal expression of ANP in the AE3-KO is 
responsible for the increased ANP expression in the TAC group. 
WT TAC 
KO TAC 
A B 
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Figure 4.6: Expression of hypertrophic markers in WT and KO-TAC ventricles 17 weeks 
post TAC by qRT-PCR. A) Expression of ANP, B) β-MHC, and C) Skeletal actin.  WT-TAC: n 
= 4, KO-TAC: n = 3.*p ≤ 0.05. 
 
 
Pressure gradients in WT and KO-TAC mice 17 weeks post-surgery 
 
The pressure gradient was measured using pressure transducers in the right carotid and 
right femoral artery to determine if the TAC surgery was successful in creating a sufficient 
pressure gradient. WT and KO TAC mice had pressure gradients of 65.03 ± 7.81 mm/Hg and 
67.36 ± 6.17 mm/Hg respectively (Table 4.2). There was no significant difference in the 
gradients between the WT and KO suggesting that both cohorts had similar degree of 
constriction of the aorta. 
 
Cardiac function of WT and KO TAC mice 17 weeks post TAC 
Cardiac performance was assessed by IVP measurements 17 weeks post TAC. The 
measurements were taken under basal conditions and in response to various doses of the β-
adrenergic agonist dobutamine. There were no significant differences in max dP/dT (Figure 
4.7A) and min dP/dt (Figure 4.7B), which are measures of contraction and relaxation of the left 
ventricle respectively.     
 
WT TAC 
KO TAC A B C 
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Figure 4.7: β-adrenergic response of WT and KO sham and TAC mice nine weeks post 
TAC. Pressure measurements were recorded using transducers in the left ventricle and right 
femoral artery under basal conditions and in response to various doses of β-adrenergic stimulation 
(intravenous infusion of dobutamine). Measure of contractility (A) +dP/dt and relaxation (B) -
dP/dt is shown. WT-TAC: n = 4, KO-TAC: n = 3. 
 
 
Conclusions   
The results from this study suggest that loss of AE3 does not protect against hypertrophy 
in response to pressure overload, indicating that the AE3 Cl-/HCO3- exchanger does not play a 
major role in the regulation of cardiac hypertrophy. Furthermore, neither WT nor KO mice 
showed any signs of decompensation or impairment in cardiac function at the end of 9 weeks. 
We anticipated that both WT and KO mice in the 17-week study would show signs of 
impairment in cardiac function. However, even after 17 weeks neither the WT nor the KO mice 
showed any signs of decompensation or impairment in cardiac function. 
The WT and KO mice were on FVBN genetic background and previous studies have 
shown that FVBN mice are particularly resistant to TAC induced hypertrophy and failure when 
compared to C57Bl/6 mice [286]. Since WT mice from the 17-week study did not have impaired 
cardiac function at the end of the study, it is difficult to comment on the effect of loss of AE3 on 
cardiac function in response to TAC. In order to determine if loss of AE3 leads to 
decompensation in response to TAC as was seen in the hypertrophic cardiomyopathy model, 
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generating AE3 KO mice on a C57Bl/6 background may be useful. C57Bl6 mice are more 
susceptible to heart failure in response to TAC and show signs of heart failure around 9 weeks 
after TAC [286]. 
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Chapter 5: Characterization of Cardiac specific AE2 KO mice: Cardiac 
physiology and Biochemistry  
Summary 
AE2 is the housekeeping Cl-/HCO3- exchanger and is expressed on basolateral 
membranes in various epithelial tissues. AE2 is expressed at lower levels in heart than AE3, 
which mediates 60-­‐70%	   of	   the	   HCO3-­‐	   extrusion	   activity	   in	   isolated	   myocytes, but its 
expression is greater than AE1 and PAT1. This	  suggests	  that	  AE2	  could	  mediate	  a	  substantial	  part	   of	   the	   remaining	   extrusion	   in	   myocytes.	   AE2 works in concert with the Na+/H+ 
exchanger, NHE1 in various tissues to facilitate NaCl uptake and volume regulation [26]. The 
function of AE2 in heart is not known. In order to determine the role of AE2 in heart, we 
generated conditional cardiac-specific AE2 (gene symbol, Slc4a2) knockout mice using Cre 
recombinase under the control of β-MHC promoter. The cardiovascular function of WT, HET 
and KO mice, as determined by intraventricular pressure (IVP) measurements was not different 
between the 3 groups. The expression of calcium handling proteins, the L-type calcium channel 
(LTCC), the Na/Ca exchanger 1 (NCX1), and the Na/H exchanger 1 (NHE1) were similar 
between HET and KO groups. Moreover, the expression of SERCA2a and its regulator, 
phospholamban  (PLN), PLN phosphorylated at serine 16 (PS16) and threonine 17 (PT17) were 
also similar between HET and KO. These results suggest that loss of AE2 does not impair 
cardiac function under normal conditions.    	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Introduction 
Slc4a2 generates three N-terminal variants (AE2a, AE2b, and AE2c) by use of alternative 
promoters [22]. AE2 mRNA is expressed in the heart [23] and its protein has been identified in 
rat neonatal cardiomyocytes [24]. RNA seq analysis indicates that AE2 is expressed at lower 
levels than AE3 in heart but greater than that of AE1 and PAT1. AE3	  has	   been	   reported	   to	  mediate	  60-­‐70%	  of	  the	  HCO3-­‐	  extrusion	  activity	  in	  isolated	  myocytes	  [119],	  but	  the	  levels	  of	  AE2	  seem	  sufficient	  to	  mediate	  much	  of	  the	  remaining	  activity.	  AE2 is known to operate in 
concert with the NHE1 Na+/H+ exchanger in various tissues to facilitate NaCl uptake and volume 
regulation [26], so it is possible that it contributes to this function in heart. The localization of 
AE2 in cardiomyocytes is not known but, if it is expressed in the vicinity of NHE1 (localized to 
intercalated discs), it could potentially be involved in Na+ loading and hypertrophy in heart.   
AE2 is the housekeeping Cl-/HCO3- exchanger and AE2-/- mice die at or before weaning, 
exhibit severe growth retardation, failure of tooth eruption, osteopetrosis, gastric achlorohydria 
and major defects in gastric HCl secretion and parietal cell development [25], and also impairs 
development of osteoclasts [17]. In order to understand the role of AE2 in heart, conditional 
cardiac-specific AE2 KO mice were generated. Cardiovascular performance was determined by 
intraventricular pressure measurements under basal conditions and in response to β-adrenergic 
stimulation. The expression levels of some of the proteins involved in calcium handling were 
determined by immunoblot analyses. 
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Results 
Targeting strategy for cardiac specific deletion of Slc4a2    
A targeting construct in which exon 8 of Slc4a2 was flanked with LoxP sites (Slc4a2flx/flx) 
was prepared (Figure 5.1). This construct also contains a neomycin resistance gene flanked  
 
Figure 5.1: Targeting strategy for generation of Slc4a2 conditional KO mice. A) The 
targeting construct contains a neomycin resistance gene flanked with flippase recognition target 
(FRT) sites to allow selection of ES cells after homologous recombination. Successive breeding 
with transgenic mice expressing Flip recombinase and Cre recombinase (under control of the β-
MHC promoter) resulted in cardiac specific AE2 KO mice, B) PCR genotyping showing bands 
for +/+ (WT), flx/+ (HET) and flx/flx (KO), and C) RTPCR showing reduction of Slc4a2 mRNA 
in KO cardiomyocytes relative to control heterozygous mice (HET). 
 
with flippase recognition target (FRT) sites to allow selection of ES cells after homologous 
recombination. The neomycin resistance gene (neo) was removed by breeding with a transgenic 
mouse expressing Flip recombinase. In order to delete Slc4a2 in heart, the Slc4a2flx/flx mouse was 
crossed with a transgenic mice expressing Cre recombinase under the control of β myosin heavy 
chain (β-MHC) promoter to obtain Slc4a2flx/+(β-MHC Cre) (HET) and Slc4a2flx/+ mice. Further 
Genomic 
Locus 
Targeting 
Vector 
Targeted 
Allele 
Flip recombinase 
Cre recombinase 
Conditional 
Allele 
Knockout 
Allele 
neo  
14-16 8 9-13 3-5 6-7 
3-5 6-7 8 9-13 
neo  3-5 6-7 8 9-13 14-16 
3-5 6-7 8 9-13 14-16 
3-5 6-7 9-13 14-16 
STOP 
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breeding between heterozygous mice was set up to obtain Slc4a2flx/flx (β-MHC Cre) (KO) mice. Cre 
expression under the control of the β-MHC promoter results in deletion of Slc4a2 during early 
embryonic development in heart and slow skeletal muscle. The loss of Slc4a2 mRNA was 
confirmed in myocytes isolated from het and KO hearts by RTPCR analysis. For all experiments, 
flx/+ mice with Cre (HET) were used as controls except for the IVP analysis where both +/+ with 
Cre (WT) and HET mice were used as controls.   
PCR genotyping of tail DNA  
 DNA isolated from tail biopsies was used to genotype mice. The PCR product size for the 
Slc4a2+/+ is 160 bp and that for the targeted allele Slc4a2flx/flx (floxed) is 257 bp (Figure 5.2A). 
An additional PCR reaction was performed, to determine the presence or absence of the Cre 
transgene.     
 
 
 
 
 
 
 
 
 
Figure 5.2. PCR genotyping and qRT-PCR. A) PCR genotyping showing bands for +/+, flx/+ 
and flx/flx, and B) RTPCR showing reduction of Slc4a2 mRNA in KO cardiomyocytes relative 
to control (HET). HET	  n=4	  	  and	  KO	  n=4.	  Although this assay was perfomed using a preparation 
of isolated myocytes, we now know that these preparations are heavily contaminated with other 
cell types. Therefore, the data are unlikely to represent the degree of knockdown in cardiac 
myocytes  
 
 
 
B A 
257 bp 
160 bp 
+/+ flx
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x 
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qRT-PCR of AE2 mRNA in cardiomyocytes 
Cre recombinase under the control of β-MHC promoter was used to knock down AE2 in 
heart. In order to determine the percent knockdown of Slc4a2 mRNA in KO cardiomyocytes, 
qRT-PCR was performed with primers specific for exon 8. The results suggest that Cre 
recombinase under the control of β-MHC promoter resulted in ~50% less Slc4a2 mRNA in KO 
cardiomyocytes relative to HET (Figure 5.2B), which already lack one functional copy of the 
gene. Because AE2 is expressed in all other cell types in heart, which contaminate myocyte 
preps, the knockdown observed here is likely to be greater.  	  
Cardiovascular performance in WT, Het and KO mice under basal conditions and in 
response to β-adrenergic stimulation 
Cardiac performance was analyzed under basal conditions and under various doses of the β-
adrenergic agonist dobutamine. There were no significant differences in heart rate (HR), mean 
arterial pressure (MAP) and systolic pressure (Figures 5.3A-C) among the WT, HET and KO 
mice. The MAP and systolic pressure, though slightly lower in the WT relative to the HET and 
KO cohorts, was not significant. Of the 3 WT mice used in the study, IVP analysis on 2 of them 
was performed ~2 years after the analysis of the rest of the mice in this study. Hence 
experimental variation and level of anesthesia could have a major effect on pressure 
measurements. However, the contractility (+dP/dT) and relaxation (-dP/dt) of the left ventricle 
(Figures 5.3D-F) were similar between WT, HET and KO mice suggesting normal cardiac 
function in AE2 deficient mice. 
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Figure 5.3. Cardiovascular performance in WT, HET and KO mice. Pressure measurements 
were recorded using transducers in the left ventricle and right femoral artery of anesthetized 2-3 
month-old control and KO mice under basal conditions and in response to β-adrenergic 
stimulation (intravenous infusion of increasing doses of dobutamine). A) Heart rate B) mean 
arterial pressure, C) systolic left ventricular pressure, D) maximum +dP/dt in mm Hg/sec E) 
+dP/dt at 40 mm Hg and F) and minimum −dP/dt in mm Hg/sec are shown for WT, HET and 
KO mice.  n = 3 WT (1 female, 2 male), 5 HET (2 female, 3 male) and 6 KO (4 female, 2 male).    
 
Expression of sarcolemmal calcium handling proteins in AE2 HET and KO mice 
  Changes in calcium handling proteins can have an effect on cardiac performance. Since 
there was no change left ventricular performance between HET and KO, we did not expect to see 
any changes in the expression of Ca2+-handling proteins. Immunoblot analysis of whole heart 
homogenates showed no difference in the expression levels of proteins involved in calcium 
influx and efflux. Specifically, the L-type calcium channel (LTCC, influx) and sodium calcium 
exchanger 1 (NCX1, efflux) (Figure 5.4A and B) were similar in HET and KO hearts. The levels 
of NHE1 (Figure 5.4C) were also similar between HET and KO.  
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Figure 5.4. Relative expression levels of sarcolemmal proteins involved directly or 
indirectly in Ca2+- handling in HET and AE2 KO hearts. Whole heart homogenates from 
mice of HET and KO were analyzed by immunoblotting and densitometry. A) LTCC α2, B) 
NCX1, and C) NHE1. HET n=4  and KO n=4. 
 
Expression of sarcoplasmic reticulum calcium handling proteins in AE2 HET and KO mice 
There were also no significant differences in the expression levels of the sarcoplasmic reticulum 
Ca2+ATPase isoform 2a (SERCA2a) (Figure 5.5A) and its regulator, phospholamban (PLN) 
(Figure 5.5B). Phosphorylation of PLN relieves its inhibition on SERCA2a. Relative 
phosphorylation of PLN on serine 16 (PS16) and threonine 17 (PT17) (Figures 5.5C and D) 
were also similar between the 2 genotypes assessed. These results suggest that loss of AE2 in 
heart does not result in changes in the major proteins involved in Ca2+-handling in heart. 
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Figure	  5.5.	  Relative	  expression	  levels	  of	  sarcoplasmic	  reticulum	  proteins	  involved	  in	  
Ca2+-­‐	  handling	  in	  HET	  and	  AE2	  KO	  hearts.	  Whole	  heart	  homogenates	  from	  mice	  of	  HET	  and	   KO	   were	   analyzed	   by	   immunoblotting	   and	   densitometry.	   A)	   SERCA2a,	   B)	   Total	  phospholamban	   (PLN),	   C)	   PLN	   phosphorylated	   on	   Ser16	   (PS16),	   and	   D)	   PLN	  phosphorylated	  on	  Thr17	  (PT17).	  	  HET	  n=4	  and	  KO	  n=4.	  	  	  
	  
	  
Conclusions	  	  	  The	  results	  from	  the	  current	  study,	  suggests	  that	  cardiac	  specific	  loss	  of	  the	  AE2	  Cl-
/HCO3- exchanger does not affect cardiac function under basal conditions or in response to β-
adrenergic stimulation. Moreover, the expression of major proteins involved in Ca2+-handling 
and regulation of cardiac function were similar in HET and KO hearts. Though AE2 is expressed 
at levels higher (RPKM = 12.57 ± 0.28) than the AE1 and PAT1 Cl-/HCO3- exchangers in the 
heart, it is expressed at much lower levels than AE3 (RPKM= 85.7 ± 0.64). Hence in the absence 
of AE2 in heart, AE3 and PAT1 may compensate for its activity and maintain normal cardiac 
function.   
AE2 works in concert with NHE1 in various tissues to facilitate pH neutral Na+ uptake. 
Moreover, in heart NHE1 coupled with Cl-/HCO3- has been proposed to result in pH neutral 
sodium uptake, Ca2+ loading and cardiac hypertrophy. Although AE3 is the most abundant Cl-
PLN 
s.actin 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
SERCA2a 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
s.actin 
A" B"
s.actin 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
PS16 
 
PT17 
H
ET
 
K
O
 
H
ET
 
K
O
 
H
ET
 
K
O
 
s.actin 
C" D"
96	  	  
/HCO3- exchanger in heart and has the potential to work in concert with NHE1, loss of AE3 in a 
hypertrophic cardiomyopathy (HCM) model did not reduce hypertrophy. If AE2 is localized in 
the vicinity of NHE1, it is possible that AE2 activity coupled with NHE1 activity could regulate 
cardiac hypertrophy. If this were the case, then AE2-null mice should exhibit reduced 
hypertrophy in response to pressure overload.  
RNA seq data showed that the levels of AE2 mRNA were slightly increased (but not 
significantly) in AE3 KO hearts, suggesting that AE2 may provide some compensation for loss 
of AE3 in the AE3 KO hearts. Currently, we are crossing our AE3 KO mouse with the AE2 
conditional KO mice to generate mice that lack both AE2 and AE3 (dKO) in heart. With most of 
the Cl-/HCO3- exchange activity in heart lost, we expect the dKO will have a significant 
impairment in cardiac function and/or force frequency response.   
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Chapter 6: Cardiac Physiology and the Role of NBCe1 in Ischemia/ 
Reperfusion Injury  
Summary  
 The electrogenic sodium dependent bicarbonate cotransporter, NBCe1, is reported to be 
one of the major acid extruding mechanisms in heart. Inhibition of NBCe1 has been reported to 
reduce infarct size and improve ventricular function during reperfusion following ischemic 
injury. To better understand the role of NBCe1 in heart and to determine whether loss of NBCe1 
is protective against ischemia/reperfusion (I/R) injury, conditional cardiac-specific NBCe1 (gene 
symbol, Slc4a4) knockout mice were generated. Cardiovascular function of NBCe1 knockout 
(KO) mice was determined by intraventricular pressure (IVP) measurements. Loss of NBCe1 did 
not affect cardiovascular performance under basal conditions or in response to β-adrenergic 
stimulation. In order to determine if loss of NBCe1 is protective against I/R injury, in vivo I/R 
injury was performed in wildtype (WT) and NBCe1 KO mice by occluding the left anterior 
descending (LAD) artery for 30 min (ischemia) followed by 3 hours of reperfusion. The percent 
fractional shortening (%FS) and ejection fraction (%EF), which are measures of systolic 
function, were similar between the WT and KO cohorts. However, KO heart sections had less 
apoptotic nuclei relative to WT. These preliminary studies indicate that loss of NBCe1 may be 
protective against in vivo I/R injury.     
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Introduction  
Regulation of intracellular pH (pHi) is critical for various physiological functions in 
heart. Cardiomyocytes express a Na+/H+ exchanger (NHE1), two Na+-dependent HCO3- 
cotransporters (NBCe1, NBCn1) and Na+-independent Cl-/HCO3- exchangers that are involved in 
the regulation of pHi. The sodium dependent acid extruders, NHE1 and the Na+-HCO3- 
cotransporters, are activated by intracellular acidification and extrude a H+ or bring in 
bicarbonate to alkalinize the cell. Studies suggest that NBC activity accounts for as much as 40% 
of the pHi recovery from an acid load in the ventricular myocardium [70]. Two Na+/HCO3- 
cotransporters, one electrogenic (NBCe1) and one electroneutral (NBCn1), are expressed in 
mouse hearts. Based on RNA seq data from mouse heart, NBCe1 mRNA (RPKM = 9.45 ± 0.25) 
is expressed at higher levels than NBCn1 (RPKM = 4.24 ± 0.05). NBCe1 has been localized to 
the lateral sarcolemma, intercalated disc, and t-tubules of cardiomyocytes, and it has been 
suggested that the presence of NBCe1 in the t-tubule may be important for proper E-C coupling 
[266]. Inhibition of NBCe1 has been shown to reduce infarct size and improve ventricular 
function during reperfusion [59, 287]. The expression of NBCe1 is elevated in hearts of human 
patients with heart failure but the levels of NBCn1 are unaltered [59]. In a rat model of pressure 
overload hypertrophy induced by aortic constriction, both NBCe1 and NBCn1 mRNAs were 
elevated [60]. These observations suggest that increased Na+-HCO3- cotransport activity may be 
a contributing factor during pathological conditions like myocardial infarction, hypertrophy and 
heart failure.  
The role of NHE1 in ischemia-reperfusion (I/R) injury has been extensively studied and it 
has been demonstrated that NHE1 null mice are protected against I/R injury [90].  Studies using 
inhibitors of NHE1 have also demonstrated cardioprotective effects [82-89]. Since NBCe1 is 
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also involved in acid extrusion, it could potentially contribute to I/R injury. Studies using 
antibodies to inhibit NBCe1 have led to better systolic and diastolic function during reperfusion 
[59, 287]. In a different study, the authors demonstrated that inhibition of NBCe1 in rat hearts 
using antibodies reduced infarct size in myocardial infarction and improved ventricular function. 
The mechanism by which NBCe1 may contribute to reperfusion injury has been suggested to be 
similar to that for NHE1. Activation of NBCe1 by intracellular acidity results in intracellular Na+ 
loading, reversal of the NCX1 Na+ / Ca2+ exchanger, and Ca2+-loading.     
Mice with a targeted global disruption of the Slc4a4 gene exhibit severe metabolic 
acidosis, growth retardation, hyperaldosteronism, splenomegaly, abnormal dentition and die 
before weaning [63]. Because of the severe phenotype it was not possible to examine the cardiac 
functions of NBCe1 using the global KO. Most of the studies to understand the function of 
NBCe1 in heart have been performed using an antibody to specifically inhibit NBCe1, or the 
compound S0859, reported to be a common inhibitor of all NBCs. To better understand the 
function of NBCe1 in heart, we generated cardiac-specific conditional NBCe1 KO mice. The 
cardiovascular function of WT and KO mice was analyzed under basal conditions and in 
response to β-adrenergic stimulation. To determine if loss of NBCe1 is protective against I/R 
injury, in vivo I/R injury was induced in WT and NBCe1 KO mice by subjecting them to 30 
minutes ligation of the LAD artery followed by 3-hour reperfusion. Echocardiography was used 
to monitor left ventricular function post reperfusion. I/R injury in WT and KO hearts was further 
assessed by Masson’s trichrome staining and TUNEL staining.   
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Results 
Targeting strategy for cardiac specific deletion of Slc4a4    
 A targeting construct in which exon 12 of Slc4a4 was flanked with LoxP sites (Slc4a4flx/flx) was 
constructed (Figure 6.1). The construct contains a neomycin resistance gene flanked with 
flippase recognition target (FRT) sites, to allow for selection of ES cells after homologous 
recombination. The neomycin resistance gene (neo) was deleted by breeding with a transgenic 
mouse expressing Flip recombinase. In order to delete Slc4a4 in heart, the Slc4a4flx/flx mouse was 
crossed with a transgenic mouse expressing Cre recombinase under the control of beta myosin 
heavy chain (β-MHC) promoter to obtain Slc4a4flx/+(β-MHC Cre) and Slc4a4flx/+ mice. Further 
breeding between heterozygous mice was set up to obtain Slc4a4flx/flx (β-MHC Cre)   (KO) mice. Cre 
expression under the control of β-MHC promoter results in deletion of Slc4a4 during early 
embryonic development in heart and slow-twitch skeletal muscle. The knockdown of Slc4a4 
mRNA was confirmed in mouse hearts by RT-PCR analysis using primers flanking exon 12. For 
all experiments, flx/flx mice without Cre (WT) were used as controls except for the RNA Seq 
analysis. An additional control, +/+(β-MHC Cre) (Cre control) was also used for RNA Seq analysis.  
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Figure 6.1. Targeting strategy for generation of Slc4a4 conditional KO mice. The targeting 
construct contains a neomycin resistance gene flanked with flippase recognition target (FRT) 
sites to allow selection of ES cells after homologous recombination. Successive breeding with 
transgenic mice expressing Flip recombinase and Cre recombinase (under the β-MHC promoter) 
resulted in cardiac-specific NBCe1 KO mice. 
  
 
Figure 6.2. PCR genotyping and qRT-PCR. A) PCR genotyping showing bands for +/+, flx/+ 
and flx/flx, and B) RT-PCR showing reduction of Slc4a4 mRNA in KO relative to control. 
 
 
 
Genomic 
Locus 
Targeting 
Vector 
Targeted 
Allele 
Flip recombinase 
Cre recombinase 
Conditional 
Allele 
Knockout 
Allele 
13 
neo  
:   LoxP site 
:   FRT site 
:   Exon 
11 12 
12 
13 11 12 neo  
13 11 12 
13 11 
STOP 
A B 
223bp 
176bp 
+/
+ 
flx
/+
 
flx
/fl
x 
102	  	  
PCR genotyping of tail DNA  
DNA isolated from tail biopsies was used to genotype mice. The PCR product size for the 
Slc4a4+/+ is 176 bp and that for the targeted allele Slc4a4flx/flx (floxed) is 223 bp (Figure 6.2A). 
An additional PCR reaction was performed to determine the presence or absence of the Cre 
transgene.    
 
qRT-PCR of NBCe1 mRNA in heart 
Cre recombinase under the control of β-MHC promoter was used to knock down NBCe1 
in heart. In order to determine the percent knockdown of Slc4a4 mRNA in KO hearts relative to 
WT, qRT-PCR was performed with primers specific to exon 12 and exon 13. The results suggest 
that Cre recombinase under the control of β-MHC promoter resulted in ~70% less Slc4a4 mRNA 
in KO hearts relative to WT (Figure 6.2B).   
 
Cardiovascular performance in control and NBCe1 KO mice under basal conditions and in 
response to β-adrenergic stimulation 
Cardiac performance was analyzed under basal conditions and under various doses of the 
β-adrenergic agonist dobutamine. There was no difference in heart rate (HR), mean arterial 
pressure (MAP) or systolic pressure (Figure 6.2 A, B and C) between control and KO mice under 
basal conditions or in response to β-adrenergic stimulation. The contractility (+dP/dT) and 
relaxation (-dP/dt) of the left ventricle (Figure 6.2 D, E and F) were also similar between WT 
and KO mice suggesting normal cardiac function in NBCe1-deficient mice. 
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Figure 6.3. Cardiovascular performance in WT and KO mice. Pressure measurements were 
recorded using transducers in the left ventricle and right femoral artery of anesthetized 2-3 
month-old control and KO mice under basal conditions and in response to β-adrenergic 
stimulation (intravenous infusion of increasing doses of dobutamine). A) Heart rate B) mean 
arterial pressure, C) systolic left ventricular pressure, D) maximum +dP/dt in mm Hg/sec E) 
+dP/dt at 40 mm Hg and F) and minimum −dP/dt in mm Hg/sec are shown for WT and KO 
mice.  n = 8 control (4 female, 4 male) and 8 KO (4 female, 4 male).    
 
RNA sequencing of mRNA from control and NBCe1 KO hearts   
To determine changes in gene expression patterns in KO hearts relative to the control, 
RNA seq analysis was performed. In addition to the WT control, +/+ (β-MHC cre) (Cre control) was 
also used as one of the controls. The Cre control was used to rule out any changes in gene 
expression caused because of the presence of Cre recombinase and not due to loss of NBCe1 in 
heart. There were ~452 genes differentially expressed between WT and KO (WT vs KO) groups.  
Interestingly, there were ~1107 genes differentially expressed between Cre control and KO 
hearts, and ~899 genes between WT and Cre control. These results suggest that the presence of 
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“Cre transgene” results in differential expression of a large number of genes. It was difficult to 
isolate the genes that are differentially expressed in the KO due to loss of NBCe1 and not 
because of the presence of “Cre transgene”. 
 
In vivo ischemia-reperfusion 
 To determine the role of NBCe1 in I/R injury, WT and KO hearts were subjected to 30 
minutes of ischemia followed by 3 hours of reperfusion. This was done by temporary ligation of 
the left anterior descending (LAD) artery. Echocardiography was used to measure left ventricular 
dimensions before ligation of the LAD (pre I/R) and 2 hours after reperfusion (post I/R). The left 
ventricular dimensions were then used to calculate EF% and FS%, measures of left ventricular 
function. Masson’s trichrome staining was performed to analyze fibrosis and TUNEL staining to 
detect apoptosis. 
 
Echocardiography to assess left ventricular function before ischemia and after reperfusion 
The inner dimensions of the left ventricle after reperfusion (post I/R) were the same in 
both WT and KO relative to pre I/R values. The Ejection fraction (EF%) and Fractional 
shortening (%FS), measures of left ventricular systolic function, calculated from the inner 
dimensions of the left ventricle, were also similar between WT and KO (Figure 6.3). There is a 
reduction in EF% and FS% post I/R, but we did not see a reduction in EF% and FS% in WT 
mice. Echocardiography is not a sensitive method to measure left ventricular function especially 
when the number of mice in the study is small. Since this study consisted of only a small cohort 
(4 WT and 6 KO) of mice, we did not see any significant changes in these measurements.   
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Figure 6.4. Ejection fraction and Fractional shortening from echocardiography in WT and 
KO hearts before I/R (pre) and after reperfusion (post). (A) EF% and (B) FS% were calculated 
from the inner dimensions of the left ventricle during systole and diastole. WT n=4, KO n=6. 
 
 
 
Masson’s trichrome staining to determine remodeling of left ventricle 
Masson’s trichrome staining of heart sections post reperfusion showed very little fibrosis 
in both WT and KO hearts (Figure 6.4). The observed fibrosis was similar in WT and KO 
sections and mainly localized to the blood vessels (perivascular fibrosis). The reason for the 
absence of major areas of fibrosis might be because of the short duration of reperfusion (3 hours) 
before collecting tissues. Although hypercontracture of cardiomyocytes was observed in some 
sections, it was not obvious and easy to detect. Hematoxylin-Eosin (H&E) staining is a better 
technique to determine morphology of the cardiac sections post reperfusion. Additionally, 
electron microscopy can be used to determine hypercontracture injury and mitochondrial damage 
in cardiomyocytes.   
A B 
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Figure 6.5. Masson’s trichrome staining to detect fibrosis in WT and KO hearts post 
reperfusion. Transverse sections of heart from (A) WT and (B) KO mice showing perivascular 
fibrosis.   
 
Detection of apoptosis of cardiomyocytes due to I/R injury by TUNEL staining   
   Studies have shown that apoptotic cell death occurs mainly during reperfusion of 
ischemic tissue [288-290]. TUNEL staining was done to detect apoptotic cell death and quantify 
apoptotic nuclei on WT and KO heart sections. Apoptotic nuclei were detected in both WT and 
KO heart sections mostly in the left ventricular free wall (Figure 6.5A). However, there were 
significantly fewer apoptotic nuclei (Figure 6.5B) in KO sections (40.58 ± 6.36 apoptotic nuclei 
per mm2) relative to WT (142 ± 13.59 apoptotic nuclei per mm2). An increase in intracellular 
Ca2+ results in the opening of the mitochondrial permeability transition pore, which then leads to 
apoptosis. These preliminary results suggest that there is less myocyte death in the NBCe1 KO 
and that loss of NBCe1 is protective against I/R injury.  
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Figure 6.6. TUNEL staining to quantify apoptosis in WT and KO heart sections post 
reperfusion. (A) Representative images from WT and KO heart sections showing nuclei stained 
with DAPI (blue), TUNEL (red) and sarcomeric actin (green). Yellow arrows point to apoptotic 
nuclei (pink). (B) Quantification of apoptotic nuclei. WT n=4, KO n=4, p ≤ 0.05.  
 
 
Conclusions   
 
The results from this study showed that loss of NBCe1, does not affect cardiac function 
under basal conditions or in response to β-adrenergic stimulation. The I/R studies suggest that 
NBCe1 KO hearts may be less susceptible to I/R injury. Though left ventricular function and 
tissue remodeling were similar in WT and KO hearts in response to I/R injury, there was 
significantly less apoptosis in the KO hearts suggesting that the loss of NBCe1 may be protective 
108	  	  
against I/R injury. NBCe1 activation during reperfusion results in an increase in intracellular 
sodium concentration, which drives the Na+/Ca2+ exchanger, NCX1 in reverse mode, thereby 
leading to an increase in intracellular calcium. Moreover, activation of NBCe1 has the potential 
to contribute to rapid restoration of physiological pH upon reperfusion. Changes in intracellular 
Ca2+ and pH cause the opening of the mitochondrial permeability transition pore (mPTP) 
resulting in mitochondrial swelling, rupture of outer mitochondrial membrane and release of pro 
apoptotic substances that mediate apoptosis [291]. Less apoptosis in the KO may therefore be 
due to reduced intracellular Ca2+ and also due to a more gradual restoration of intracellular pH. 
These studies are preliminary and additional experiments will be required to confirm that loss of 
NBCe1 protects against I/R injury.  
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Chapter 7 Strain Differences in Cardiac mRNA and Protein Expression 
between C57Bl/6 and FVB/N Mouse Strains  
Summary 
The genetic background often exerts a major effect on the phenotypes of knockout and 
transgenic models of human cardiovascular disease. We intended to study in-vivo cardiac 
performance and expression levels of proteins regulating cardiac function in C57Bl/6 and FVB/N 
mouse strains. Cardiovascular performance measured under basal conditions and in response to β-
adrenergic stimulation was not significantly different between the strains. Western blot analysis 
indicates that levels of total phospholamban (PLN), a regulator of sarcoplasmic reticulum calcium 
ATPase (SERCA2a), are higher and the relative PLN phosphorylation at serine 16 (PS16) lower in 
FVBN hearts compared to C57Bl/6 hearts. The expression of L-type calcium channel (LTCC) was 
significantly higher in C57Bl/6 hearts whereas that of Na,K-ATPase (α1) was higher in FVBN. The 
expression of other calcium and sodium handling proteins, including the ryanodine receptor (RyR), 
SERCA2a, Na/H exchanger 1 (NHE1), the Na/Ca exchanger 1 (NCX1), and its regulator, 
phospholemman, did not differ between these strains. FVB/N hearts also had increased levels of the 
catalytic subunit of protein phosphatase 1 (PP1-C), unmethylated PP2A-C, total calcium 
calmodulin kinase II (CaMKII), phosphorylated CaMKII, and CaMKII delta. The levels of 
sarcomeric proteins, Troponin I (TnI), pTnI, myosin	   regulatory	   light	   chain	   2	   (RLC-­‐2),	  myosin 
binding protein C (MyBP-C), and phospho MyBP-C were not different between the two strains.  
The qRT-PCR analyses indicate significantly increased mRNA expression of L-type calcium 
channel, CaMKII delta, PLN, SERCA2a, and PP1-C in FVB/N hearts compared to C57Bl/6. These 
results demonstrate that there are substantial strain differences in the expression of both calcium 
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handling proteins and major phosphatases and kinases involved in the modulation of cardiac 
function.  
 
Introduction 
C57Bl/6 and FVB/N are two of the most commonly used mouse strains to study various 
mechanisms involved in the pathogenesis of cardiac disease. Previous studies have emphasized 
the importance of strain selection by demonstrating differences in intracellular calcium 
regulation, exercise performance, and cardiomyocyte excitation-contraction coupling. Studies 
have shown that in response to pressure overload, FVBN mice did not show signs of heart 
failure, even after 12 week of TAC [286]. In a different study, C57Bl mice showed decreased left 
ventricular ejection fraction (LVEF), 1 week after pressure overload, whereas FVB/N mice 
maintained baseline levels even after 2 weeks of TAC [292]. 
FVB/NJ demonstrated better performance on treadmill and C57Bl/6J demonstrated the 
lowest performance among the seven different mouse strains compared [293]. However, in 
voluntary wheel-running, C57Bl/6J mice exhibited the best performance and were much better 
than FVB/NJ.  Regarding susceptibility to cardiovascular disease, C57Bl/6J mice are more prone 
than FVB/NJ mice to atherosclerosis induced by high-fat diet and loss of ApoE [294]. C57Bl/6 
mice are more susceptible than FVB/N mice to pressure overload induced cardiac hypertrophy 
and in vivo acute hypoxia [286, 295]. In contrast, the TM180 mutation in α-tropomyosin, which 
causes hypertrophic cardiomyopathy in humans [296], causes hypertrophy in FVB/N mice [297] 
but not in C57Bl/6 mice [298]. In addition, we observed major differences in expression of 
protein phosphatases in AE3-null mice on 129Svj and FVB/N backgrounds (unpublished data).  
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Although strain differences in cardiac physiology, Ca2+ handling in isolated myocytes, 
and disease susceptibility have been studied previously, there is little published information 
about biochemical differences between mouse strains. Two of the mouse strains used most 
commonly for cardiovascular studies are C57Bl/6 and FVB/N. Here we have performed 
biochemical analyses to determine whether there are differences in relative expression levels of a 
number of proteins that play a critical role in the regulation of cardiac function. These included 
analyses of phosphatase levels, which differed significantly in two background strains used for 
our studies of the AE3 cardiac phenotype. Our results reveal dramatic differences in expression 
of CaM Kinase II and the major phosphatases involved in heart disease. 
 
Results 
Expression levels of sarcolemmal proteins involved in Ca2+- handling  
Immunoblot analysis of whole heart homogenates was performed to assess levels of 
major proteins of the sarcolemma and t-tubules that are involved directly or indirectly in Ca2+-
handling (Figure 7.1). These include the L-type Ca2+ channel (LTCC), which mediates entry of 
Ca2+ into the cell; the ryanodine receptor (RyR), which mediates release of Ca2+ from the SR; the 
NCX1 Na+/Ca2+ exchanger, which extrudes Ca2+ from the cell; phospholemman (PLM), which 
affects Ca2+-handling by regulating both NCX1 and the Na+,K+-ATPase [299]; and the NHE1 
Na+/H+ exchanger and the Na+,K+-ATPase, both of which can affect NCX1 activity via 
modulation of intracellular Na+. Expression of LTCC (Figure7.1A) was significantly lower and 
the Na+,K+-ATPase (Figure7.1F) was significantly higher in FVB/N hearts than in C57Bl/6 
hearts. None of the other proteins differed significantly between the two strains.  
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Figure 7.1. Expression of sarcolemmal Ca2+-handling proteins in C57Bl/6 and FVB/N 
hearts. Whole heart homogenates from mice of both strains were analyzed by immunoblotting 
and densitometry. A) L-type calcium channel α2 subunit (DHPR), B) Ryanodine receptor (RyR), 
C) Sodium Ca+2 exchanger 1 (NCX), D) regulator of NCX and Na+,K+-ATPase), 
phospholemman (PLM), E) Na+/H+ exchanger 1 (NHE1), and F) Na+,K+-ATPase α1 subunit. n=4 
for each strain. *≤ 0.05.  
 
 
Expression levels of sarcoplasmic reticulum proteins involved in Ca2+- handling  
Immunoblot analysis of whole heart homogenates was performed to assess levels of 
major proteins of the sarcoplasmic reticulum (SR) that are involved directly or indirectly in Ca2+-
handling (Figure 7.2). These include SERCA2a, the SR Ca2+ pump; phospholamban (PLN), 
which serves as a negative regulator of SERCA2a when in its non-phosphorylated form; and 
PLN phosphorylated on Ser16 (PS16) or Thr17 (PT17), both of which relieve the inhibition of 
A
F#E
D#C
B#
* 
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SERCA2a. Expression of total PLN was significantly higher in FVB/N hearts (Figure 7.2B). 
When normalized to the levels of total PLN, PT17 levels ((Figure7.1D) were not different 
between the two strains; however, PS16 levels (Figure7.1C) were significantly reduced (p < 
0.05). The level of SERCA2a was not different between the 2 strains. 
 
 
Figure 7.2. Relative expression levels of sarcoplasmic reticulum proteins involved directly 
or indirectly in Ca2+- handling in C57Bl/6 and FVB/N hearts. Whole heart homogenates from 
mice of both strains were analyzed by immunoblotting and densitometry. A) SERCA2a 
(Serca2a), B) Total phospholamban (PLN), C) PLN phosphorylated on Ser17 (PS16), and D) 
PLN phosphorylated on Thr17 (PT17). n = 4 for each strain and *p ≤ 0.05. 
 
Expression levels of the major phosphatases involved in cardiac function 
 
 The same heart homogenates were analyzed to determine strain differences in the relative 
expression of the major protein phosphatases. The catalytic subunit of protein phosphatase 1 
(PP1-C) was ~3-fold higher in FVB/N than in C57Bl/6 hearts (Figure 7.3A). Total expression of 
the catalytic subunit of protein phosphatase 2A (PP2A-C), consisting of both the non-methylated 
and carboxymethylated forms of the protein, was the same in both strains (Figure 7.3B); 
however, there was ~7-fold greater levels of unmethylated PP2A-C in FVB/N hearts (Figure. 
7.3C). 
A"
D"C"
B"
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Figure 7.3. Expression of the catalytic subunits of protein phosphatases PP1 and PP2A 
(PP1-C and PP2A-C) in C57Bl/6 and FVB/N hearts. A) catalytic subunit of protein 
phosphatase1 (PP1-A), B) catalytic subunit of total protein phosphatase 2A (PP2A-C), and C) 
unmethylated PP2A-C. n = 4 for each strain and *p ≤ 0.05.   
  
Expression of calcium calmodulin kinase involved in cardiac function 
The heart homogenates were analyzed to determine strain differences in the relative 
expression of the calcium calmodulin kinase. The expression levels of CaMKIIδ (~4-fold), total 
CaMKII (~2.5-fold), and phosphorylated CaMKII (~1.8 fold) were significantly higher in 
FVB/N hearts (Figures 7.4A-C)    
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Figure 7.4. Expression of CaMKIIδ and pCaMKII proteins in C57Bl/6 and FVB/N hearts. 
A) Ca+2 Calmodulin kinase II delta (CaMKIId), B) Total CaMKII, and C) Phosphorylated 
CaMKII (pCaMKII). n = 4 for each strain and *p ≤ 0.05. 
 
 
 
Expression of Myofibrillar proteins TnI, pTnI, RLC-2, and relative pMBPc  
There were no significant differences in the expression of myofibrillar proteins, total 
troponin I (TnI), relative levels of phosphorylated TnI (pTnI) (Figure 7.5A), myosin regulatory 
light chain 2 (RLC-2) (Figure 7.5B), total myosin binding protein C (MyBP-C) and relative 
levels of phosphorylated MyBP-C (pMBP) (Figure 7.5C) between the C57Bl/6 and FVB/N mice.   
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Figure 7.5. Expression of Myofibrillar proteins TnI, pTnI, RLC-2, and relative pMBPc in 
C57Bl/6 and FVB/N hearts. A) TroponinI (TnI), and pTnI, B) Myosin	  regulatory	  light	  chain	  2	  (RLC-­‐2),	  and	  C)	  Myosin binding protein C (MyBP-C) and pMyBP-C. n = 4 for each strain.   
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Figure 7.6. Cardiovascular performance BL6 and FVBN hearts under basal and β-
adrenergic stimulation: Pressure measurements were recorded using transducers in the left 
ventricle and right femoral artery of anesthetized 2.5-month-old BL6 or FVBN mice under basal 
conditions and in response to β-adrenergic stimulation (intravenous infusion of increasing doses 
of dobutamine). There was no significant difference in A) heart rate, B) mean arterial pressure, 
C) systolic left ventricular pressure, D) maximum +dP/dt, E) +dP/dt at 40 mm Hg, and F) 
minimum -dP/dt between BL6 and FVBN hearts.  (n = 4 for each strain of mice). 
  
  
Cardiovascular performance in C57Bl/6 and FVB/N mice under basal conditions and in 
response to β-adrenergic stimulation 
Cardiac performance was analyzed under basal conditions and under various doses of the 
β-adrenergic agonist dobutamine. There was no difference in heart rate (HR), mean arterial 
pressure (MAP) and systolic pressure (Figures 7.6 A-C) between C57Bl/6 and FVB/N mice 
under basal conditions and in response to β-adrenergic stimulation. The contractility (+dP/dT) 
and relaxation (-dP/dt) of the left ventricle (Figures 7.6 D-F) were also similar between C57Bl/6 
and FVB/N mice suggesting similar cardiac performance in both strains of mice.  
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Expression of mRNA of some of the significantly changed proteins  
 To determine the mRNA expression of some of the significantly changed proteins 
identified by densitometry of immunoblots, qRT-PCR was performed with specific primers. 
mRNAs for CaMKIIδ, LTCCα1, SERCA2a, PLN, and PP1-Cα were significantly higher 
(Figures 7.7A-E) in FVBN hearts. The increased expression of CaMKIIδ, PLN, and PP1-Cα 
mRNA levels correlated with increased protein expression. The levels of SERCA2a mRNA was 
increased significantly in FVB/N hearts, but protein levels remain unchanged. For the qRT-PCR, 
primers were designed for the α1-subunit of the LTCC whereas in immunoclot analysis, the α2-
subunit was detected.  
 
Figure 7.7. Expression of m-RNA levels in C57Bl/6 and FVBN hearts. Proteins that were 
significantly different in immunoblot analysis only were selected for RTPCR analysis: RTPCR 
analysis of m-RNA expression levels relative to GAPDH showed significantly higher expression 
of the A) CaMKIIδ, B) L-type calcium channel (α-1), C) Serca2a, D) PLN, and E) catalytic 
subunit of protein phosphatase 1α (PP1-Cα) in FVBN hearts compared to BL6 hearts. n = 4 for 
each strain and *p ≤ 0.05.    
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Conclusions 
 
The results from this study show that there are major differences in the expression of 
signaling proteins in C57Bl/6 and FVB/N mice hearts. The protein phosphatases and CaMKII 
that can modulate the activity of a number of proteins, involved in cardiac function were 
significantly higher in FVB/N hearts. However, cardiovascular performance was not 
significantly different between C57Bl/6 and FVB/N mice. Previous studies have demonstrated 
that strain differences have a major impact on disease expression in response to genetic 
manipulations and various pathological stresses and could, therefore, affect the results of our 
AE3 studies. 
As noted earlier, there are dramatic differences in the degree of hypertrophy in the 
TM180 hypertrophic cardiomyopathy models developed on the FVB/N [297] and C57Bl/6 [298] 
backgrounds. This suggests that use of the C57Bl/6 background for the AE3/TM180 double 
mutants could have led to a different phenotype than observed on the FVB/N background [37]. 
Also as noted earlier, C57Bl/6 mice are more susceptible to both pressure overload hypertrophy 
and in vivo acute hypoxia than FVB/N mice [286, 295]. Thus, it is possible that the C57Bl/6 
strain would be a more sensitive background for uncovering the pathological effects of AE3 
ablation. These considerations emphasize why it is important to consider differences in 
background strains when studying particular diseases using mouse models.   
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Chapter 8: Conclusions and future directions 
 
The AE3 Cl-/HCO3- exchanger is predominantly expressed in brain, retina and heart. A 
cardiac variant of AE3 (cAE3) is the most abundant isoform in heart and is expressed in the 
sarcolemma and T-tubules of cardiomyocytes [20]. The presence of a novel relatively cardiac-
specific isoform and the very high levels of expression in cardiac myocytes suggest that it is a 
bulk transporter of HCO3- and serves a specialized function. AE3-null mice have defects in the 
inner retina and degeneration of photoreceptors [36]. Moreover, AE3 KO mice exhibit reduced 
seizure threshold and increased seizure-induced mortality [35]. In contrast, AE3 KO mice exhibit 
normal cardiovascular function under most conditions, which was unexpected. However, loss of 
AE3 in the TM180 HCM model resulted in rapid decompensation and heart failure. More 
recently it was reported that AE3 KO mice have an impaired force frequency response, 
accompanied by sharply increased AKT signaling at higher heart rates [38], clearly indicating 
that AE3 has an important function in heart. 
Though a convincing function of AE3 in heart has not yet been reported, various studies 
have proposed the hypothesis that Cl-/HCO3- exchange coupled to the NHE1 Na+/H+ exchanger 
leads to pH neutral Na+-loading, reversal of Na+/Ca2+ exchange and Ca2+-loading. The increase 
in intracellular Ca2+ can affect both contractility and cardiac hypertrophy. If AE3 is involved in 
hypertrophy, then AE3 KO mice should be less susceptible to hypertrophy. Previous studies have 
shown that AE3 KO mice have a slightly reduced heart weight to body weight ratio, consistent 
with the hypothesis that AE3 may play a role in hypertrophy [1]. However, loss of AE3 in an 
HCM model did not reduce hypertrophy [37]. In order to determine if loss of AE3 was protective 
against pressure overload hypertrophy, WT and AE3 KO mice were subjected to transverse 
aortic constriction (TAC). There was no difference in the level of hypertrophy between WT and 
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AE3 KO hearts suggesting that AE3 is not involved in the hypertrophic response at least in the 
TAC model (Chapter 4). A surprising observation in the TAC study was that even after 17 
weeks, neither the WT nor the KO showed any signs of cardiac decompensation or failure. The 
AE3 KO mice were on the FVB/N background and previous studies have reported that FVB/N 
mice are resistant to TAC-induced heart failure [286]. In order to determine if loss of AE3 leads 
to decompensation in response to TAC, as was seen in the hypertrophic cardiomyopathy model, 
generating AE3 KO mice on a C57Bl/6 background may be necessary.   
To further understand the function of AE3 in heart and why loss of AE3 leads to heart 
failure in the HCM model and impairs FFR, RNA seq analysis was performed. Analysis of RNA 
Seq data  (Chapter 3) revealed differential expression patterns for genes encoding proteins 
involved in hypoxia responses, angiogenesis, vasodilation, glucose and fatty acid metabolism, 
cardiac conduction and electrical activity, and myofibrillar organization in AE3 KO hearts. Some 
of these changes strongly indicate impaired O2/CO2 balance in AE3 KO hearts. These results 
provided support for the hypothesis that the major function of AE3 in heart is CO2 disposal.  
Modest changes in genes encoding proteins involved in hypoxia responses and 
downregulation of angiogenesis genes in AE3 null hearts indicates that the hypoxia response is 
restricted to myocytes and that non-myocyte cardiac tissues are likely to be well-oxygenated. 
These patterns suggest mild hypoxia in myocytes in response to lack of AE3 that is partially 
resolved by an increase in ANP and adrenomedullin, which are major mediators of vasodilation. 
Genes involved in ion channel activities and cardiac conduction were also differentially 
regulated in AE3 KO hearts. Various studies have reported effects of hypoxia on ion channels 
[227-229] and so changes in ion channel and cardiac conduction genes are consistent with 
hypoxia. Interestingly most of the genes in this category were upregulated in AE3 KO hearts.   
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 The myocardium is an obligate aerobic tissue, consuming huge amounts of oxygen and 
relying mostly on fatty acid metabolism for energy. The differential expression of hypoxia 
response, vasodilation, and angiogenesis genes was the most direct indication of impaired 
O2/CO2 balance in AE3-null hearts. In future studies it will be necessary to perform 
comprehensive analyses of the expression levels of the proteins involved in these hypoxia 
responses, as well as nuclear localization studies of some of the relevant transcription factors. In 
addition, the sensitivity of AE3 KO and WT mice to altered O2 and CO2 in the air they are 
breathing should be studied. If AE3 KO myocytes are relying more heavily on diffusion as a 
means of CO2 disposal, then they could be much more sensitive to increased CO2.  
The changes in metabolic genes strongly suggest an increase in glucose metabolism and a 
reduction in fatty acid metabolism. These changes are fully consistent with an O2/CO2 imbalance 
in AE3-null hearts, as they would provide a more favorable ATP/O2 ratio during mild hypoxia. 
Interestingly, the proteins encoded by many of the genes involved in glucose metabolism that 
were upregulated are known to serve as effector proteins in response to Akt signaling. 
Phosphorylation of Akt is sharply increased in paced AE3 KO hearts [38], suggesting that the 
increased expression of genes encoding Akt effector proteins during pacing may enhance glucose 
uptake and metabolism under this stress condition. Additional experiments to determine changes 
in substrate utilization and quantitation of cellular ATP levels and other metabolic substrates and 
products, as well as studies of isolated cardiac mitochondria, will be required to confirm shifts in 
energy metabolism in AE3 KO hearts. Additionally, the expression levels of proteins involved in 
metabolism and their phosphorylation status might provide additional evidence for alterations in 
metabolism that are consistent with impaired O2/CO2 balance in AE3 KO hearts. Of particular 
interest will be the large number of glucose metabolism proteins that are upregulated at the 
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mRNA level and that are also known to be regulated by Akt. If glucose metabolism in AE3 KO 
mice is more heavily stimulated by Akt activation during pacing, then use of an Akt inhibitor 
may reveal a greater deficit in AE3 KO mice than in WT mice. 
Previous studies using our mouse model have reported that AE3 mediates ~60-70% of 
HCO3- extrusion in isolated cardiomyocytes [119], suggesting that the activity of AE2 and PAT1 
Cl-/HCO3- exchangers might provide some compensation for the loss of AE3. AE2 is expressed 
at levels higher than PAT1 in mouse heart and studies using conditional cardiac-specific AE2 
KO mice (Chapter 5) demonstrate normal cardiovascular function and expression of Ca2+ 
handling proteins in heart. This is not unexpected given the very high levels of AE3 relative to 
AE2, but it is likely that AE2 contributes much of the residual HCO3--extrusion activity, 
consistent with a compensatory function in AE3-null hearts. Although the high level of AE3-
mediated HCO3--extrusion activity is consistent with the hypothesis that AE3 functions in pHi 
regulation, it is unlikely that the impaired force frequency response of AE3 KO mice at elevated 
heart rates, which would generate increased metabolic acid, is due to an increased alkaline load. 
Therefore, the data are not consistent with the hypothesis that the function of AE3 is to mediate 
recovery from an alkaline load. 
The RNA seq data combined with the previously proposed CO2 disposal activity of AE3 
in retina and brain provides strong evidence for a CO2 disposal function for AE3 in heart. 
Currently, we are crossing the AE3 KO mouse with the conditional cardiac-specific AE2 KO 
mice to generate mice that lack both AE2 and AE3 in heart. With most of the Cl-/HCO3- 
exchange activity in heart lost, we expect that AE2/AE3 double KO mice will have a significant 
impairment in cardiac function and force frequency response. For these studies it would probably 
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be best to inbreed onto the C57Bl/6 background (which the AE2 KO is being placed on) in order 
to compare the double KO mice with WT, AE2 KO, and AE3 KO controls.   
The identification of HVCN1 expression in mouse heart is another novel finding of this 
study, and analysis of the EBI Expression Atlas showed that it is also expressed in all other 
mammalian hearts examined. The myocardium is a highly aerobic tissue generating huge 
amounts of acid. So far, NHE1 has been considered as the predominant H+ extruding mechanism 
in heart. However, extrusion of H+ by NHE1 is not an energetically efficient mechanism. This 
will result in the uptake of Na+ that will have to be removed by the Na,K-ATPase using 
additional ATP.  HVCN1 in heart would be an energetically efficient system for H+ extrusion 
because the channel is activated by a positive membrane potential, does not require use of ATP 
to reestablish ion gradients, and its activity would provide charge balance. Unpublished data 
from Dr. HongSheng Wang’s laboratory further confirm the expression and activity of HVCN1 
in both whole heart and isolated cardiomyocytes. Additional studies on the HVCN1 channel 
using global and conditional cardiac-specific KO mice are needed to understand the role of this 
channel in heart. 
In chapter 6, the function of the NBCe1 electrogenic sodium bicarbonate cotransporter in 
heart was characterized. Cardiac specific NBCe1 KO mice exhibit normal cardiovascular 
function. However, preliminary studies demonstrate less ischemia reperfusion (I/R) injury in the 
KO mice in response to in vivo I/R. Though quantitation of apoptotic nuclei showed significantly 
fewer numbers of apoptotic nuclei in the KO sections, no differences were observed in the EF% 
or FS% (calculated from the inner dimensions of the LV by echocardiography) between WT and 
KO cohorts. Echocardiography is a less sensitive method to measure function of the LV, 
particularly when there are relatively few mice in each cohort. The initial study was carried out 
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with 4 WT and 6 KO mice. Adding additional mice to the study will help us determine the 
decline in EF% and FS% in both WT and NBCe1 KO hearts.  
  The genetic background often exerts a major effect on the phenotypes of knockout and 
transgenic models of human cardiovascular disease. In chapter 7, we looked at differences in the 
relative expression of major proteins that play a critical role in the regulation of cardiac function 
in the 2 most commonly used mouse strains, C57Bl/6 and FVB/N. Our results reveal dramatic 
differences in expression of CaM Kinase II and the major phosphatases involved in heart disease. 
The increased susceptibility of C57Bl/6 mice to hypertrophy and hypoxia discussed in that 
chapter suggest that the C57Bl/6 background might be better for studies of the effects of AE3 
ablation on pressure overload hypertrophy and for further tests of the CO2 disposal hypothesis. 
In summary, the data presented in this thesis, as well as previous studies of the 
AE3/TM180 double mutant mice [37], strongly indicate that the loss of AE3 is not 
cardioprotective, as previously suggested [119]. Instead the data support the hypothesis that the 
major function of AE3 is to serve in a coupled system in which HCO3- and H+, generated from 
the hydration of CO2, is continuously extruded from the myocyte. The use of an active transport 
mechanism to extrude CO2 in the form of HCO3- and H+ would allow the cell to increase O2 
utilization and CO2 generation during periods of high metabolic demand, without inhibiting 
oxidative phosphorylation by a buildup of CO2.    
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Appendix	  1:	  Differential expression of genes involved in hypoxia responses, vasodilation, 
or angiogenesis. 
	  
Gene 
Symbol 
Wt 
average 
KO 
average 
Wt SE KO SE Fold 
Change 
p-value FDR 
Egln3 89.66 47.54 1.71 1.35 0.52 8.89E-62 5.62E-58 
Agtr1a 9.33 16.64 0.81 0.32 1.76 8.72E-18 3.31E-14 
Gja5 9.70 14.57 0.39 0.47 1.48 2.55E-14 4.84E-11 
Ezr 21.50 29.79 0.53 0.78 1.37 5.41E-13 7.33E-10 
Txnrd1 24.60 18.51 0.21 0.39 0.74 1.21E-12 1.44E-09 
Col4a2 72.91 58.76 0.37 1.99 0.79 7.53E-11 4.61E-08 
Col4a1 91.31 71.96 1.36 3.38 0.78 5.40E-10 2.69E-07 
Map2k6 3.15 5.30 0.16 0.27 1.66 1.23E-09 4.94E-07 
Sema3f 9.28 6.50 0.39 0.15 0.69 2.35E-09 8.72E-07 
Slc40a1 6.04 4.17 0.27 0.08 0.68 3.44E-09 1.21E-06 
Fgf1 4.82 6.96 0.30 0.18 1.43 5.48E-09 1.89E-06 
Nr3c2 5.23 8.31 0.53 0.20 1.57 2.31E-08 6.94E-06 
Slc24a2 0.88 1.36 0.06 0.02 1.51 8.17E-08 2.06E-05 
Anxa2 60.22 49.02 0.76 1.81 0.80 1.05E-07 2.61E-05 
Adra1b 12.61 17.82 0.65 0.79 1.39 1.31E-07 3.11E-05 
Dbh 1.72 3.05 0.14 0.14 1.75 1.36E-07 3.18E-05 
Kcnj4 1.56 0.70 0.10 0.06 0.44 2.72E-07 6.00E-05 
Egf 2.43 3.75 0.21 0.14 1.52 2.91E-07 6.28E-05 
Nppa 2484.91 3378.46 115.19 116.09 1.34 5.05E-07 9.64E-05 
Bmpr2 11.69 9.12 0.32 0.13 0.77 6.27E-07 0.000113244 
Sqstm1 242.96 204.54 5.87 2.84 0.83 6.53E-07 0.00011687 
Mrvi1 4.30 5.72 0.11 0.13 1.31 7.08E-07 0.000124255 
Bnip3 90.52 65.09 3.78 3.34 0.71 7.81E-07 0.000133461 
Adora2a 5.35 3.76 0.13 0.17 0.69 8.73E-07 0.000146414 
Notch4 10.57 8.30 0.23 0.31 0.77 9.23E-07 0.000153438 
Dkk3 40.17 49.37 0.49 0.82 1.21 2.06E-06 0.000319835 
Ucp2 20.75 17.17 0.78 0.53 0.82 4.96E-06 0.000676959 
Pvr 10.27 7.99 0.23 0.14 0.77 5.23E-06 0.000707757 
Retnla 13.91 23.40 1.99 0.82 1.66 6.14E-06 0.000807636 
Lepr 1.70 2.34 0.07 0.08 1.36 9.03E-06 0.001071868 
Ramp1 0.63 1.20 0.11 0.05 1.87 1.06E-05 0.001207795 
Nrp2 10.60 9.00 0.37 0.21 0.84 1.22E-05 0.001363567 
Hif1a 13.83 17.06 0.51 0.41 1.22 1.24E-05 0.001380548 
Ptk2b 2.09 2.95 0.09 0.15 1.39 1.63E-05 0.001737674 
Ccnd2 29.63 23.90 1.07 0.53 0.80 1.71E-05 0.001804552 
Bdh1 107.60 83.89 3.02 4.28 0.77 2.22E-05 0.002194845 
Adam15 33.77 28.90 0.49 0.86 0.84 2.34E-05 0.002276885 
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Cryab 1574.20 1276.31 65.47 25.96 0.80 2.46E-05 0.002347527 
Kcnd2 9.11 11.62 0.53 0.26 1.26 2.49E-05 0.002359541 
Camk2g 19.16 23.21 0.76 0.55 1.20 2.89E-05 0.002684276 
Prkcz 1.54 0.98 0.12 0.05 0.63 2.92E-05 0.002684276 
Fhl2 752.99 658.95 14.19 9.31 0.86 3.78E-05 0.003322186 
Vegfa 79.05 63.49 3.55 0.44 0.79 4.26E-05 0.003673807 
Crhr2 11.70 14.57 0.40 0.52 1.23 4.73E-05 0.003994844 
Kcnc1 0.58 0.40 0.02 0.04 0.68 5.03E-05 0.004186376 
Rcor2 7.18 10.09 0.66 0.34 1.39 5.87E-05 0.004778381 
Prkcb 0.66 0.95 0.04 0.06 1.42 6.01E-05 0.004872765 
Ppard 15.88 13.19 0.23 0.11 0.82 7.55E-05 0.005890514 
P4ha2 38.95 30.28 2.11 0.49 0.77 7.55E-05 0.005890514 
Eef2k 7.46 9.92 0.52 0.34 1.31 7.82E-05 0.006024687 
Kcnh2 28.00 35.94 1.55 1.35 1.27 8.10E-05 0.006145675 
Kdr 60.75 47.16 3.47 1.44 0.77 8.17E-05 0.006167493 
Flnb 12.00 10.38 0.21 0.18 0.85 8.22E-05 0.006182182 
Rapgef1 47.04 41.32 1.20 0.61 0.87 9.11E-05 0.006636251 
Efnb2 9.52 8.00 0.29 0.36 0.83 0.000101974 0.007268152 
Rxfp1 2.72 3.90 0.10 0.18 1.42 0.000107573 0.007609978 
Thra 32.15 38.53 0.93 0.91 1.18 0.000114091 0.007952361 
Tfpi 32.31 38.15 0.42 0.86 1.16 0.000115635 0.008030516 
Alas2 14.45 9.83 1.11 0.78 0.67 0.000145821 0.009700394 
Serpinh1 110.86 81.61 7.52 2.29 0.73 0.000155332 0.010261109 
Map3k7 16.04 18.95 0.29 0.39 1.17 0.000159832 0.010521698 
Mmp9 1.36 0.83 0.10 0.03 0.60 0.000176456 0.011226247 
Prkab1 18.05 21.94 0.68 0.52 1.20 0.000211485 0.013060434 
Abra 37.97 22.93 3.86 1.88 0.59 0.000236332 0.014191881 
Myh9 46.82 41.50 0.88 0.58 0.87 0.000264145 0.015643414 
Dab2ip 14.03 12.24 0.25 0.13 0.86 0.000264667 0.015643414 
Rbm3 9.41 13.52 1.04 0.41 1.42 0.000264863 0.015643414 
E2f8 0.50 0.89 0.04 0.05 1.74 0.000317438 0.017858502 
Rcan2 176.13 157.22 1.19 2.05 0.88 0.000329561 0.018302192 
Mtss1 7.23 8.81 0.26 0.28 1.20 0.000329757 0.018302192 
Tbx5 11.15 13.53 0.42 0.52 1.20 0.000366587 0.019833447 
Cadm1 1.01 1.52 0.08 0.12 1.48 0.000384777 0.020555726 
Notch1 11.90 10.25 0.44 0.09 0.85 0.000390465 0.020794448 
Pparg 6.85 5.30 0.29 0.38 0.76 0.000399451 0.021154176 
Npr3 12.12 14.27 0.15 0.23 1.16 0.00041751 0.021821622 
Cd248 8.85 6.81 0.44 0.44 0.76 0.000431731 0.022425165 
Met 1.59 1.16 0.10 0.07 0.72 0.000445579 0.022889218 
Wif1 11.84 15.65 0.65 0.79 1.31 0.000452514 0.022990029 
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Mafg 16.85 13.92 0.35 0.33 0.81 0.000469188 0.02370384 
Eltd1 24.05 19.09 0.97 1.37 0.78 0.000510454 0.025023166 
Hspb2 46.27 54.81 1.87 1.52 1.17 0.000526791 0.02554331 
Lrp5 19.69 17.23 0.61 0.18 0.86 0.000530017 0.025560881 
Sema5a 1.36 1.75 0.05 0.05 1.27 0.000592504 0.027465244 
Abcc8 14.02 16.33 0.28 0.55 1.15 0.000619089 0.02811567 
Ncor2 17.93 15.76 0.34 0.39 0.87 0.000638306 0.028609095 
Vcan 3.46 2.79 0.16 0.14 0.79 0.000679875 0.030186777 
Stc2 10.68 13.45 0.57 0.59 1.24 0.000690663 0.030594126 
P4ha1 31.99 19.29 3.68 0.75 0.59 0.000733132 0.031305071 
Sparc 234.62 207.33 8.47 6.02 0.87 0.000762215 0.032328489 
Mitf 12.92 15.29 0.27 0.22 1.17 0.000776435 0.032645446 
Cirbp 21.12 33.82 3.23 2.11 1.58 0.000776576 0.032645446 
Vash1 7.08 5.97 0.19 0.17 0.83 0.000782444 0.032819366 
Grb2 33.68 39.03 1.17 0.30 1.14 0.000858829 0.035167461 
Ackr3 47.99 40.91 2.16 0.92 0.84 0.000880671 0.035829721 
St3gal1 15.01 13.21 0.35 0.27 0.87 0.001014577 0.039990371 
Grb10 30.28 26.87 0.88 0.64 0.87 0.001040642 0.040595735 
Abcc9 84.86 96.05 1.34 1.58 1.12 0.001071067 0.0415525 
Tbc1d1 7.28 8.65 0.21 0.23 1.17 0.00111095 0.042636661 
Igfbp3 11.23 13.53 0.50 0.49 1.19 0.001172999 0.044656399 
Eng 68.45 58.75 2.31 1.76 0.85 0.001229331 0.046061053 
Lum 45.85 57.58 3.40 0.95 1.24 0.001238648 0.046318611 
F2r 22.58 20.18 0.55 0.70 0.88 0.001268914 0.047110856 
Adam12 0.38 0.23 0.04 0.02 0.59 0.001269774 0.047110856 
Gata6 23.85 27.88 0.72 0.49 1.15 0.001307012 0.047744954 
Wee1 9.06 11.17 0.40 0.52 1.22 0.00131554 0.047780328 
Gpr4 6.33 5.26 0.21 0.22 0.82 0.001331934 0.04825825 
Prex2 6.17 5.40 0.18 0.05 0.86 0.001352508 0.04865691 
Usp20 18.49 21.54 0.28 0.39 1.15 0.00138544 0.04965322 
Fgf6 0.75 0.31 0.12 0.05 0.40 0.00140595 0.049919323 
Calcrl 10.81 9.46 0.44 0.32 0.86 0.001620283 0.054660035 
Anxa3 16.09 13.65 0.29 0.56 0.84 0.001940142 0.061203246 
Ednrb 4.33 3.68 0.11 0.12 0.84 0.002316332 0.070264556 
Esm1 1.41 0.94 0.12 0.09 0.66 0.002536583 0.075259897 
Amot 2.31 1.82 0.16 0.04 0.78 0.002752248 0.079542496 
Acvrl1 14.07 12.44 0.30 0.27 0.87 0.003199246 0.088288941 
Tnfrsf12a 44.87 27.53 5.97 1.51 0.60 0.003976719 0.104746319 
C3 76.02 69.63 1.73 1.40 0.90 0.004078919 0.106079881 
Mfge8 72.89 65.39 1.28 1.83 0.88 0.004290324 0.109734773 
Nus1 21.89 19.75 0.56 0.49 0.89 0.004368581 0.110875406 
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Cx3cr1 1.94 3.25 0.27 0.33 1.66 0.004626104 0.115555074 
Sod3 30.96 27.50 0.35 1.27 0.88 0.00485722 0.118739894 
Uts2d 1.76 0.92 0.13 0.15 0.52 0.00499498 0.121254573 
Hyou1 18.49 15.54 1.05 0.19 0.83 0.005080704 0.122395253 
Pdcl3 24.28 28.35 0.70 0.57 1.15 0.005311626 0.125878895 
Flt1 25.27 22.57 0.78 0.37 0.88 0.005470205 0.128353485 
Nos3 13.83 12.17 0.42 0.10 0.87 0.006113397 0.137816766 
Pdgfb 20.25 18.30 0.41 0.62 0.89 0.006197961 0.139557183 
Ccbe1 2.54 3.08 0.06 0.11 1.20 0.006309342 0.141059928 
Epas1 81.59 90.65 1.65 1.58 1.10 0.006340133 0.141414799 
Hsp90b1 196.85 169.67 9.80 5.17 0.85 0.006497149 0.143649759 
Loxl2 6.93 5.81 0.36 0.21 0.83 0.007573937 0.157768529 
Camk2d 50.25 56.27 0.98 1.29 1.10 0.008156532 0.165037022 
Ecm1 42.73 38.89 0.98 1.29 0.90 0.00825055 0.166307437 
Dll4 13.35 10.96 0.83 0.52 0.81 0.00825733 0.166307437 
Adm 7.54 10.77 0.67 0.92 1.41 0.009339162 0.17975753 
Angpt1 16.11 19.84 0.91 0.87 1.22 0.009475351 0.181542425 
Gja1 179.41 200.29 4.60 3.95 1.10 0.009475788 0.181542425 
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Appendix 2: Differential expression of genes involved in energy, glucose, and fatty acid 
metabolism. 
 
Gene 
Symbol 
Wt 
average 
KO 
average 
Wt SE KO SE Fold 
Change 
p-value FDR 
Egln3 89.66 47.54 1.71 1.35 0.52 8.89184E-62 5.61934E-58 
Agtr1a 9.33 16.64 0.81 0.32 1.76 8.72458E-18 3.30819E-14 
Txnrd1 24.60 18.51 0.21 0.39 0.74 1.21216E-12 1.43633E-09 
Ehbp1 22.03 29.71 0.43 0.86 1.33 2.81684E-12 2.81076E-09 
Iqgap2 6.68 4.56 0.25 0.16 0.67 3.85321E-12 3.65265E-09 
Abcd2 2.12 3.46 0.16 0.06 1.61 4.14327E-12 3.74058E-09 
Mboat2 7.33 11.20 0.32 0.25 1.51 4.45936E-12 3.84296E-09 
Ppip5k2 32.69 45.84 1.49 1.22 1.38 2.36483E-11 1.7934E-08 
Map2k6 3.15 5.30 0.16 0.27 1.66 1.23286E-09 4.93871E-07 
Fgf1 4.82 6.96 0.30 0.18 1.43 5.47842E-09 1.88846E-06 
Pfkfb2 20.76 16.11 0.72 0.37 0.77 8.09106E-09 2.64909E-06 
Nr3c2 5.23 8.31 0.53 0.20 1.57 2.30673E-08 6.94179E-06 
Ankrd23 323.08 213.72 16.94 11.46 0.65 5.32076E-08 1.42079E-05 
Anxa2 60.22 49.02 0.76 1.81 0.80 1.04679E-07 2.61133E-05 
Adra1b 12.61 17.82 0.65 0.79 1.39 1.31335E-07 3.11247E-05 
Egf 2.43 3.75 0.21 0.14 1.52 2.914E-07 6.27802E-05 
Nppa 2484.91 3378.46 115.19 116.09 1.34 5.05042E-07 9.63584E-05 
Mlxipl 13.23 10.40 0.36 0.35 0.77 5.06394E-07 9.63584E-05 
Entpd5 43.69 59.05 2.98 0.97 1.33 5.10297E-07 9.63584E-05 
Sqstm1 242.96 204.54 5.87 2.84 0.83 6.53422E-07 0.00011687 
Scd2 8.65 11.96 0.44 0.50 1.36 7.71313E-07 0.000132939 
Rbp7 53.46 38.36 0.35 3.41 0.71 1.23E-06 0.000201031 
Dkk3 40.17 49.37 0.49 0.82 1.21 2.05812E-06 0.000319835 
Stard3 11.32 14.66 0.48 0.55 1.28 2.16081E-06 0.000332768 
Mgll 65.31 49.80 2.47 3.10 0.75 2.60833E-06 0.000392471 
Hexa 40.78 33.56 1.53 0.59 0.81 3.02513E-06 0.000444601 
Hist1h2bc 36.58 27.89 1.80 0.41 0.75 3.44559E-06 0.00048033 
Ucp2 20.75 17.17 0.78 0.53 0.82 4.9632E-06 0.000676959 
Sorbs1 150.63 116.10 6.48 3.40 0.76 6.81421E-06 0.000878848 
Prkag2 8.46 11.16 0.31 0.55 1.30 8.15541E-06 0.001017226 
Slc6a8 81.62 66.94 2.77 0.67 0.81 8.34761E-06 0.001034394 
Aldh1b1 12.72 16.35 0.51 0.15 1.27 8.87524E-06 0.001071868 
Lepr 1.70 2.34 0.07 0.08 1.36 9.03228E-06 0.001071868 
Ramp1 0.63 1.20 0.11 0.05 1.87 1.05737E-05 0.001207795 
Hif1a 13.83 17.06 0.51 0.41 1.22 1.2379E-05 0.001380548 
Ppif 130.24 155.61 2.76 0.56 1.18 1.36638E-05 0.00149741 
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Ptk2b 2.09 2.95 0.09 0.15 1.39 1.63145E-05 0.001737674 
Bdh1 107.60 83.89 3.02 4.28 0.77 2.22295E-05 0.002194845 
Prkcz 1.54 0.98 0.12 0.05 0.63 2.91661E-05 0.002684276 
Dctn6 35.16 43.92 1.23 0.71 1.23 3.41198E-05 0.003085349 
Sfrp5 1.14 2.13 0.22 0.11 1.85 3.63315E-05 0.00321873 
Fhl2 752.99 658.95 14.19 9.31 0.86 3.78497E-05 0.003322186 
Crhr2 11.70 14.57 0.40 0.52 1.23 4.7258E-05 0.003994844 
Prkcb 0.66 0.95 0.04 0.06 1.42 6.01417E-05 0.004872765 
Ppard 15.88 13.19 0.23 0.11 0.82 7.54893E-05 0.005890514 
Eef2k 7.46 9.92 0.52 0.34 1.31 7.8175E-05 0.006024687 
Adamts9 5.21 4.22 0.22 0.21 0.80 8.43155E-05 0.00631833 
Cd28 1.44 2.20 0.10 0.15 1.51 8.72547E-05 0.006478092 
Inppl1 62.29 72.73 0.42 1.44 1.15 8.90046E-05 0.006540457 
Thra 32.15 38.53 0.93 0.91 1.18 0.000114091 0.007952361 
Herc1 6.96 8.21 0.23 0.14 1.16 0.000128885 0.008789648 
Nqo2 9.91 12.09 0.33 0.20 1.20 0.000138596 0.009351051 
Stard10 66.87 78.87 1.78 2.21 1.16 0.000181366 0.011500075 
Prkab1 18.05 21.94 0.68 0.52 1.20 0.000211485 0.013060434 
Mid1ip1 43.36 53.60 1.52 2.28 1.22 0.000226162 0.013815421 
Dab2ip 14.03 12.24 0.25 0.13 0.86 0.000264667 0.015643414 
Aplp2 141.27 124.94 2.09 0.95 0.87 0.000272109 0.015971851 
Smarcd3 39.01 46.08 0.64 1.45 1.17 0.000330152 0.018302192 
Tlr4 5.78 4.25 0.40 0.20 0.73 0.000336907 0.018622206 
Pparg 6.85 5.30 0.29 0.38 0.76 0.000399451 0.021154176 
Npr3 12.12 14.27 0.15 0.23 1.16 0.00041751 0.021821622 
Hspb2 46.27 54.81 1.87 1.52 1.17 0.000526791 0.02554331 
Lrp5 19.69 17.23 0.61 0.18 0.86 0.000530017 0.025560881 
Napepld 1.93 2.65 0.07 0.07 1.35 0.000530316 0.025560881 
Plcl2 3.83 4.74 0.12 0.23 1.22 0.000581059 0.027133751 
Agtpbp1 30.09 34.73 0.70 0.65 1.14 0.000613004 0.028004659 
Abcc8 14.02 16.33 0.28 0.55 1.15 0.000619089 0.02811567 
Ncor2 17.93 15.76 0.34 0.39 0.87 0.000638306 0.028609095 
Gdpd5 7.32 9.06 0.47 0.27 1.22 0.000710153 0.031022558 
Sparc 234.62 207.33 8.47 6.02 0.87 0.000762215 0.032328489 
Ide 2.89 2.10 0.11 0.15 0.72 0.00076615 0.032422862 
Mitf 12.92 15.29 0.27 0.22 1.17 0.000776435 0.032645446 
Aldh1l1 1.39 2.12 0.03 0.23 1.51 0.000805963 0.033509339 
Grb2 33.68 39.03 1.17 0.30 1.14 0.000858829 0.035167461 
Hexb 16.53 20.45 0.88 0.66 1.22 0.000863094 0.035265962 
Ptges3 45.67 35.40 2.93 1.02 0.76 0.00088393 0.035885304 
Dhcr7 4.19 5.51 0.17 0.28 1.30 0.000903169 0.036509988 
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Gclm 13.81 11.52 0.52 0.40 0.82 0.000928854 0.037230742 
Soga1 5.16 4.49 0.18 0.18 0.86 0.000936504 0.037344819 
Ide 20.45 23.92 0.97 0.37 1.15 0.000955803 0.037910171 
Ckmt2 1573.83 1409.06 19.02 20.28 0.88 0.001030371 0.040528633 
App 124.31 111.62 2.20 1.22 0.89 0.001040302 0.040595735 
Grb10 30.28 26.87 0.88 0.64 0.87 0.001040642 0.040595735 
Abcc9 84.86 96.05 1.34 1.58 1.12 0.001071067 0.0415525 
Tbc1d1 7.28 8.65 0.21 0.23 1.17 0.00111095 0.042636661 
Alox8 0.34 0.65 0.06 0.08 1.90 0.00116541 0.044456762 
Igfbp3 11.23 13.53 0.50 0.49 1.19 0.001172999 0.044656399 
Ldhd 21.66 18.40 0.26 0.89 0.84 0.001197328 0.045489129 
Sort1 13.42 15.52 0.13 0.46 1.14 0.001207854 0.045584336 
Snca 1.65 0.87 0.25 0.07 0.51 0.001299687 0.047661071 
Socs7 10.11 8.89 0.41 0.18 0.87 0.001303425 0.04770586 
Gata6 23.85 27.88 0.72 0.49 1.15 0.001307012 0.047744954 
Rbp1 5.01 6.42 0.21 0.39 1.26 0.00131143 0.047780328 
Mgea5 34.75 31.08 1.03 0.34 0.88 0.001314147 0.047780328 
Impa2 7.87 10.55 0.46 0.64 1.32 0.00133379 0.04825825 
Lass4 13.47 15.82 0.54 0.46 1.16 0.001399885 0.049919323 
Stat5a 12.47 14.71 0.27 0.47 1.16 0.00141767 0.050051407 
Pitpnc1 16.70 19.10 0.57 0.38 1.13 0.001465198 0.051256978 
Acsl1 240.71 273.09 5.80 4.25 1.12 0.001508224 0.052084544 
Acsl4 3.83 4.67 0.21 0.07 1.20 0.001572456 0.053812613 
Pcx 11.39 9.79 0.24 0.21 0.85 0.00170693 0.056379248 
Sgk1 17.15 14.70 0.50 0.80 0.85 0.001765109 0.05705738 
Stat3 51.91 46.87 1.21 0.96 0.89 0.001873305 0.059690741 
Cyp2d22 16.47 19.31 0.34 0.42 1.16 0.001901681 0.060290936 
Irs1 9.05 7.55 0.47 0.11 0.82 0.001925386 0.060838994 
Cyp2e1 5.33 3.66 0.52 0.32 0.68 0.00200778 0.06302234 
Grb14 93.93 106.41 2.29 1.73 1.12 0.002123646 0.065787927 
Pgam1 73.29 60.97 3.59 2.53 0.82 0.00221932 0.067864655 
Cd36 471.72 435.90 3.67 14.83 0.91 0.002633004 0.077035698 
Plce1 7.36 8.54 0.23 0.24 1.14 0.002839192 0.081311555 
C2cd2 4.68 4.00 0.18 0.10 0.84 0.002884004 0.082024347 
Thrsp 54.50 42.80 3.05 2.49 0.77 0.003193852 0.088268568 
Npc1 32.13 36.29 0.62 0.62 1.11 0.003458332 0.093800466 
Prkag3 1.94 1.44 0.10 0.05 0.73 0.00358386 0.09692781 
Inpp4a 6.67 5.86 0.20 0.08 0.87 0.003911164 0.103419469 
Prkcq 3.44 2.72 0.14 0.16 0.78 0.00397843 0.104746319 
C3 76.02 69.63 1.73 1.40 0.90 0.004078919 0.106079881 
Sf1 19.41 17.42 0.34 0.55 0.88 0.004529655 0.114002688 
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Ugp2 144.94 109.96 12.33 2.49 0.75 0.004860075 0.118739894 
Pla2g12a 19.33 16.78 0.72 0.43 0.86 0.005105587 0.122838612 
Pdpk1 10.90 9.79 0.39 0.24 0.88 0.005143052 0.123270701 
A4galt 3.88 3.01 0.16 0.14 0.76 0.005435366 0.127852494 
Flt1 25.27 22.57 0.78 0.37 0.88 0.005470205 0.128353485 
Ywhag 91.51 84.04 2.14 1.46 0.91 0.005634955 0.130397816 
Pdgfb 20.25 18.30 0.41 0.62 0.89 0.006197961 0.139557183 
Comt 76.25 66.59 3.24 1.46 0.86 0.006401149 0.142273609 
Cav3 48.76 56.17 0.65 1.11 1.14 0.006509327 0.143649759 
Apod 5.33 6.87 0.25 0.46 1.27 0.006673148 0.145575722 
Adh1 12.57 17.16 0.96 1.34 1.35 0.006884377 0.147982884 
Acadl 690.72 635.86 5.80 5.06 0.91 0.006943487 0.148915808 
Fig4 18.33 20.76 0.49 0.44 1.12 0.007049098 0.150669497 
Pigg 7.56 6.55 0.15 0.16 0.86 0.007841801 0.161075512 
Naaa 4.74 5.74 0.19 0.26 1.19 0.008199451 0.165552069 
Mtm1 4.84 5.80 0.28 0.18 1.18 0.008363279 0.167256763 
Adm 7.54 10.77 0.67 0.92 1.41 0.009339162 0.17975753 
Pdp1 8.92 10.78 0.64 0.21 1.19 0.009736675 0.185153076 
Smpd3 1.43 1.14 0.08 0.04 0.78 0.009888221 0.187846478 
Acsf2 14.51 12.88 0.28 0.49 0.88 0.010072426 0.190202317 	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Appendix 3: Differential expression of genes involved in membrane excitability and cardiac 
conduction. 
Gene 
Symbol 
Wt 
average 
KO 
average 
Wt std 
err 
Ko std 
err 
Fold 
Change p-value FDR 
Slc4a3 85.70 7.46 0.64 0.17 0.09 0 0 
Kcnj5 26.19 37.37 0.97 1.12 1.41 2.27823E-15 5.39913E-12 
Gja5 9.70 14.57 0.39 0.47 1.48 2.55292E-14 4.84008E-11 
Slc38a3 25.02 18.32 0.66 0.74 0.72 1.59012E-12 1.77335E-09 
Fgf12 3.52 5.33 0.14 0.16 1.49 2.09515E-12 2.20678E-09 
Cngb3 0.34 0.87 0.05 0.05 2.55 1.1811E-10 6.99766E-08 
Tfrc 23.19 45.24 3.13 1.62 1.92 1.79236E-10 9.99454E-08 
Myl4 510.01 681.76 10.20 25.55 1.32 1.25037E-09 4.93871E-07 
Cacna1s 2.16 1.36 0.09 0.07 0.62 2.91524E-09 1.04283E-06 
Slc40a1 6.04 4.17 0.27 0.08 0.68 3.4355E-09 1.20618E-06 
Slc36a2 12.47 16.97 0.66 0.30 1.34 1.27257E-08 3.95519E-06 
Slc24a2 0.88 1.36 0.06 0.02 1.51 8.16788E-08 2.06473E-05 
Sln 305.39 382.75 4.89 12.88 1.24 1.18911E-07 2.8903E-05 
Adra1b 12.61 17.82 0.65 0.79 1.39 1.31335E-07 3.11247E-05 
Cacna2d2 3.34 4.61 0.13 0.21 1.36 1.53959E-07 3.51676E-05 
Kcnj4 1.56 0.70 0.10 0.06 0.44 2.72114E-07 5.99885E-05 
Camk2b 5.93 4.43 0.14 0.15 0.74 2.7882E-07 6.07603E-05 
Egf 2.43 3.75 0.21 0.14 1.52 2.914E-07 6.27802E-05 
Dsc2 15.90 20.20 0.52 0.63 1.25 3.95863E-07 7.98422E-05 
Dhrs7c 95.68 117.40 3.70 2.43 1.21 5.13329E-07 9.63584E-05 
Atp6v1b2 39.36 32.33 0.98 1.27 0.81 6.25586E-07 0.000113244 
Bnip3 90.52 65.09 3.78 3.34 0.71 7.8138E-07 0.000133461 
Kcnn2 2.79 4.68 0.26 0.31 1.66 7.98443E-07 0.000135158 
Adora2a 5.35 3.76 0.13 0.17 0.69 8.72664E-07 0.000146414 
Hopx 123.54 147.86 3.99 2.76 1.18 2.74715E-06 0.000410104 
Popdc2 127.77 152.13 2.49 3.89 1.17 2.94348E-06 0.00043598 
Chrm2 44.98 54.90 1.02 1.40 1.20 3.11934E-06 0.000451447 
Slc4a4 9.45 7.68 0.25 0.30 0.80 3.39733E-06 0.000478618 
Slc6a8 81.62 66.94 2.77 0.67 0.81 8.34761E-06 0.001034394 
Myoc 3.37 5.20 0.26 0.30 1.52 9.50464E-06 0.001119245 
Ramp1 0.63 1.20 0.11 0.05 1.87 1.05737E-05 0.001207795 
Slc25a42 30.00 36.25 1.19 0.49 1.19 1.55455E-05 0.001665128 
Ptk2b 2.09 2.95 0.09 0.15 1.39 1.63145E-05 0.001737674 
Slc17a7 21.87 26.71 0.88 0.57 1.20 1.8932E-05 0.001961375 
Dsg2 18.79 22.48 0.75 0.49 1.18 2.18982E-05 0.002185098 
Kcnd2 9.11 11.62 0.53 0.26 1.26 2.4891E-05 0.002359541 
Camk2g 19.16 23.21 0.76 0.55 1.20 2.88952E-05 0.002684276 
Prkcz 1.54 0.98 0.12 0.05 0.63 2.91661E-05 0.002684276 
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Cacna1g 4.47 5.46 0.10 0.17 1.21 3.44574E-05 0.003096101 
Kcnj3 34.10 44.12 2.26 0.93 1.28 4.09661E-05 0.003562736 
Crhr2 11.70 14.57 0.40 0.52 1.23 4.7258E-05 0.003994844 
Kcnc1 0.58 0.40 0.02 0.04 0.68 5.03452E-05 0.004186376 
P2rx5 12.94 10.36 0.47 0.27 0.79 5.75658E-05 0.004724634 
Prkcb 0.66 0.95 0.04 0.06 1.42 6.01417E-05 0.004872765 
Fxyd5 13.98 11.05 0.41 0.34 0.78 6.63778E-05 0.005332443 
Kcna4 0.21 0.47 0.01 0.04 2.14 7.0034E-05 0.005578885 
Kcnh2 28.00 35.94 1.55 1.35 1.27 8.1039E-05 0.006145675 
Thra 32.15 38.53 0.93 0.91 1.18 0.000114091 0.007952361 
Cpox 19.26 16.46 0.54 0.24 0.84 0.000278695 0.016207881 
Scn10a 3.32 4.05 0.08 0.19 1.20 0.000294161 0.016798201 
Clic5 101.39 85.10 4.05 2.93 0.83 0.000311211 0.017560289 
Ibtk 12.34 14.77 0.23 0.32 1.18 0.000321274 0.018020825 
Met 1.59 1.16 0.10 0.07 0.72 0.000445579 0.022889218 
Camk2a 10.28 12.40 0.40 0.49 1.19 0.000532546 0.025560881 
Abcc8 14.02 16.33 0.28 0.55 1.15 0.000619089 0.02811567 
Gnao1 6.72 7.98 0.14 0.28 1.17 0.000619882 0.02811567 
Stc2 10.68 13.45 0.57 0.59 1.24 0.000690663 0.030594126 
Slc12a5 0.62 0.37 0.03 0.05 0.60 0.000719275 0.031137367 
Gpm6a 4.25 5.38 0.05 0.33 1.25 0.000731386 0.031305071 
Scn4b 34.87 23.69 3.23 0.66 0.67 0.000738593 0.031467391 
Jph2 175.38 154.59 4.98 2.40 0.87 0.000924839 0.037227213 
Gclm 13.81 11.52 0.52 0.40 0.82 0.000928854 0.037230742 
Abcc9 84.86 96.05 1.34 1.58 1.12 0.001071067 0.0415525 
F2r 22.58 20.18 0.55 0.70 0.88 0.001268914 0.047110856 
Snca 1.65 0.87 0.25 0.07 0.51 0.001299687 0.047661071 
Mgea5 34.75 31.08 1.03 0.34 0.88 0.001314147 0.047780328 
Scn1b 24.61 19.96 1.11 0.75 0.80 0.001468038 0.051256978 
Slc26a6 4.56 5.89 0.26 0.34 1.27 0.001551633 0.053389142 
Calcrl 10.81 9.46 0.44 0.32 0.86 0.001620283 0.054660035 
Cacna1d 0.48 0.67 0.04 0.02 1.38 0.001633987 0.055024433 
Atp1a4 7.33 6.19 0.12 0.13 0.83 0.001671315 0.055786021 
Slc9a3r2 57.13 50.98 1.77 1.13 0.88 0.001687366 0.056124152 
Capn3 2.31 1.77 0.15 0.09 0.75 0.001913509 0.060564631 
Dlg1 19.74 17.67 0.62 0.05 0.88 0.00278253 0.080295259 
Hcn4 3.34 4.16 0.23 0.08 1.23 0.003171898 0.0877898 
Slc39a8 1.38 1.87 0.12 0.07 1.33 0.003655836 0.098174219 
Popdc3 16.81 13.51 1.08 0.53 0.79 0.004009824 0.104833043 
Cux2 3.72 4.44 0.19 0.17 1.18 0.00423686 0.108696373 
Slc20a1 9.84 8.12 0.59 0.17 0.81 0.004845385 0.118739894 
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Pdpk1 10.90 9.79 0.39 0.24 0.88 0.005143052 0.123270701 
Ptpn3 10.97 13.47 0.85 0.18 1.21 0.005226835 0.124335718 
Panx2 0.92 1.31 0.09 0.04 1.41 0.00523548 0.124385297 
Slc7a1 8.67 7.05 0.07 0.53 0.80 0.005653176 0.130546355 
Pln 2169.68 2423.54 34.29 27.57 1.10 0.005680661 0.130862281 
Cnga3 3.29 2.68 0.15 0.05 0.80 0.005863483 0.133612709 
Nos3 13.83 12.17 0.42 0.10 0.87 0.006113397 0.137816766 
Pdgfb 20.25 18.30 0.41 0.62 0.89 0.006197961 0.139557183 
Epas1 81.59 90.65 1.65 1.58 1.10 0.006340133 0.141414799 
Cav3 48.76 56.17 0.65 1.11 1.14 0.006509327 0.143649759 
Ank2 20.65 23.05 0.30 0.46 1.10 0.006789789 0.146781769 
Gaa 52.11 44.31 2.59 1.03 0.84 0.006854661 0.147679005 
Kcnt1 0.15 0.27 0.02 0.04 1.78 0.007208891 0.153049689 
Camk2d 50.25 56.27 0.98 1.29 1.10 0.008156532 0.165037022 
Slc20a2 68.46 76.37 1.27 1.02 1.10 0.008263179 0.166307437 
Aqp8 7.11 3.42 1.44 0.22 0.47 0.008670029 0.171402594 
Gas6 79.77 89.10 1.05 0.91 1.10 0.009026552 0.176064189 
Slc24a4 0.25 0.52 0.05 0.09 2.04 0.009338723 0.17975753 
Adm 7.54 10.77 0.67 0.92 1.41 0.009339162 0.17975753 
Gja1 179.41 200.29 4.60 3.95 1.10 0.009475788 0.181542425 
Cybb 3.87 5.02 0.34 0.19 1.28 0.009729229 0.185153076 
Scn5a 77.42 88.51 2.10 3.51 1.13 0.01070961 0.197513125 
Kcne4 2.05 1.49 0.07 0.15 0.72 0.011327986 0.202193358 
Kcne1 0.30 0.51 0.03 0.04 1.66 0.015060422 0.24075088 
Atp1a2 162.60 150.59 2.34 1.10 0.91 0.01610897 0.250763787 
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Appendix 4: Differential expression of genes encoding transporters, pumps and channels  
Gene 
Symbol 
Wt 
average 
KO 
average Wt SE Ko SE 
Fold 
Change p-value FDR 
Slc4a3 85.70 7.46 0.64 0.17 0.09 0 0 
Kcnj5 26.19 37.37 0.97 1.12 1.41 2.27823E-15 5.39913E-12 
Gja5 9.70 14.57 0.39 0.47 1.48 2.55292E-14 4.84008E-11 
Slc38a3 25.02 18.32 0.66 0.74 0.72 1.59012E-12 1.77335E-09 
Abcd2 2.12 3.46 0.16 0.06 1.61 4.14327E-12 3.74058E-09 
Cngb3 0.34 0.87 0.05 0.05 2.55 1.1811E-10 6.99766E-08 
Tfrc 23.19 45.24 3.13 1.62 1.92 1.79236E-10 9.99454E-08 
Cacna1s 2.16 1.36 0.09 0.07 0.62 2.91524E-09 1.04283E-06 
Slc40a1 6.04 4.17 0.27 0.08 0.68 3.4355E-09 1.20618E-06 
Slc36a2 12.47 16.97 0.66 0.30 1.34 1.27257E-08 3.95519E-06 
Slco3a1 28.32 23.19 0.49 0.35 0.81 4.22675E-08 1.15847E-05 
Slc24a2 0.88 1.36 0.06 0.02 1.51 8.16788E-08 2.06473E-05 
Sln 305.39 382.75 4.89 12.88 1.24 1.18911E-07 2.8903E-05 
Cacna2d2 3.34 4.61 0.13 0.21 1.36 1.53959E-07 3.51676E-05 
Kcnj4 1.56 0.70 0.10 0.06 0.44 2.72114E-07 5.99885E-05 
Atp6v1b2 39.36 32.33 0.98 1.27 0.81 6.25586E-07 0.000113244 
Kcnn2 2.79 4.68 0.26 0.31 1.66 7.98443E-07 0.000135158 
Slc4a4 9.45 7.68 0.25 0.30 0.80 3.39733E-06 0.000478618 
Slc6a8 81.62 66.94 2.77 0.67 0.81 8.34761E-06 0.001034394 
Slc25a42 30.00 36.25 1.19 0.49 1.19 1.55455E-05 0.001665128 
Slc17a7 21.87 26.71 0.88 0.57 1.20 1.8932E-05 0.001961375 
Ostm1 13.73 11.18 0.29 0.15 0.80 2.348E-05 0.002276885 
Kcnd2 9.11 11.62 0.53 0.26 1.26 2.4891E-05 0.002359541 
Cacna1g 4.47 5.46 0.10 0.17 1.21 3.44574E-05 0.003096101 
Kcnj3 34.10 44.12 2.26 0.93 1.28 4.09661E-05 0.003562736 
Kcnc1 0.58 0.40 0.02 0.04 0.68 5.03452E-05 0.004186376 
P2rx5 12.94 10.36 0.47 0.27 0.79 5.75658E-05 0.004724634 
Fxyd5 13.98 11.05 0.41 0.34 0.78 6.63778E-05 0.005332443 
Kcna4 0.21 0.47 0.01 0.04 2.14 7.0034E-05 0.005578885 
Abca8b 7.76 9.42 0.30 0.22 1.20 7.64039E-05 0.005936645 
Kcnh2 28.00 35.94 1.55 1.35 1.27 8.1039E-05 0.006145675 
Abca8a 35.10 44.01 2.24 0.42 1.24 0.000170265 0.010942555 
Scn10a 3.32 4.05 0.08 0.19 1.20 0.000294161 0.016798201 
Clic5 101.39 85.10 4.05 2.93 0.83 0.000311211 0.017560289 
Ano5 0.93 0.47 0.12 0.03 0.50 0.000473566 0.023815201 
Abcc8 14.02 16.33 0.28 0.55 1.15 0.000619089 0.02811567 
Slc12a5 0.62 0.37 0.03 0.05 0.60 0.000719275 0.031137367 
Scn4b 34.87 23.69 3.23 0.66 0.67 0.000738593 0.031467391 
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Jph2 175.38 154.59 4.98 2.40 0.87 0.000924839 0.037227213 
Abcc9 84.86 96.05 1.34 1.58 1.12 0.001071067 0.0415525 
Slc16a6 3.75 3.04 0.13 0.12 0.80 0.001110474 0.042636661 
Ano4 2.00 2.64 0.11 0.14 1.30 0.001343467 0.048515775 
Slc25a39 86.75 77.72 0.46 1.37 0.88 0.001412128 0.049948759 
Scn1b 24.61 19.96 1.11 0.75 0.80 0.001468038 0.051256978 
Slc26a6 4.56 5.89 0.26 0.34 1.27 0.001551633 0.053389142 
Abcc3 1.19 0.82 0.03 0.06 0.68 0.001560102 0.053583274 
Cacna1d 0.48 0.67 0.04 0.02 1.38 0.001633987 0.055024433 
Atp1a4 7.33 6.19 0.12 0.13 0.83 0.001671315 0.055786021 
Slc9a3r2 57.13 50.98 1.77 1.13 0.88 0.001687366 0.056124152 
Slc16a7 2.99 3.97 0.18 0.12 1.31 0.001725643 0.056799413 
Slc37a1 2.33 3.00 0.07 0.11 1.27 0.002261475 0.068931353 
Cd36 471.72 435.90 3.67 14.83 0.91 0.002633004 0.077035698 
Atp11a 25.25 28.49 0.26 0.47 1.11 0.003118172 0.086809718 
Hcn4 3.34 4.16 0.23 0.08 1.23 0.003171898 0.0877898 
Slc39a8 1.38 1.87 0.12 0.07 1.33 0.003655836 0.098174219 
Slc25a34 69.43 63.11 1.57 1.05 0.90 0.004041051 0.105239411 
Slc19a1 1.73 2.40 0.14 0.06 1.37 0.004642541 0.115793408 
Slc20a1 9.84 8.12 0.59 0.17 0.81 0.004845385 0.118739894 
Atp2b3 0.25 0.13 0.02 0.02 0.51 0.005496459 0.128651061 
Slc7a1 8.67 7.05 0.07 0.53 0.80 0.005653176 0.130546355 
Pln 2169.68 2423.54 34.29 27.57 1.10 0.005680661 0.130862281 
Cnga3 3.29 2.68 0.15 0.05 0.80 0.005863483 0.133612709 
Slc25a35 4.20 5.29 0.26 0.15 1.24 0.005947224 0.134711369 
Slc44a2 37.41 45.08 2.63 1.31 1.19 0.007143293 0.152168185 
Kcnt1 0.15 0.27 0.02 0.04 1.78 0.007208891 0.153049689 
Bsg 647.04 590.52 11.38 6.84 0.90 0.008094769 0.164137683 
Slc20a2 68.46 76.37 1.27 1.02 1.10 0.008263179 0.166307437 
Abca12 0.97 1.26 0.05 0.09 1.28 0.008386067 0.167359411 
Slc24a4 0.25 0.52 0.05 0.09 2.04 0.009338723 0.17975753 
Gja1 179.41 200.29 4.60 3.95 1.10 0.009475788 0.181542425 
Scn5a 77.42 88.51 2.10 3.51 1.13 0.01070961 0.197513125 
Lrrc8c 9.75 8.57 0.33 0.31 0.87 0.010869762 0.199107192 
Slc2a12 7.19 6.17 0.40 0.09 0.85 0.010982058 0.199819041 
Kcne4 2.05 1.49 0.07 0.15 0.72 0.011327986 0.202193358 
Ano8 8.51 9.78 0.39 0.34 1.13 0.01136178 0.202193358 
Slc1a1 1.61 1.07 0.21 0.04 0.65 0.012554215 0.216158218 
Slc15a4 9.30 7.67 0.64 0.20 0.81 0.013596033 0.227709527 
Jph1 7.90 8.98 0.24 0.23 1.12 0.013912483 0.230689104 
Slc35e4 2.95 2.38 0.16 0.17 0.80 0.014143078 0.233164006 
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Kcne1 0.30 0.51 0.03 0.04 1.66 0.015060422 0.24075088 
Atp1a2 162.60 150.59 2.34 1.10 0.91 0.01610897 0.250763787 
Slc41a3 10.94 13.31 0.70 0.56 1.20 0.016315917 0.252378561 
Slc2a9 0.47 0.72 0.08 0.06 1.54 0.016556316 0.254162911 
Slc22a3 4.26 5.06 0.24 0.18 1.17 0.016980879 0.257758601 
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Appendix 5: Differential expression of genes encoding sarcomere and sarcomeric 
cytoskeletal proteins 
Gene 
Symbol 
Wt 
average 
KO 
average 
Wt SE KO SE 
Fold 
Chang
e 
p-value FDR 
Myl1 67.41 14.79 2.34 0.73 0.22 1.6337E-132 1.5486E-128 
Obsl1 32.58 17.25 0.31 0.23 0.52 9.68848E-56 4.5921E-52 
Kcnj5 26.19 37.37 0.97 1.12 1.41 2.27823E-15 5.39913E-12 
Gja5 9.70 14.57 0.39 0.47 1.48 2.55292E-14 4.84008E-11 
Ezr 21.50 29.79 0.53 0.78 1.37 5.41003E-13 7.32634E-10 
Myot 57.34 31.22 3.34 1.18 0.54 1.03202E-12 1.30441E-09 
Iqgap2 6.68 4.56 0.25 0.16 0.67 3.85321E-12 3.65265E-09 
Mybphl 52.61 71.19 1.40 2.06 1.33 1.33597E-11 1.05536E-08 
Myl7 468.29 655.70 10.48 25.25 1.38 4.05996E-11 2.65423E-08 
Tpm4 53.14 42.16 0.97 1.25 0.78 9.26548E-10 4.08521E-07 
Myom2 236.63 315.95 11.53 3.84 1.32 9.99096E-10 4.30497E-07 
Myl4 510.01 681.76 10.20 25.55 1.32 1.25037E-09 4.93871E-07 
Spta1 1.62 2.65 0.17 0.03 1.62 2.15345E-09 8.16546E-07 
Cacna1s 2.16 1.36 0.09 0.07 0.62 2.91524E-09 1.04283E-06 
Fmn1 7.36 9.44 0.01 0.06 1.27 1.76439E-08 5.39533E-06 
Ankrd23 323.08 213.72 16.94 11.46 0.65 5.32076E-08 1.42079E-05 
Actr3b 27.27 35.22 0.84 1.09 1.28 7.9478E-08 2.03625E-05 
Anxa2 60.22 49.02 0.76 1.81 0.80 1.04679E-07 2.61133E-05 
Dstn 62.06 77.53 0.74 1.79 1.23 1.13695E-07 2.79941E-05 
Adra1b 12.61 17.82 0.65 0.79 1.39 1.31335E-07 3.11247E-05 
Kcnj4 1.56 0.70 0.10 0.06 0.44 2.72114E-07 5.99885E-05 
Synpo 21.15 15.87 0.61 0.78 0.74 2.99926E-07 6.38909E-05 
Fam101b 23.47 18.86 0.48 1.07 0.79 3.47665E-07 7.16454E-05 
Dsc2 15.90 20.20 0.52 0.63 1.25 3.95863E-07 7.98422E-05 
Adrbk2 4.43 6.08 0.23 0.20 1.35 4.4608E-07 8.71879E-05 
Pecam1 68.51 58.01 1.14 1.60 0.84 6.6443E-07 0.000117728 
Kcnn2 2.79 4.68 0.26 0.31 1.66 7.98443E-07 0.000135158 
Adora2a 5.35 3.76 0.13 0.17 0.69 8.72664E-07 0.000146414 
Lrrc39 28.50 34.82 1.07 0.32 1.21 2.5373E-06 0.000384837 
Phactr1 2.40 3.39 0.15 0.15 1.40 3.06501E-06 0.000446996 
Acta1 492.17 182.88 65.16 7.27 0.37 3.40806E-06 0.000478618 
Sorbs1 150.63 116.10 6.48 3.40 0.76 6.81421E-06 0.000878848 
Neb 0.74 0.46 0.05 0.03 0.61 7.99636E-06 0.001003993 
Myoc 3.37 5.20 0.26 0.30 1.52 9.50464E-06 0.001119245 
Palld 50.28 60.46 1.25 1.53 1.19 1.05751E-05 0.001207795 
Ptk2b 2.09 2.95 0.09 0.15 1.39 1.63145E-05 0.001737674 
Cryab 1574.20 1276.31 65.47 25.96 0.80 2.46404E-05 0.002347527 
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Tagln2 58.53 49.79 0.90 1.64 0.84 2.78428E-05 0.002626173 
Pacsin1 1.25 0.70 0.12 0.06 0.55 2.80142E-05 0.002626173 
Fhl2 752.99 658.95 14.19 9.31 0.86 3.78497E-05 0.003322186 
Kcnj3 34.10 44.12 2.26 0.93 1.28 4.09661E-05 0.003562736 
Nebl 40.46 48.18 1.37 1.02 1.18 4.63074E-05 0.003936958 
Crhr2 11.70 14.57 0.40 0.52 1.23 4.7258E-05 0.003994844 
Fxyd5 13.98 11.05 0.41 0.34 0.78 6.63778E-05 0.005332443 
Flnb 12.00 10.38 0.21 0.18 0.85 8.21726E-05 0.006182182 
Myh11 13.21 16.68 0.18 0.82 1.25 8.74725E-05 0.006478092 
Inppl1 62.29 72.73 0.42 1.44 1.15 8.90046E-05 0.006540457 
Scin 0.69 1.24 0.07 0.03 1.77 0.000107012 0.007598662 
Pdlim5 148.86 127.38 5.16 1.25 0.84 0.000206765 0.012893026 
Mid1ip1 43.36 53.60 1.52 2.28 1.22 0.000226162 0.013815421 
Abra 37.97 22.93 3.86 1.88 0.59 0.000236332 0.014191881 
Myo1e 4.46 3.55 0.26 0.09 0.78 0.000241473 0.014441925 
Myh9 46.82 41.50 0.88 0.58 0.87 0.000264145 0.015643414 
Mtss1l 22.48 19.78 0.43 0.58 0.87 0.000301925 0.017138298 
Clic5 101.39 85.10 4.05 2.93 0.83 0.000311211 0.017560289 
Mtss1 7.23 8.81 0.26 0.28 1.20 0.000329757 0.018302192 
Mypn 45.71 34.88 2.94 0.72 0.75 0.000394096 0.020929042 
Ppfia1 14.88 11.91 0.78 0.31 0.79 0.000415004 0.021795189 
Gas2l1 4.72 3.87 0.17 0.17 0.81 0.000496813 0.024657254 
Ppp1r9b 22.37 19.51 0.22 0.14 0.86 0.000537942 0.02575465 
Ncald 1.81 2.54 0.11 0.16 1.38 0.000577974 0.02712327 
Sema5a 1.36 1.75 0.05 0.05 1.27 0.000592504 0.027465244 
Sphkap 0.50 0.79 0.07 0.04 1.56 0.000627949 0.028278576 
Scn4b 34.87 23.69 3.23 0.66 0.67 0.000738593 0.031467391 
Twf2 82.46 72.64 1.94 1.39 0.87 0.000797358 0.03329762 
Grb2 33.68 39.03 1.17 0.30 1.14 0.000858829 0.035167461 
Jph2 175.38 154.59 4.98 2.40 0.87 0.000924839 0.037227213 
Abcc9 84.86 96.05 1.34 1.58 1.12 0.001071067 0.0415525 
Xirp2 114.44 97.47 4.98 2.79 0.84 0.001209395 0.045584336 
Trim54 195.51 172.94 5.37 3.06 0.87 0.001227549 0.046061053 
Fam129b 14.22 12.37 0.14 0.29 0.86 0.001249311 0.04662535 
Snca 1.65 0.87 0.25 0.07 0.51 0.001299687 0.047661071 
Epb4.1l3 2.34 3.05 0.17 0.05 1.29 0.001443549 0.050775976 
Scn1b 24.61 19.96 1.11 0.75 0.80 0.001468038 0.051256978 
Cacna1d 0.48 0.67 0.04 0.02 1.38 0.001633987 0.055024433 
Plec 45.97 41.57 0.69 0.34 0.89 0.001641654 0.055184603 
Capn3 2.31 1.77 0.15 0.09 0.75 0.001913509 0.060564631 
Svil 68.05 77.43 1.59 1.11 1.12 0.002001869 0.062941016 
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Myo10 20.29 18.28 0.57 0.24 0.89 0.002459598 0.073784035 
Sptan1 60.94 55.27 1.51 0.75 0.89 0.002559263 0.075794393 
Pknox2 4.21 5.22 0.12 0.11 1.22 0.0026132 0.076744889 
Amot 2.31 1.82 0.16 0.04 0.78 0.002752248 0.079542496 
Dlg1 19.74 17.67 0.62 0.05 0.88 0.00278253 0.080295259 
Shroom4 6.08 5.07 0.27 0.17 0.82 0.0028647 0.081837662 
Arhgap6 2.27 3.32 0.32 0.05 1.45 0.003401748 0.092397902 
Enah 65.46 49.54 5.56 1.22 0.75 0.004038103 0.105239411 
Fscn1 15.66 12.70 1.14 0.41 0.80 0.004401868 0.111421914 
Arpc3 68.53 61.17 1.96 1.83 0.88 0.005126197 0.123022234 
Abi2 2.71 3.24 0.08 0.08 1.18 0.005529382 0.128969846 
Eml2 13.46 15.84 0.66 0.57 1.16 0.005598334 0.130072082 
Nos3 13.83 12.17 0.42 0.10 0.87 0.006113397 0.137816766 
Add3 17.34 20.59 0.64 0.82 1.17 0.006269798 0.14034133 
Hsp90b1 196.85 169.67 9.80 5.17 0.85 0.006497149 0.143649759 
Cav3 48.76 56.17 0.65 1.11 1.14 0.006509327 0.143649759 
Tmod1 136.46 152.06 2.15 1.06 1.10 0.006516761 0.143649759 
Ank2 20.65 23.05 0.30 0.46 1.10 0.006789789 0.146781769 
Rcsd1 30.80 35.11 0.12 0.78 1.12 0.006828178 0.147275806 
Peg13 18.76 16.83 0.24 0.26 0.88 0.006882263 0.147982884 
Fbxo32 32.47 29.58 0.72 0.66 0.90 0.00693958 0.148915808 
Pdlim7 11.96 10.41 0.30 0.25 0.86 0.007004552 0.15005571 
Tmod4 10.82 8.45 0.66 0.48 0.77 0.007019842 0.150213522 
Capg 10.91 9.18 0.43 0.14 0.83 0.007136422 0.152168185 
Ablim1 81.73 76.12 1.20 2.00 0.92 0.007552794 0.157543244 
Cdc42ep1 23.98 21.28 0.79 0.24 0.88 0.007950872 0.162522798 
Camk2d 50.25 56.27 0.98 1.29 1.10 0.008156532 0.165037022 
Mtap1a 3.23 3.93 0.19 0.15 1.20 0.008194211 0.165552069 
Coro2b 3.82 3.20 0.11 0.11 0.83 0.00831237 0.166806511 
Mtm1 4.84 5.80 0.28 0.18 1.18 0.008363279 0.167256763 
Synpo2 27.73 25.01 0.89 0.89 0.89 0.008451151 0.168303952 
Obscn 97.09 82.34 5.16 1.50 0.84 0.008494806 0.168995822 
Myl12b 255.70 233.96 3.81 2.83 0.90 0.009183249 0.178021697 
Gja1 179.41 200.29 4.60 3.95 1.10 0.009475788 0.181542425 
Klhl40 13.33 11.03 0.81 0.42 0.82 0.009952453 0.188784779 
Myl12a 297.78 276.84 4.88 3.50 0.92 0.011005113 0.199819041 
Fhl1 102.74 77.52 9.84 3.60 0.74 0.012840295 0.218723409 
Jph1 7.90 8.98 0.24 0.23 1.12 0.013912483 0.230689104` 
 
 
